HY-100006A "MR|44 47|ULK1
HY-100006A "MR|51 54|ULK2
HY-100015 "Miv|118 119|domain Ki
HY-100016 "AZD|30 32|ATM
HY-100023 "LY3|9 12|CDC7
HY-100023 "LY3|16 20|pMCM2
HY-10005 "Flav|48 51|CDKs
HY-10005 "Flav|73 76|CDK4
HY-10006 "Flav|39 41|CDK
HY-10006 "Flav|68 71|CDKs
HY-10006 "Flav|91 94|CDK4
HY-10008 "SNS-|51 54|CDK9
HY-10009 "Sema|10 20|γ - secretase
HY-10009 "Sema|39 47|β - amyloid
HY-10009 "Sema|118 122|Notch
HY-100114 "TA-|19 22|p38 MAPK
HY-100114 "TA-|76 78|p38
HY-10012 "AZD-|127 130|438 CDK6
HY-10013 "Tara|32 43|cannabinoid 1
HY-10013 "Tara|144 145|CB1 Ki
HY-10014 "R547|469 489|. R547 retinoblastoma protein
HY-10015 "PAP-|169 170|1 ]
HY-100155 "4-I|52 61|σ1 receptor
HY-100155 "4-I|63 64|Ki
HY-100155 "4-I|98 107|σ2 receptor
HY-100155 "4-I|109 110|Ki
HY-100155 "4-I|136 137|Ki
HY-100155 "4-I|164 173|Target σ1 receptor
HY-100155 "4-I|289 301|theσ1 receptor
HY-100155 "4-I|477 488|proapoptotic
HY-100155 "4-I|491 503|proautophagic
HY-100209 "Suf|47 81|luteinizing hormone - releasing hormone
HY-100209 "Suf|83 86|LHRH
HY-100221 "AM-|26 45|glucokinase activator
HY-100221 "AM-|68 78|glucokinase
HY-100221 "AM-|80 81|GK
HY-100233 "IQ-|26 48|NF - κB / activating protein
HY-100233 "IQ-|51 54|AP-1
HY-100233 "IQ-|76 86|2.3±0.41 μM.
HY-100233 "IQ-|149 152|JNKs
HY-100233 "IQ-|190 193|JNK1
HY-100233 "IQ-|198 201|JNK2
HY-100235 "EPZ|37 61|protein methyltransferase 5
HY-100337 "WWL|13 37|0 alpha / beta hydrolase domain
HY-100366 "Lu |21 48|brain - penetrant mGlu4 receptor
HY-10037 "MK59|34 65|5-Lipoxygenase - activating protein
HY-10037 "MK59|67 70|FLAP
HY-100370 "MRK|50 64|GABAA α5 receptor
HY-100370 "MRK|84 88|GABAA
HY-100407 "JNJ|31 43|mGlu1 receptor
HY-100416A "LY|214 216|CSF
HY-100416A "LY|267 270|NMDA
HY-100416A "LY|322 338|GlyT1 transporters
HY-10042 "Odan|46 55|cathepsin K
HY-10044 "WYE-|57 66|mTOR kinase
HY-10044 "WYE-|120 124|PI3Ks
HY-10045 "AEE7|19 22|EGFR
HY-10045 "AEE7|26 30|ErbB2
HY-100452 "TCS|27 37|OX2 receptor
HY-100452 "TCS|226 250|G - protein coupled receptors
HY-100452 "TCS|361 366|orexin ERK1/2
HY-100452 "TCS|410 420|OX2 receptor
HY-10046 "Pler|17 21|CXCR4
HY-100463 "TPI|4 8|SHP-1
HY-100483 "A-8|37 48|P2X7 receptor
HY-100483 "A-8|98 115|human P2X7 receptors
HY-100514 "GSK|5 30|peptidylarginine deiminase 4
HY-100519 "NVS|27 36|PAK1 - 1 allosteric
HY-100563 "Cyc|45 56|αVβ3 integrin
HY-100576 "NH1|33 65|eukaryotic elongation factor 2 kinase
HY-100576 "NH1|67 72|eEF-2K
HY-100583 "(-)|33 48|estrogen receptor
HY-100583 "(-)|55 56|Ki
HY-100614 "AS1|14 18|STAT6
HY-10067 "Y-33|14 17|ROCK
HY-100686 "U93|5 17|GABAA receptor
HY-100686 "U93|150 174|recombinant GABAA receptors
HY-100686 "U93|413 416|GABA
HY-100686 "U93|461 479|GABA - bound receptors
HY-100686 "U93|504 522|accelerates receptor
HY-10069 "Y-33|29 32|ROCK
HY-10071 "Y-27|32 37|ROCK - I
HY-10071 "Y-27|41 47|ROCK - II
HY-10071 "Y-27|53 54|Ki
HY-10071 "Y-27|73 78|ROCK - I
HY-10071 "Y-27|82 88|ROCK - II
HY-100736 "ML3|153 168|lysophospholipase 1 14-fold serine hydrolases
HY-100737 "ML3|21 44|acyl protein thioesterase 2
HY-100737 "ML3|66 67|Ki
HY-100769 "YL0|51 64|5-HT1A receptor
HY-100769 "YL0|85 101|serotonin reuptake
HY-100769 "YL0|267 294|5-HT1A receptor IC50:1.78±0.34
HY-100769 "YL0|503 516|5-HT1A receptor
HY-10087 "Navi|30 47|Bcl-2 family protein
HY-10087 "Navi|76 79|anti
HY-10087 "Navi|90 108|Bcl-2 family proteins
HY-10087 "Navi|116 121|Bcl - xL
HY-10087 "Navi|123 127|Bcl-2
HY-10087 "Navi|131 135|Bcl - w
HY-10087 "Navi|142 143|Ki
HY-10088 "Zibo|53 64|ETA - receptor
HY-10088 "Zibo|66 84|endothelin A receptor
HY-10088 "Zibo|219 222|ET-1
HY-10088 "Zibo|238 248|ETA receptor
HY-100895 "SAR|25 28|JAK1
HY-100895 "SAR|30 33|JAK2
HY-100895 "SAR|37 40|JAK3
HY-100946 "CEP|59 63|c - Met
HY-101023 "MK-|34 76|hypoxia - inducible factor prolyl hydroxylase 1 - 3
HY-101023 "MK-|78 85|HIF PHD1 -
HY-101032 "RIP|62 89|receptor - interacting protein 1
HY-101032 "RIP|91 94|RIP1
HY-101039A "AR|54 68|M δ opioid receptor
HY-101053 "Src|39 55|Inhibitor Src tyrosine kinase
HY-101053 "Src|88 90|Src
HY-101053 "Src|101 103|Lck
HY-10108 "LY29|31 34|PI3 K
HY-10109 "AS-6|70 71|Ki
HY-101094 "Oca|54 58|5-HT2
HY-101094 "Oca|62 71|dopamine D2
HY-101094 "Oca|87 92|5-HT1A
HY-101094 "Oca|147 151|5-HT2
HY-101094 "Oca|153 173|a1-adrenergic receptor
HY-101094 "Oca|175 184|dopamine D2
HY-101094 "Oca|186 196|histamine H1
HY-101094 "Oca|200 220|a2-adrenergic receptor
HY-10111 "TG10|16 20|PI3Kγ
HY-10111 "TG10|52 54|235
HY-101120 "666|23 26|CREB
HY-101126 "TP-|23 31|Pim kinase
HY-101126 "TP-|45 46|Ki
HY-101126 "TP-|66 70|Pim-1
HY-10115 "PI-1|10 13|PI3 K
HY-10115 "PI-1|17 20|mTOR
HY-10115A "PI-|22 25|PI3 K
HY-10115A "PI-|29 32|mTOR
HY-101177 "Nal|88 89|δ opioid receptor Ki
HY-101192 "GSK|52 58|epstein
HY-101214 "UK-|8 41|urokinase - type plasminogen activator
HY-101214 "UK-|43 45|uPA
HY-101214 "UK-|61 62|Ki
HY-10122 "Silo|51 73|α1-adrenoceptor with high uroselectivity ;
HY-10122 "Silo|262 262|-
HY-10122 "Silo|500 501|of
HY-10122 "Silo|543 553|the alpha 1b-
HY-10122 "Silo|557 567|alpha 1d - ARs
HY-10122 "Silo|660 678|- expressing tissue ) ,
HY-10126 "AZD1|112 118|Aurora B
HY-10127 "AZD1|54 60|Aurora B
HY-101270 "STK|9 19|STK16 kinase
HY-101271 "WAY|18 34|estrogen receptor β
HY-101272 "GDC|44 45|Ki
HY-10128 "ZM-4|8 19|aurora kinase
HY-10128 "ZM-4|54 60|aurora A
HY-101285 "DMU|73 78|CYP1A1
HY-101294 "TTP|11 26|epoxide hydrolase
HY-101296 "PD1|16 34|FGFR1 tyrosine kinase
HY-101312 "Cil|67 71|PDE3A
HY-101383 "PF-|80 101|recombinant human Nav1.8
HY-101384A "Ro|34 51|dopamine D4 receptor
HY-101384A "Ro|71 72|Ki
HY-101419 "CYM|27 48|allosteric S1P3 receptor
HY-101430 "PGD|21 22|DP
HY-101458A "IT|25 29|t dihydrochloride CXCR4
HY-101458A "IT|49 54|CXCL12
HY-101458A "IT|56 60|CXCR4
HY-101502A "SB|42 52|C3a receptor
HY-101563 "GSK|47 79|protein arginine methyltransferase 5
HY-10162 "Olap|38 41|PARP
HY-10171 "NPS-|150 161|respectively
HY-10171 "NPS-|264 264|IC50 (
HY-10171 "NPS-|381 383|microM the
HY-101736 "AMG|29 46|vanilloid receptor 1
HY-101772 "Zir|45 47|ATX
HY-101772 "Zir|79 80|Ki
HY-10178 "PHA-|9 20|aurora kinase
HY-10178 "PHA-|58 64|aurora A
HY-10178 "PHA-|66 66|B
HY-10179 "Danu|8 14|pyrrolo
HY-10179 "Danu|27 38|pyrazole aurora kinase
HY-10179 "Danu|74 80|Aurora A
HY-10180 "MLN8|39 51|aurora A kinase
HY-10181 "Dasa|27 29|Bcr - Abl
HY-10181 "Dasa|42 55|Src family tyrosine kinase
HY-10181 "Dasa|96 98|Abl
HY-10181 "Dasa|100 102|Src
HY-10181 "Dasa|104 108|c - Kit
HY-10181 "Dasa|112 121|c - KitD816V
HY-10181A "Das|34 38|AblWT
HY-10181A "Das|40 42|Src
HY-10181A "Das|94 100|c - KitWT
HY-10181A "Das|102 111|c - KitD816V
HY-10182 "CHIR|81 99|closest homologs CDC2
HY-10182 "CHIR|103 106|ERK2
HY-10182 "CHIR|121 134|protein kinases
HY-10182A "CHI|87 91|GSK-3
HY-10182A "CHI|123 126|homologs CDC2 ERK2
HY-10182A "CHI|141 154|protein kinases
HY-10182B "CHI|86 90|GSK-3
HY-10182B "CHI|122 125|homologs CDC2 ERK2
HY-10182B "CHI|140 153|protein kinases
HY-101843 "ML2|32 44|Kv7.4 channels
HY-101872 "GSK|31 40|RIP3 kinase
HY-101903 "BMS|53 76|fatty acid binding protein 4
HY-101903 "BMS|89 90|Ki
HY-10191 "Losm|26 38|IGF-1 receptor
HY-10191 "Losm|42 56|insulin receptor
HY-10192 "NVP-|32 34|ALK
HY-10192 "NVP-|82 84|ALK
HY-101920 "Aut|102 117|lipid kinase VPS34
HY-101923A "LY|27 30|ULK1
HY-10193 "AZD-|33 36|JAK1
HY-10193 "AZD-|40 43|JAK2
HY-10194 "YM-1|4 11|survivin
HY-101941 "BTK|13 15|BTK
HY-10197 "Wort|91 105|Polo - like kinase
HY-101980 "AZD|11 29|adenosine 2A receptor
HY-101980 "AZD|31 34|A2AR
HY-101980 "AZD|50 51|Ki
HY-10200 "BMS-|41 73|insulin - like growth factor 1 receptor
HY-10200 "BMS-|75 110|IGF-1R)/insulin receptor family kinases
HY-10200 "BMS-|112 113|IR
HY-10200 "BMS-|152 153|Ki
HY-10200 "BMS-|207 209|RON
HY-102003 "Ruc|20 23|PARP
HY-102003 "Ruc|29 30|Ki
HY-102003 "Ruc|86 89|PARP
HY-10201 "Sora|5 14|Bay 43 - 9006
HY-10201 "Sora|75 79|Raf-1
HY-10201 "Sora|81 85|B - Raf
HY-10201A "Sor|73 77|Raf-1
HY-10201A "Sor|79 83|B - Raf
HY-10202 "Tand|134 141|100-fold
HY-10202 "Tand|304 310|PKC , PKA
HY-10202 "Tand|552 558|Molm-13
HY-102020 "RG3|40 58|brain - penetrant DcpS
HY-102023 "GNF|9 31|aryl hydrocarbon receptor
HY-102023 "GNF|33 35|AHR
HY-102023 "GNF|80 82|AHR
HY-102023 "GNF|104 106|AHR
HY-10204 "OSI-|25 25|,
HY-10204 "OSI-|136 147|Flt-3 and Abl .
HY-10204 "OSI-|233 248|: OSI-930 inhibits
HY-10204 "OSI-|252 255|cell
HY-10204 "OSI-|279 282|cell
HY-10205 "Cedi|59 77|VEGFR tyrosine kinase
HY-10205 "Cedi|145 149|c - Kit
HY-102058 "WM-|30 34|KAT6A
HY-10206 "Amuv|15 19|multi
HY-10206 "Amuv|75 79|receptor tyrosine kinases c - Kit
HY-10206 "Amuv|88 92|c - Kit
HY-10206 "Amuv|101 105|c - Kit
HY-10206 "Amuv|107 110|V560
HY-10206 "Amuv|114 118|c - Kit
HY-10207 "Dovi|48 78|fibroblast growth factor receptor 3
HY-10207 "Dovi|80 84|FGFR3
HY-10208 "Pazo|73 77|c - Kit
HY-10208 "Pazo|79 83|FGFR1
HY-10208 "Pazo|88 92|c - Fms
HY-10209A "Mas|99 101|ABL
HY-10209A "Mas|105 109|c - Fms
HY-10212 "BIIB|56 57|Ki
HY-10215 "Lumi|6 8|NVP
HY-10223 "CUDC|23 26|HDAC
HY-10223 "CUDC|28 31|EGFR
HY-10223 "CUDC|36 39|HER2
HY-10225 "Beli|14 17|HDAC
HY-10227 "Bort|22 34|20S proteasome
HY-10227 "Bort|49 50|Ki
HY-10228 "Mote|162 166|of?VEGFR1/2/3?with?IC50s?of 2 nM/3 PDGFR
HY-10229 "Mote|178 182|PDGFR
HY-10234 "Sara|24 26|Src
HY-10234 "Sara|65 69|c - Src
HY-10234 "Sara|71 73|Lck
HY-10234 "Sara|75 79|c - YES
HY-10234 "Sara|81 83|Lyn
HY-10234 "Sara|85 87|Fyn
HY-10234 "Sara|131 145|tyrosine kinases
HY-10237 "Boce|82 83|bioavailable HCV NS3 protease Ki
HY-10238 "Dano|8 21|NS3/4A protease
HY-10238 "Dano|34 48|hepatitis C virus
HY-10249 "GSK-|28 30|Akt
HY-10253 "AG-1|362 363|μM
HY-10253 "AG-1|365 376|respectively
HY-10253 "AG-1|386 391|breast
HY-10253 "AG-1|469 479|and induced apoptosis in
HY-10254 "PD03|32 34|MEK
HY-10255A "Sun|6 12|SU 11248
HY-10259A "PD |44 67|AT2 angiotensin II receptor
HY-10261 "Afat|29 38|EGFR family
HY-10261 "Afat|102 110|EGFRL858R
HY-10261 "Afat|112 116|T790 M
HY-10261 "Afat|120 123|HER2
HY-10261A "Afa|29 38|EGFR family
HY-10261A "Afa|102 110|EGFRL858R
HY-10261A "Afa|112 116|T790 M
HY-10261A "Afa|120 123|HER2
HY-10268 "Betr|60 62|efficacious factor Xa fXa
HY-10295 "SB 2|21 32|p38 MAP kinase
HY-10295 "SB 2|68 70|p38
HY-10299 "GSK-|16 25|allosteric
HY-10299 "GSK-|37 49|CENP - E kinesin
HY-10299 "GSK-|55 60|ATPase
HY-10299 "GSK-|74 75|Ki
HY-103007 "TC-|42 46|GPR39
HY-10301 "MK-3|110 116|AM1 , AM2
HY-10302 "MK-3|88 89|bioavailable CGRP receptor Ki
HY-103020 "BAY|57 78|benzimidazoles 1 ) kinase
HY-103022 "Rep|28 30|ALK
HY-103022 "Rep|32 35|ROS1
HY-103022 "Rep|91 93|SRC
HY-103022 "Rep|97 99|ALK
HY-103022 "Rep|101 103|ALK
HY-103022 "Rep|113 121|ALK L1196 M
HY-103050 "ML-|79 83|PDE4A
HY-103088 "E70|67 68|EP4 Ki
HY-103107 "LY3|16 29|5-HT1F receptor
HY-103107 "LY3|42 43|Ki
HY-103161 "ABT|27 41|adenosine kinase
HY-103161 "ABT|43 44|AK
HY-103186 "MRS|25 28|A(2B
HY-10320 "Dora|30 36|796 p38 MAPK
HY-10320 "Dora|76 80|B - Raf
HY-10321 "PD17|12 16|FGFR1
HY-10321 "PD17|115 119|FGFR1
HY-10321 "PD17|124 128|PDGFR
HY-10321 "PD17|132 136|c - Src
HY-10322 "Faln|45 62|EGFR tyrosine kinase
HY-10322 "Faln|111 115|ErbB2
HY-10322 "Faln|144 165|related tyrosine kinases
HY-10325 "CL-3|78 91|is able to overcome
HY-10325 "CL-3|204 204|-
HY-103254 "ML2|132 141|β - arrestin
HY-10326 "GW78|69 87|TGF - β type II receptor
HY-10326 "GW78|91 111|activin type II receptor
HY-10326 "GW78|140 156|BMP type II receptor
HY-10329 "JNJ-|15 26|aurora kinase
HY-10329 "JNJ-|102 109|Aurora - A
HY-10329 "JNJ-|113 120|Aurora - B
HY-10331 "Rego|21 25|multi
HY-10331 "Rego|128 130|receptor tyrosine kinase RET
HY-10331 "Rego|134 138|Raf-1
HY-10331A "Reg|67 69|RET
HY-10331A "Reg|73 77|Raf-1
HY-10336 "Briv|105 110|FGFR-1
HY-10337 "Briv|97 102|FGFR-1
HY-10337 "Briv|123 129|PDGFR - β
HY-10338 "Fore|19 32|tyrosine kinase
HY-10339 "KW-2|5 9|multi
HY-10339 "KW-2|36 39|targeted kinase FLT3
HY-10339 "KW-2|41 43|ABL
HY-10339 "KW-2|45 52|ABLT315I
HY-10339 "KW-2|56 67|Aurora kinase
HY-103531 "CGP|7 19|GABAB receptor
HY-10358 "MK 2|28 30|Akt
HY-103610 "4,4|19 49|human intestinal carboxyl esterase
HY-103610 "4,4|69 70|Ki
HY-10366 "BI-7|45 47|JNK
HY-10366 "BI-7|59 67|JNK kinase
HY-103663 "EED|46 60|US20160176882 A1
HY-10367A "Can|64 67|irreversible EGFR
HY-10367A "Can|101 105|EGFR ErbB2
HY-103682 "PF-|46 47|Ki
HY-103683 "PF-|28 37|allosteric
HY-103683 "PF-|49 52|AMPK
HY-10372 "PP12|62 65|mTOR
HY-10372 "PP12|67 72|DNK - PK
HY-10372 "PP12|74 79|VEGFR2
HY-10372 "PP12|81 83|Src
HY-10372 "PP12|85 89|PDGFR
HY-10395 "PD17|123 125|and
HY-10395 "PD17|253 254|. IC50 nM
HY-10395 "PD17|338 338|a
HY-10395 "PD17|365 366|to
HY-10395 "PD17|422 424|and
HY-10395 "PD17|553 562|activity in
HY-10395 "PD17|575 583|cancer cells with
HY-10403 "PH-7|510 514|or of 3 nM
HY-10403 "PH-7|517 523|primary
HY-10406 "Talm|42 44|p38
HY-10407 "SU 5|94 98|receptor tyrosine kinase FGFR1
HY-10409 "Fedr|39 42|JAK2
HY-10409 "Fedr|95 98|JAK1
HY-10409 "Fedr|102 105|JAK3
HY-10410 "TG10|15 18|JAK2
HY-10410 "TG10|54 57|Flt3
HY-10410 "TG10|61 63|RET
HY-10410 "TG10|109 112|JAK2
HY-10410 "TG10|117 120|JAK3
HY-10410 "TG10|148 155|MPLW515L
HY-10418 "AH 6|4 10|an EP and
HY-10418 "AH 6|250 253|4.45
HY-10418 "AH 6|330 331|or
HY-10418 "AH 6|458 478|inhibited PGE2-induced
HY-10422 "AZD-|37 46|mTOR kinase
HY-10424 "Milc|41 43|CDK
HY-10424 "Milc|119 125|Tropomyosin receptor kinase cyclin A
HY-10424 "Milc|132 138|cyclin H
HY-10424 "Milc|145 152|cyclin D1
HY-10424 "Milc|154 157|CDK4
HY-10424 "Milc|159 165|cyclin E
HY-10424 "Milc|172 178|cyclin B
HY-10431 "SB-4|41 45|TGF - β
HY-10432A "A 8|33 60|TGF - β type I receptor ALK5 kinase
HY-10432A "A 8|62 65|type
HY-10432A "A 8|186 189|activin I nodal receptor ALK7 ALK7
HY-10439 "HPGD|11 12|is
HY-10439 "HPGD|73 81|inhibitor
HY-10439 "HPGD|305 305|an )
HY-10439 "HPGD|357 358|to
HY-10439 "HPGD|474 475|L-
HY-10439 "HPGD|517 521|, 10000
HY-10439 "HPGD|566 568|3.9
HY-10440 "Vism|31 38|hedgehog
HY-10440 "Vism|85 88|P - gp
HY-10446 "Pral|326 350|reduced folate carrier type 1
HY-10452 "Ixaz|46 73|chymotrypsin - like proteolytic
HY-10452 "Ixaz|85 97|20S proteasome
HY-10452 "Ixaz|119 120|Ki
HY-10453 "Ixaz|81 108|chymotrypsin - like proteolytic
HY-10453 "Ixaz|122 134|20S proteasome
HY-10453 "Ixaz|153 154|Ki
HY-10456 "TAK-|4 4|a
HY-10456 "TAK-|128 137|IC50 value :
HY-10458 "PF-5|58 60|FAK
HY-10458 "PF-5|64 73|Pyk2 kinase
HY-10459 "PF-5|50 52|FAK
HY-10459 "PF-5|56 65|Pyk2 kinase
HY-10461 "PF-5|25 27|FAK
HY-10461 "PF-5|91 93|catalytic fragment FAK
HY-10468 "NM10|301 313|Target HCV HCV polymerase
HY-10472 "LY28|259 268|β - secretase cathepsin D
HY-10472 "LY28|270 275|pepsin
HY-10472 "LY28|279 283|renin
HY-10474 "Tork|4 8|PP 242
HY-10474 "Tork|40 43|mTOR
HY-10492 "Dina|25 27|CDK
HY-10492 "Dina|73 76|of 1 CDK9
HY-10493 "Cobi|37 52|cytochrome P450 3A
HY-10493 "Cobi|54 58|CYP3A
HY-10497 "BMS-|17 19|Met
HY-10501A "SU1|13 17|multi
HY-10510 "BI-D|33 43|RSK isoforms
HY-10514 "BX79|80 82|PKA
HY-10514 "BX79|84 86|PKC
HY-10521 "Dara|25 61|lipoprotein - associated phospholipase A2
HY-10521 "Dara|63 69|Lp - PLA2
HY-10527 "Tela|33 45|small molecule
HY-10531 "The |57 60|HER2
HY-10531 "The |143 146|HER2
HY-10542 "GW 5|23 27|c - Raf
HY-10542 "GW 5|91 94|MEK1
HY-10542 "GW 5|110 114|c - Src
HY-10542 "GW 5|116 121|p38 MAP
HY-10542 "GW 5|131 135|c - Fms
HY-10564 "Sarp|41 55|5-HT2 antagonist
HY-10564 "Sarp|179 188|Recepter at the 5HT2A
HY-10569 "Pone|42 73|sphingosine-1-phosphate receptor 1
HY-10572 "Efav|27 60|wild - type HIV-1 reverse transcriptase
HY-10572 "Efav|66 67|Ki
HY-10578 "PD 1|40 51|p38 MAP kinase
HY-10579 "Plur|23 26|ERK1
HY-10579 "Plur|103 106|RSK3
HY-10580 "GSK |102 107|GSK-3α
HY-10590 "TWS1|62 64|wnt
HY-10590 "TWS1|66 74|β - catenin
HY-10617 "Ruca|67 68|Ki
HY-10617 "Ruca|139 142|PARP
HY-10626 "T090|40 42|FXR
HY-10655 "Palo|250 254|human
HY-10655 "Palo|257 273|receptors almost as
HY-10655 "Palo|284 289|cold U -
HY-10678 "BMS-|113 116|PPARα PPAR
HY-10678 "BMS-|118 121|GAL4
HY-10680 "MK-6|115 126|GPR109A. Ki Human GPR109A
HY-10684 "Prid|49 66|dopamine D2 receptor
HY-10684 "Prid|68 70|D2R
HY-10684 "Prid|112 132|towards sigma 1 receptor
HY-10684 "Prid|142 143|Ki
HY-107145 "Nin|113 117|small molecule tyrosine kinase c - Met
HY-107145A "Ni|106 110|small molecule tyrosine kinase c - Met
HY-107384 "Asi|16 30|κ opioid receptor
HY-107424 "BAY|48 64|BRPF2 bromodomains
HY-107723 "CGP|31 52|neuropeptide Y5 receptor
HY-107723 "CGP|68 69|Ki
HY-107723 "CGP|105 114|Y1 receptor
HY-107723 "CGP|116 117|Ki
HY-107723 "CGP|130 139|Y2 receptor
HY-107723 "CGP|141 142|Ki
HY-107765 "LY2|26 50|retinoic acid receptor gamma
HY-107765 "LY2|72 73|Ki
HY-10790 "Cilo|230 235|: PDE 4 Cilomilast Ki ≈100
HY-10804 "CCT |32 43|aurora kinase
HY-10804 "CCT |80 86|aurora A
HY-10804 "CCT |88 88|B
HY-10805A "Alm|47 61|orexin 1 receptor
HY-10805A "Alm|63 82|OX1)/orexin 2 receptor
HY-10805A "Alm|102 103|Ki
HY-10820 "Peme|27 28|Ki
HY-10820 "Peme|93 111|thymidylate synthase
HY-10820 "Peme|117 138|TS dihydrofolate reductase
HY-10820 "Peme|140 143|DHFR
HY-108329 "AM-|31 49|receptor potential A1
HY-108331 "3-T|13 17|P SIRT3
HY-108463 "A-9|16 28|TRPA1 receptor
HY-108463 "A-9|72 88|rat TRPA1 receptors
HY-108474 "Nol|67 85|thymidylate synthase
HY-108474 "Nol|143 144|cofactor Ki
HY-108474 "Nol|154 179|human thymidylate synthase[1
HY-10864 "URB5|90 109|- related targets . IC50
HY-10864 "URB5|115 115|:
HY-10864 "URB5|122 129|1 ] Target
HY-10864 "URB5|531 544|. [ 3H]anandamide
HY-10864 "URB5|555 559|in rat
HY-10865 "LY21|82 104|fatty acid amide hydrolase
HY-10871 "Oten|25 46|cannabinoid receptor CB1
HY-10871 "Oten|61 62|Ki
HY-10871 "Oten|115 130|human CB2 receptor
HY-10888 "Istr|47 66|adenosine A2A receptor
HY-10888 "Istr|81 82|Ki
HY-10895A "SB-|271 280|no effect on
HY-10898 "SB-6|112 123|peptide orexin OX1 receptor OX2 receptors
HY-10898 "SB-6|152 162|OX1 receptor
HY-10898 "SB-6|224 242|purinergic receptors
HY-10898 "SB-6|322 332|OX1 receptor
HY-10900 "TCS |17 30|orexin receptor
HY-10900 "TCS |42 43|Ki
HY-10900 "TCS |65 67|OX2
HY-10900 "TCS |71 82|OX1 receptors
HY-10900 "TCS |113 114|Ki
HY-10900 "TCS |116 126|OX2 receptor
HY-10900 "TCS |133 134|Ki
HY-10900 "TCS |136 146|OX1 receptor
HY-10900 "TCS |164 174|OX1 receptor
HY-109044 "Tap|15 37|aryl hydrocarbon receptor
HY-109044 "Tap|39 41|AhR
HY-109049 "Ada|46 48|Wnt
HY-109049 "Ada|96 98|TCF
HY-10929 "UNC0|138 140|GLP
HY-10930 "UNC0|295 298|and 9
HY-10930 "UNC0|374 384|( . 40-fold more
HY-10942 "VER-|5 7|NVP
HY-10942 "VER-|53 57|BEP800 Hsp90
HY-10943 "GNF-|9 12|  inhibits Bcr -
HY-10943 "GNF-|48 55|and 61 nM ,
HY-10943 "GNF-|114 121|) Target :
HY-10943 "GNF-|175 181|capable
HY-10943 "GNF-|199 200|inhibiting to
HY-10943 "GNF-|268 273|generation Bcr - Abl kinase
HY-10943 "GNF-|325 325|)
HY-10961 "Mome|44 47|JAK1
HY-10961 "Mome|49 52|JAK2
HY-10961 "Mome|123 126|JAK3
HY-10962 "Mome|58 61|JAK1
HY-10962 "Mome|63 66|JAK2
HY-10962 "Mome|111 114|JAK3
HY-10969 "Obat|22 40|BCL-2 family proteins
HY-10969 "Obat|51 55|BCL-2
HY-10969 "Obat|61 62|Ki
HY-10971 "Alis|25 37|Aurora A kinase
HY-10974 "MK-0|68 71|with
HY-10974 "MK-0|76 77|of
HY-10974 "MK-0|274 281|cells [ 1 ]
HY-10974 "MK-0|283 289|In vitro
HY-10974 "MK-0|309 329|- intracellular domain (
HY-10974 "MK-0|348 378|subsequent nuclear translocation [
HY-10977 "Tivo|46 55|VEGFR 1/2/3
HY-10981 "Lenv|210 214|tyrosine kinase FGFR1
HY-10984 "Poma|72 76|TNF - α
HY-10987A "ENM|8 12|multi
HY-10987A "ENM|85 91|targeted kinase Aurora A
HY-10987A "ENM|122 126|FGFR1
HY-10987A "ENM|134 136|Src
HY-10991 "MGCD|338 347|, 0.33 L/(kg
HY-10991 "MGCD|502 507|to be 12
HY-10992 "AZD-|44 46|checkpoint kinase Chk
HY-10992 "AZD-|77 80|Chk1
HY-10993 "Adav|33 36|Wee1
HY-10995 "Toza|9 28|adenosine A2A receptor
HY-10995 "Toza|44 45|Ki
HY-10997 "Ibru|40 42|Btk
HY-10999 "Tram|14 16|MEK
HY-10999 "Tram|38 41|MEK1
HY-10999 "Tram|45 48|MEK2
HY-10999 "Tram|104 124|Trametinib DMSO solvate
HY-10999 "Tram|126 128|Cat
HY-10999A "Tra|26 28|MEK
HY-11001 "PHA-|30 32|CDK
HY-11001 "PHA-|53 56|Cdk2
HY-11001 "PHA-|136 157|glycogen synthase kinase
HY-11004 "AZ62|8 16|Raf kinase
HY-11004 "AZ62|53 57|B - Raf
HY-11004 "AZ62|59 68|B - RafV600E
HY-11004 "AZ62|73 79|c - Raf-1
HY-11006 "KU-5|101 104|PK mTOR
HY-11006 "KU-5|106 110|PI 3-K
HY-11006 "KU-5|112 114|ATM
HY-11009 "CGP6|70 72|PKC
HY-11027 "MK-0|14 29|androgen receptor
HY-11027 "MK-0|58 59|AR
HY-110279 "Oge|111 112|Ki
HY-110279 "Oge|160 161|Ki
HY-110279 "Oge|171 184|5-HT2B receptor
HY-110279 "Oge|186 191|Ogerin
HY-110390 "GR1|8 30|triacyglycerol hydrolase
HY-11054 "TH-2|189 198|Aβ peptides
HY-11054 "TH-2|328 333|Aβ1 - 42
HY-11054 "TH-2|463 472|Aβ peptides
HY-11054 "TH-2|521 522|TH
HY-11063 "Fing|8 29|sphingosine 1-phosphate
HY-11068 "SB 2|25 31|p38 MAPK
HY-11068 "SB 2|100 102|ERK
HY-11068 "SB 2|104 107|JNK1
HY-11100 "Asen|25 26|2A
HY-11100 "Asen|34 35|5A
HY-11100 "Asen|60 61|Ki
HY-11101 "Alen|24 50|farnesyl diphosphate synthase
HY-11102 "RO49|86 90|secretase Notch
HY-11106 "Nint|13 27|BIBF 1120 esylate
HY-11107 "PHA-|42 46|c - Met
HY-11108 "R406|117 130|in vitro : R406 is
HY-11108 "R406|132 137|potent
HY-111341 "AZD|38 57|human Myeloperoxidase
HY-111341 "AZD|59 61|MPO
HY-111371 "PF-|10 28|phosphodiesterase 2A
HY-111371 "PF-|30 34|PDE2A
HY-111388A "SE|55 58|CDK8
HY-111388A "SE|95 98|CDK8
HY-111388A "SE|185 194|SEL120 - 34A
HY-111388A "SE|226 229|CDK9
HY-111388A "SE|353 361|STAT1 S727
HY-111388A "SE|365 369|STAT5
HY-111455 "LP-|70 71|penetrant 5-HT7 receptor Ki
HY-111455 "LP-|104 117|5-HT1A receptor
HY-111455 "LP-|119 120|Ki
HY-111455 "LP-|131 140|D2 receptor
HY-111455 "LP-|142 143|Ki
HY-111457 "BAY|113 135|human neutrophil elastase
HY-111457A "BA|77 99|human neutrophil elastase
HY-111530 "GST|15 44|glutathione S - transferase omega 1
HY-112061 "8-O|57 62|5-HT1A
HY-112061 "8-O|67 68|Ki
HY-112096 "eCF|52 80|non - receptor tyrosine kinase Src
HY-112158 "NSC|6 9|ERGi
HY-112161 "BMS|48 69|Bruton ’s tyrosine kinase
HY-112161 "BMS|71 73|BTK
HY-112167 "GDC|58 61|- molecule Chk1
HY-112215 "ARQ|62 64|BTK
HY-112215 "ARQ|99 101|BTK
HY-112215 "ARQ|105 109|C481S
HY-112305 "AZ3|56 58|ATM
HY-112305 "AZ3|89 97|ATM enzyme
HY-112305 "AZ3|119 121|ATM
HY-112316 "BAY|38 40|BET
HY-112316 "BAY|50 57|histones
HY-112316 "BAY|184 188|c - Myc
HY-112316 "BAY|238 239|TR
HY-112627 "CAY|33 35|AhR
HY-112627 "CAY|49 50|Ki
HY-112627 "CAY|77 92|estrogen receptor
HY-112627 "CAY|94 95|Ki
HY-112629 "PDM|27 49|aryl hydrocarbon receptor
HY-112629 "PDM|51 53|AhR
HY-112629 "PDM|71 72|Ki
HY-112708A "PF|25 28|06700841 P - Tosylate JAK1
HY-112709 "LIT|79 80|Ki
HY-112820 "Chl|71 87|ryanodine receptor
HY-112842 "MBQ|10 12|Rac
HY-112842 "MBQ|14 18|Cdc42
HY-112842 "MBQ|48 55|Rac 1/2/3
HY-112842 "MBQ|66 70|Cdc42
HY-113134 "25-|93 109|Toll - like receptor
HY-113134 "25-|191 193|IgA
HY-114025 "H4 |39 57|histamine H4 receptor
HY-114403 "VU6|55 72|glutamate receptor 7
HY-115364 "Par|48 66|destabilizes tubulin
HY-117273 "AZ3|24 33|BRAF kinase
HY-117273 "AZ3|73 87|V600E mutant BRAF
HY-117273 "AZ3|195 197|p38
HY-117273 "AZ3|209 213|CSF1R
HY-117273 "AZ3|226 245|Anti - tumor activity[1
HY-117288 "S55|37 41|BCL-2
HY-117288 "S55|57 58|Ki
HY-12001 "WZ31|19 22|EGFR
HY-12001 "WZ31|82 86|T790 M
HY-12001 "WZ31|102 114|EGFRE746_A750
HY-12001 "WZ31|116 120|T790 M
HY-12001 "WZ31|124 127|EGFR
HY-12003 "SNS-|23 34|aurora kinase
HY-12003 "SNS-|69 75|aurora A
HY-12003 "SNS-|77 77|B
HY-12005 "Fing|21 42|sphingosine 1-phosphate
HY-12008 "Erlo|33 42|EGFR kinase
HY-120081A "Me|91 112|quinuclidinyl benzilate
HY-120081A "Me|123 140|muscarinic receptor
HY-12009 "Pazo|76 80|c - Kit
HY-12009 "Pazo|82 86|FGFR1
HY-12009 "Pazo|91 95|c - Fms
HY-12010 "AC48|61 68|with IC50
HY-12010 "AC48|75 77|20 and
HY-12010 "AC48|107 115|> 100-fold
HY-12010 "AC48|124 125|, c
HY-12010 "AC48|183 191|HER1 / HER2
HY-12010 "AC48|340 357|Biochemical studies
HY-12014 "SU11|14 16|Met
HY-12014 "SU11|65 68|EGFR
HY-12014 "SU11|71 74|Tie2
HY-12016 "KU-5|12 14|ATM
HY-12016 "KU-5|37 38|Ki
HY-12016 "KU-5|90 92|ATM
HY-12016 "KU-5|112 115|PI3K
HY-12016 "KU-5|117 120|PI4 K
HY-12016 "KU-5|128 131|mTOR
HY-12017 "PF-0|520 522|but
HY-12017 "PF-0|526 545|no inhibitory activity
HY-12017A "PF-|527 527|,
HY-12017A "PF-|540 546|, but has
HY-12019 "SGX-|40 49|no activity
HY-12019 "SGX-|64 66|Raf
HY-12020 "TW-3|28 29|Ki
HY-12020 "TW-3|63 67|Bcl-2
HY-12020 "TW-3|71 76|Bcl - xL
HY-12024 "Alve|40 44|Hsp90
HY-12024 "Alve|55 59|Hsp90
HY-12026 "WZ40|19 22|2 EGFR
HY-12026 "WZ40|67 75|EGFRL858R
HY-12026 "WZ40|77 81|T790 M
HY-12026 "WZ40|113 117|T790 M
HY-12031 "U012|31 34|MEK1
HY-12031 "U012|38 41|MEK2
HY-12032 "AG14|32 33|Ki
HY-12034 "WYE-|21 24|mTOR
HY-12035 "AMG-|67 69|9.3
HY-12035 "AMG-|78 80|: c -
HY-12035 "AMG-|337 349|minutes shows a
HY-12035 "AMG-|356 359|time
HY-12036 "GSK1|49 52|mTOR
HY-12041 "SP60|34 36|JNK
HY-12041 "SP60|72 75|JNK1
HY-12041 "SP60|77 80|JNK2
HY-12043 "SB 5|25 58|transforming growth factor β1 receptor
HY-12043 "SB 5|60 63|ALK5
HY-12044 "Cabo|8 15|S - malate
HY-12044 "Cabo|34 56|receptor tyrosine kinases
HY-12044 "Cabo|85 89|c - Met
HY-12046 "PIK-|18 30|synthetic PI4 K
HY-12047 "Pona|29 33|multi
HY-12047 "Pona|105 107|targeted kinase Abl
HY-12047 "Pona|123 127|FGFR1
HY-12047 "Pona|132 134|Src
HY-12048 "Chel|51 64|protein kinase C
HY-12049 "CCT |9 20|aurora kinase
HY-12049 "CCT |59 65|aurora A
HY-12049 "CCT |67 67|B
HY-12050 "CP-6|36 40|PDGFR
HY-12054 "Hesp|35 47|aurora B kinase
HY-12057 "Vemu|50 60|B - RAF kinase
HY-12057 "Vemu|96 102|c - RAF-1
HY-12058 "AZD8|38 41|MEK1
HY-12058 "AZD8|43 46|MEK2
HY-12059 "AT78|36 39|Akt1
HY-12059 "AT78|60 62|PKA
HY-12059A "AT7|52 55|Akt1
HY-12059A "AT7|76 78|PKA
HY-12061 "KU-6|15 23|ATM kinase
HY-12066 "GSK1|99 99|:
HY-12066 "GSK1|113 120|selected
HY-12066 "GSK1|224 235|respectively
HY-12066 "GSK1|296 297|in
HY-12066 "GSK1|408 414|peptide
HY-12066 "GSK1|521 528|enhanced
HY-12066 "GSK1|552 553|of
HY-12066 "GSK1|570 576|in the glucose
HY-12067 "R406|14 16|Syk
HY-12067 "R406|44 45|Ki
HY-12067 "R406|69 77|Syk kinase
HY-12069 "SB-7|27 43|mitotic kinesin KSP
HY-12069 "SB-7|55 56|Ki
HY-12071A "LDN|21 23|BMP
HY-12071A "LDN|58 61|ALK2
HY-12072 "Lck |43 61|inhibitors of Lck with
HY-12072 "Lck |68 72|value
HY-12072 "Lck |79 87|IC50 Value
HY-12076 "BMS |8 18|Met - related
HY-12076 "BMS |31 35|c - Met
HY-12076 "BMS |150 152|related Lck
HY-12076 "BMS |165 168|TrkA
HY-12080 "BX47|63 64|Ki
HY-12080 "BX47|117 120|1 CCR5
HY-12080 "BX47|124 128|CXCR4
HY-12085 "Apre|35 73|type-4 cyclic nucleotide phosphodiesterase
HY-12089 "Torc|221 235|treatment with an
HY-12089 "Torc|403 418|effect μM ) significantly
HY-12090 "Anac|15 18|CETP
HY-12090 "Anac|74 87|C13S CETP mutant
HY-12111 "BMS-|9 24|androgen receptor
HY-12111 "BMS-|26 27|AR
HY-12111 "BMS-|44 59|androgen receptor
HY-12111 "BMS-|61 62|AR
HY-12111 "BMS-|69 70|Ki
HY-12113 "Opro|53 54|CT
HY-12113 "Opro|67 81|20S proteasome β5
HY-12113 "Opro|83 86|LMP7
HY-12113 "Opro|140 141|nM(20S β5
HY-12113 "Opro|143 146|LMP7
HY-12113 "Opro|158 160|20S
HY-12113 "Opro|174 180|anti - MM
HY-12113 "Opro|238 246|caspase-9
HY-12113 "Opro|248 256|caspase-3
HY-12113 "Opro|261 264|PARP
HY-12137 "Vola|20 35|Polo - like kinase 1
HY-12163 "Enti|25 34|class I HDAC
HY-12163 "Enti|79 83|HDAC1
HY-12176 "Alis|23 27|renin
HY-12176 "Alis|78 82|Target renin
HY-12176 "Alis|252 256|renin
HY-12176 "Alis|402 412|plasma renin
HY-12177 "Alis|35 39|iren renin
HY-12177 "Alis|90 94|Target renin
HY-12177 "Alis|264 268|renin
HY-12177 "Alis|414 424|plasma renin
HY-122186 "SGC|24 47|cyclin G - associated kinase
HY-122186 "SGC|49 51|GAK
HY-122186 "SGC|67 68|Ki
HY-12220A "MM-|3 19|HMTase Inhibitor IX
HY-12220A "MM-|33 36|WDR5
HY-12220A "MM-|38 51|MLL interaction
HY-12220A "MM-|95 96|Ki
HY-12222 "INT-|23 40|farnesoid X receptor
HY-12222 "INT-|42 44|FXR
HY-122312 "BAY|47 73|monocarboxylate transporter 1
HY-122312 "BAY|168 187|Anti - tumor activity[1
HY-12235 "PI-3|22 30|PI3 K p110δ
HY-12235 "PI-3|43 44|Ki
HY-12241 "AZ82|12 15|HSET
HY-12241 "AZ82|37 38|Ki
HY-12242 "GBR |185 188|has a
HY-12245 "SB-3|37 53|vanilloid receptor
HY-12245 "SB-3|55 57|VR1
HY-12245 "SB-3|105 109|TRPV1
HY-12248 "Tela|48 58|glutaminase
HY-12270 "T-52|30 45|c - Fos / activator protein
HY-12273 "DMH-|71 74|ALK2
HY-12274 "ML34|28 31|ALK1
HY-12274 "ML34|33 36|ALK2
HY-12274 "ML34|93 96|ALK2
HY-12274 "ML34|127 130|ALK2
HY-12274 "ML34|184 187|ALK2
HY-12278 "K022|10 33|bone morphogenetic protein
HY-12278 "K022|35 37|BMP
HY-12278 "K022|39 51|type I receptor
HY-12278 "K022|93 96|ALK2
HY-12279 "Umbr|23 27|PI3Kδ
HY-12279C "Umb|50 54|PI3Kδ
HY-12283 "Rost|11 14|2238
HY-12283 "Rost|16 17|is
HY-12283 "Rost|139 144|: 1.5 nM
HY-12283 "Rost|230 266|from the dog kidney Na+,K+-ATPase receptor
HY-12283 "Rost|287 292|M ) devoid
HY-12283 "Rost|347 352|showed
HY-12288 "Ozan|24 27|S1P1
HY-12288 "Ozan|31 42|S1P5 receptor
HY-12288 "Ozan|61 69|410±160 pM
HY-12292 "IM-1|55 57|Wnt
HY-12294A "PEA|213 216|high
HY-12294A "PEA|360 360|)
HY-12299 "WH-4|32 34|Lck / Src
HY-12299 "WH-4|64 66|Lck
HY-12299 "WH-4|70 78|Src kinase
HY-12300 "CFI-|71 72|bioavailable PLK4 Ki
HY-12300B "CFI|72 73|bioavailable PLK4 Ki
HY-12301 "MK-3|62 76|molecule Orexin 2 receptor
HY-12301 "MK-3|91 92|Ki
HY-12301 "MK-3|128 142|Orexin 2 receptor
HY-12301 "MK-3|203 217|orexin 2 receptor
HY-12302 "Kenp|26 29|CDK1
HY-12302 "Kenp|31 37|cyclin B
HY-12302 "Kenp|87 90|CDK2
HY-12302 "Kenp|100 103|cyclin A CDK2
HY-12302 "Kenp|105 111|cyclin E
HY-12319A "Car|127 129|cardiomyocytes nM )
HY-12319A "Car|144 146|nM (
HY-12319A "Car|159 166|in vitro :
HY-12319A "Car|371 372|90 of
HY-12319A "Car|386 390|cells
HY-12319A "Car|583 583|cell cardiomyocytes . (
HY-12319A "Car|585 609|diaminopyrimidine ) induces
HY-12319A "Car|640 647|in P19Cl6
HY-12319A "Car|669 681|could activate
HY-12320 "Cycl|9 18|Naramycin A
HY-12320 "Cycl|24 39|eukaryote protein
HY-12325 "GSK2|39 57|β - ketoacyl reductase
HY-12330 "AZD8|5 8|PI3 K
HY-12331 "KRCA|157 160|Ack1
HY-12332 "JW 6|21 42|2 monoacylglycerol lipase
HY-12332 "JW 6|188 196|human MAGL
HY-12332 "JW 6|298 320|fatty acid amide hydrolase
HY-12334 "HTH-|17 21|NUAK1
HY-12334 "HTH-|23 26|ARK5
HY-12343 "ML27|126 141|K(v)7.1 activator
HY-12343 "ML27|186 197|KCNQ channels
HY-12344 "UNC2|110 113|nM(MER FLT3
HY-12344 "UNC2|311 319|Kinome pro
HY-12344A "UNC|124 127|FLT3
HY-12347 "Ro 6|250 260|gerbil brain
HY-12355 "Sipo|96 99|S1P S1P1
HY-12355 "Sipo|103 115|S1P5 receptors
HY-12380 "Atip|61 62|Ki
HY-12380A "Ati|49 50|Ki
HY-12432 "Gilt|16 19|FLT3
HY-12432 "Gilt|21 23|AXL
HY-12452 "Diar|51 54|non - steroidal estrogen receptor β(ER
HY-12452 "Diar|56 56|)
HY-12452 "Diar|83 88|Target
HY-12452 "Diar|90 91|ER
HY-12452 "Diar|101 107|vitro :  
HY-12452 "Diar|206 206|a
HY-12452 "Diar|275 279|of pro
HY-12452 "Diar|314 314|,
HY-12452 "Diar|391 401|alterations
HY-12452 "Diar|449 464|pro - inflammatory
HY-12452 "Diar|474 485|IL-1β and IL-6
HY-12452 "Diar|638 641|Aβ1 -
HY-12452 "Diar|644 662|[ 1 ] . ERβ was expressed
HY-12462 "WS3 |283 286|were
HY-12462 "WS3 |376 376|-
HY-12462 "WS3 |382 384|per
HY-124634 "PZ-|125 134|penetrant pantothenate kinase allosteric
HY-12468 "A-12|46 47|Ki
HY-12470 "PF-4|37 49|casein kinase 1
HY-12493A "LY-|55 60|p70S6 K
HY-12493A "LY-|79 82|S6K1
HY-12494 "LDC1|30 32|Axl
HY-12494 "LDC1|204 220|IC50 < 5 inhibits Tyro3,Axl
HY-12494 "LDC1|257 265|by tracer -
HY-12494 "LDC1|393 410|apparent additional
HY-12494 "LDC1|539 554|NKG2D ligand Rae-1
HY-12496 "NS-1|5 13|selective
HY-12496 "NS-1|647 659|noradrenaline
HY-12496 "NS-1|661 667|induced
HY-12513 "LY30|53 58|I PI3 K isoforms DNA - PK
HY-12513 "LY30|158 161|PK mTOR
HY-12520A "SKF|144 147|D1DR
HY-12520A "SKF|320 333|dopamine D1 receptor serotonin SR-2C
HY-12520A "SKF|335 348|5-HT1C receptor
HY-12520A "SKF|460 472|D1 / D5 receptor
HY-12560A "PNU|196 207|26 resulted in an
HY-12560A "PNU|243 255|MPTP - lesioned
HY-12560A "PNU|259 270|Furthermore ,
HY-12560A "PNU|514 515|and at
HY-12588 "Thia|90 91|Ki
HY-12589 "ZM39|18 21|JAK3
HY-12600 "AZD5|6 8|IAP
HY-12624 "ON12|21 22|of
HY-12624 "ON12|108 111|nM [ 1
HY-12624 "ON12|229 237|lymphomas
HY-12624 "ON12|244 247|. [ 1 ]
HY-12624 "ON12|259 314|low molecular weight multi - kinase inhibitor identified through
HY-12624 "ON12|440 443|Ark5
HY-12624 "ON12|465 470|factor
HY-12624 "ON12|553 553|.
HY-12624 "ON12|571 583|U87 glioma cell
HY-12624 "ON12|608 619|3.4 ± 0.1 μM and
HY-12649 "Y16 |73 88|in inhibiting LARG
HY-12649 "Y16 |129 154|mediated signaling functions
HY-12649 "Y16 |356 371|Cdc42 catalyzed by
HY-12649 "Y16 |503 510|affinity
HY-12649 "Y16 |563 574|Rhosin and Y16
HY-12654 "Moli|36 75|hypoxia - inducible factor prolyl hydroxylase
HY-12654 "Moli|77 82|HIF - PH
HY-12678 "Entr|33 35|Trk
HY-12678 "Entr|45 47|ALK
HY-12678 "Entr|88 90|ALK
HY-12681 "CCT2|73 73|5
HY-12681 "CCT2|93 99|Target :
HY-12681 "CCT2|404 417|probe for - molecule based screening
HY-12681 "CCT2|603 603|1
HY-12681 "CCT2|605 613|CCT251545
HY-12710A "Rau|40 59|α2 adrenergic receptor
HY-12710A "Rau|75 76|Ki
HY-12725 "ML32|79 90|920 nM(JMJD2E
HY-12725 "ML32|102 117|Target JMJD2 demethylase
HY-12725 "ML32|300 311|JMJD proteins
HY-12725 "ML32|572 582|viral IE gene
HY-12740 "Lota|32 49|phosphodiesterase 4
HY-12750 "AZD3|32 33|Ki
HY-12755 "ML14|32 34|( and
HY-12755 "ML14|98 100|low
HY-12755 "ML14|180 184|potency and selectivity Rab2 ,
HY-12755 "ML14|241 243|the
HY-12755 "ML14|551 556|caused
HY-12768 "BLZ9|115 151|- penetrant CSF-1R closest receptor tyrosine kinase homologs
HY-12794 "Vps3|40 44|-PIK - III VPS34
HY-12807 "FIPI|50 53|PLD1
HY-12808 "STF-|239 244|cells .
HY-12814 "TH58|136 139|hydrolase MTH1
HY-12814 "TH58|226 237|nudix protein
HY-12814 "TH58|399 403|SW480
HY-12833 "AMZ3|145 148|PP2A
HY-12833 "AMZ3|445 447|3.5
HY-12833 "AMZ3|637 652|demethylated PP2A
HY-12838 "Mirk|24 40|Dyrk1B(Mirk kianse
HY-12838 "Mirk|137 140|Dyrk
HY-12838 "Mirk|287 289|ABL
HY-12838 "Mirk|291 294|FLT3
HY-12838 "Mirk|341 344|Mirk
HY-12859 "BAY |60 70|monopolar spindle 1 ( MPS1 ) kinase
HY-12861 "CB-5|30 44|bioavailable p97
HY-12868 "Bimi|69 72|I PI3K
HY-12868 "Bimi|74 77|mTOR
HY-12868 "Bimi|156 159|mTOR
HY-12870 "AZD9|23 38|estrogen receptor
HY-12870A "AZD|31 46|estrogen receptor
HY-12942 "PF-0|21 41|acetyl - CoA carboxylase
HY-12942 "PF-0|43 45|ACC
HY-12948 "AMG3|22 32|PI3Kδ kinase
HY-12953 "R-26|104 131|a novel and specific inhibitor of
HY-12953 "R-26|158 164|5 ( ALK5 )
HY-12953 "R-26|166 184|a transforming growth
HY-12953 "R-26|191 195|β ( TGF
HY-12953 "R-26|290 324|5000-fold more selectivity for ALK5 than
HY-12953 "R-26|328 334|mitogen
HY-12953 "R-26|366 376|R-268712 is a
HY-12963 "Dube|37 61|Axl receptor tyrosine kinase
HY-12965 "S490|31 33|AXL
HY-12974 "PRT-|44 60|tyrosine kinase Syk
HY-12975 "AZ61|22 26|2 TNKS2
HY-12975 "AZ61|112 121|PARP family
HY-12980 "Bate|34 51|muscarinic receptor
HY-12980 "Bate|115 127|hM3 muscarinic
HY-12980 "Bate|151 152|Ki
HY-12987 "Pimo|6 21|dopamine receptor
HY-12987 "Pimo|64 73|dopamine D2
HY-12987 "Pimo|146 147|D3 and D1 receptors Ki
HY-12987 "Pimo|175 179|STAT3
HY-12987 "Pimo|183 187|STAT5
HY-13002 "Tori|56 59|mTOR
HY-13002 "Tori|103 106|PI3 K
HY-13002 "Tori|120 125|Torin 2
HY-13002 "Tori|180 185|Torin 2
HY-13009 "PF-0|404 404|v + m
HY-13011 "Alec|53 55|ALK
HY-13011A "Ale|80 82|ALK
HY-13011A "Ale|143 145|ALK
HY-13012 "RepS|27 33|TGFβR-1
HY-13016 "Cabo|24 46|receptor tyrosine kinases
HY-13016 "Cabo|75 79|c - Met
HY-13017 "Ivac|34 37|CFTR
HY-13017 "Ivac|65 68|CFTR
HY-13017 "Ivac|80 83|CFTR
HY-13018 "MRT6|91 94|ULK1
HY-13018 "MRT6|98 101|ULK2
HY-13020 "GSK1|28 33|IGF - IR
HY-13020 "GSK1|40 54|insulin receptor
HY-13020 "GSK1|114 116|ALK
HY-13022 "CC-4|49 51|JNK
HY-13022 "CC-4|56 57|Ki
HY-13024 "Reba|43 45|Bcr - Abl
HY-13024 "Reba|110 112|SRC
HY-13024 "Reba|114 116|KDR
HY-13024 "Reba|118 121|FLT3
HY-13026 "Idel|121 130|PI3 K class I
HY-13027 "DAPT|3 3|γ
HY-13034 "Gand|25 28|JAK2
HY-13034 "Gand|85 88|FLT3
HY-13038 "Fost|73 75|Syk
HY-13038B "Fos|96 98|Syk
HY-13044 "ADL5|5 20|δ - opioid receptor
HY-13044 "ADL5|32 33|Ki
HY-13044 "ADL5|60 74|opioid receptor κ
HY-13044 "ADL5|184 199|opioid receptor δ - opioid receptor
HY-13049 "Cedi|131 135|c - Kit
HY-13050 "Sapi|42 45|EGFR
HY-13050 "Sapi|80 83|EGFR
HY-13050 "Sapi|85 89|ErbB2
HY-13050 "Sapi|93 97|ErbB3
HY-13058 "ADX-|138 171|positive allosteric modulator ( PAM ) of
HY-13060 "ACHP|40 44|IKK - β
HY-13064 "Cobi|49 51|MEK
HY-13064 "Cobi|81 84|MEK1
HY-13064A "Cob|36 38|MEK
HY-13064A "Cob|71 74|MEK1
HY-13068 "Golv|41 45|c - Met
HY-13068 "Golv|49 61|VEGFR2 kinases
HY-13074 "VO-O|39 42|PTEN
HY-13076 "CHIR|29 33|GSK-3
HY-13076 "CHIR|133 136|cdc2
HY-13104 "MRS2|48 55|exhibits
HY-13104 "MRS2|84 87|P2Y2
HY-13104 "MRS2|111 111|.
HY-13104 "MRS2|352 352|activity at P2Y1 [
HY-13104 "MRS2|562 563|μM
HY-13105 "WAY-|85 89|nM for
HY-13201A "CGS|30 49|adenosine A2A receptor
HY-13201A "CGS|62 63|Ki
HY-13202 "T007|32 33|Ki
HY-13203 "NVP-|12 25|tyrosine kinase
HY-13203 "NVP-|37 39|FAK
HY-13203 "NVP-|55 60|IGF - IR
HY-13205 "Beln|60 68|caspase-1
HY-13205 "Beln|83 84|Ki
HY-13206 "MTEP|66 67|Ki
HY-13206 "MTEP|136 149|5 mGlu5 receptors
HY-13206 "MTEP|267 279|mGlu5 receptor
HY-13221 "BRL |41 52|values are 8.7
HY-13221 "BRL |100 103|over
HY-13221 "BRL |134 143|5-HT and IC50 value :
HY-13221 "BRL |367 371|respectively , 7.2 ,
HY-13222 "BAN |25 35|NOP receptor
HY-13222 "BAN |96 97|μ-
HY-13222 "BAN |101 111|δ - receptors
HY-13222 "BAN |263 270|receptor BAN ORL 24
HY-13225B "Riv|38 38|)
HY-13226 "Galu|30 42|TGF - β receptor
HY-13227 "SD-2|81 88|TGF - βRII
HY-13231 "CDK9|22 25|CDK9
HY-13231 "CDK9|84 87|CDK9
HY-13233A "Tal|76 81|peptidase IV DPP - IV
HY-13233A "Tal|97 98|Ki
HY-13237 "GSK2|33 37|LRRK2
HY-13238 "Dolu|27 38|HIV integrase
HY-13238A "Dol|29 42|HIV-1 integrase
HY-13241 "Rali|69 72|p38 MAPK
HY-13246 "Apit|71 80|bioavailable Class I PI3 kinase mTOR kinase
HY-13246 "Apit|175 178|mTOR
HY-13252 "MK-5|39 51|Aurora A kinase
HY-13253 "AMG |29 31|pan
HY-13253 "AMG |81 87|Aurora kinases Aurora A
HY-13253 "AMG |89 89|B
HY-13258 "NVP-|16 20|EphB4
HY-13258 "NVP-|210 210|:
HY-13258 "NVP-|582 591|signaling .
HY-13260 "CCT1|92 100|PKA kinase
HY-13263 "CHIR|24 27|Chk1
HY-13263 "CHIR|75 79|PDGFR
HY-13263 "CHIR|83 86|FLT3
HY-13269 "BMS-|9 22|HIV-1 integrase
HY-13272 "Daco|46 49|ERBB
HY-13272 "Daco|98 101|EGFR
HY-13280 "IRAK|25 62|interleukin-1 receptor associated kinase 4
HY-13281 "PIK-|13 16|PI3 K
HY-13283 "MF63|249 263|other prostanoid
HY-13283 "MF63|398 407|expressing
HY-13287 "SGI-|18 27|Pim kinases
HY-13287 "SGI-|60 67|Pim-1 , -2
HY-13289A "Nep|20 27|RS-25560
HY-13289A "Nep|39 62|197 dopamine beta - hydroxylase
HY-13289A "Nep|190 213|dopamine beta - hydroxylase Dopamine beta - hydroxylase
HY-13290 "KN-6|33 67|calmodulin - dependent protein kinase II
HY-13290 "KN-6|69 75|CaMK - II
HY-13290 "KN-6|136 148|P2X7 receptors
HY-13298 "Mps1|41 50|Mps1 kinase
HY-13300 "SR-3|23 29|ROCK - II
HY-13304 "LY28|11 14|FGFR
HY-13304 "LY28|53 57|FGFR1
HY-13304 "LY28|65 69|FGFR3
HY-13307 "JK18|19 20|Hh
HY-13308 "Rego|68 70|RET
HY-13308 "Rego|74 78|Raf-1
HY-13311 "Infi|39 42|FGFR
HY-13311 "Infi|86 90|FGFR1
HY-13311 "Infi|98 102|FGFR3
HY-13318 "GS 4|47 73|influenza virus neuraminidase
HY-13319 "JNK-|12 14|JNK
HY-13319 "JNK-|57 60|JNK1
HY-13319 "JNK-|62 65|JNK2
HY-13322 "Prac|15 32|histone deacetylase
HY-13322 "Prac|34 37|HDAC
HY-13323A "CX-|59 62|Pol I
HY-13323A "CX-|174 178|Pol II
HY-13326 "ASP3|34 36|ALK
HY-13327 "Evac|29 32|CETP
HY-13327 "Evac|56 82|human recombinant CETP protein
HY-13327 "Evac|97 100|CETP
HY-13328 "Sapa|66 75|mTOR kinase
HY-13330 "AZD4|25 28|FGFR
HY-13330 "AZD4|75 79|FGFR1
HY-13330 "AZD4|87 91|FGFR3
HY-13334 "BGT2|30 33|PI3 K
HY-13340 "VU01|175 175|.
HY-13342 "Apat|101 105|c - Kit
HY-13342 "Apat|109 113|c - Src
HY-13402 "LY31|188 209|on sPLA2 activity in serum
HY-13404 "Capm|37 47|c - MET kinase
HY-13404 "Capm|87 97|c - MET kinase
HY-13406 "TAK-|45 48|CCR5
HY-13406 "TAK-|63 64|Ki
HY-13406 "TAK-|75 78|CCR5
HY-13406 "TAK-|170 173|MAGI
HY-13410 "Xano|55 63|eline(LY246708 IC50 value
HY-13410 "Xano|350 354|and A9
HY-13410 "Xano|506 513|cells affinity
HY-13410 "Xano|634 642|guinea pig
HY-13413 "Tofo|156 160|value
HY-13413 "Tofo|201 207|Target :
HY-13413 "Tofo|525 529|under
HY-13413 "Tofo|578 579|to
HY-13413 "Tofo|618 624|CYP2C18
HY-13418 "Dors|83 86|AMPK
HY-13418 "Dors|102 103|Ki
HY-13439 "SR14|24 34|CB2 receptor
HY-13439 "SR14|50 51|Ki
HY-13449 "TAK-|23 35|MEK allosteric
HY-13452 "CID-|9 17|pan GTPase
HY-13452 "CID-|52 62|Ras - related
HY-13452 "CID-|82 83|7 Ki
HY-13459 "PF-5|445 459|Shh - functional assay
HY-13461A "PHA|26 29|Cdc7
HY-13461A "PHA|31 34|Cdk9
HY-13462 "LY-3|39 45|TGFβR - I
HY-13462 "LY-3|93 97|TGFβR
HY-13488 "HG-1|19 38|selective inhibitor of
HY-13488 "HG-1|120 121|) ;
HY-13488 "HG-1|125 132|nM ( LRRK2
HY-13488 "HG-1|267 277|01 exhibited
HY-13491 "GNF-|102 104|and
HY-13491 "GNF-|107 108|nM
HY-13491 "GNF-|369 374|Tel - reversible and ( IC50 =
HY-13495 "ML28|127 129|PKA
HY-13495 "ML28|198 213|recombinant STK33
HY-13501 "Mubr|35 39|EGFR2
HY-13501 "Mubr|41 44|HER2
HY-13506 "M344|1 4|D 237
HY-13506 "M344|21 38|histone deacetylase
HY-13508 "JNJ-|35 36|Ki
HY-13508 "JNJ-|86 102|4 histamin receptors
HY-13508 "JNJ-|120 121|Ki
HY-13508 "JNJ-|180 190|H4 receptor fibronectin
HY-13510 "Cuta|52 65|dihydrochloride Sigma 1 receptor
HY-13521 "SB-5|119 122|ALK7
HY-13522 "Fime|142 146|I PI3Ks and II HDAC HDAC1
HY-13524 "AG-1|14 31|EGFR tyrosine kinase
HY-13526 "YO-0|93 97|secretase Notch
HY-13536 "AZD-|12 15|PARP
HY-13537A "BPR|35 38|FLT3
HY-13561 "AZM4|25 42|Src kinase inhibitor
HY-13561 "AZM4|87 92|, Tie-2
HY-13561 "AZM4|188 200|of Src tyrosine
HY-13561 "AZM4|220 240|L3.6pl human pancreatic
HY-13577A "Ocl|22 24|JAK
HY-13577A "Ocl|70 73|JAK1
HY-13604 "Cypr|143 152|activity .  
HY-13604 "Cypr|228 228|,
HY-13604 "Cypr|569 569|,
HY-13604 "Cypr|578 581|they
HY-13606 "Daci|14 17|HDAC
HY-13606 "Daci|67 71|HDAC1
HY-13623A "Ent|25 33|BMS 200475
HY-13632 "Exem|94 98|nM and
HY-13632 "Exem|141 141|:
HY-13632 "Exem|437 442|HOXD11
HY-13632 "Exem|478 496|2 ] . Exemestane causes
HY-13635 "Fina|34 50|5-alpha - reductase
HY-13635 "Fina|184 208|steroid Type II 5α - reductase
HY-13635 "Fina|466 481|5alpha - reductase
HY-13635 "Fina|505 506|Ki
HY-13635 "Fina|545 546|Ki
HY-13638 "GDC-|42 55|XIAP BIR3 domain
HY-13638 "GDC-|60 68|BIR domain
HY-13638 "GDC-|71 76|ML - IAP
HY-13638 "GDC-|114 115|Ki
HY-13668 "Lome|47 50|methyltransferase MGMT
HY-13683 "Mife|10 29|progesterone receptor
HY-13683 "Mife|31 32|PR
HY-13683 "Mife|37 58|glucocorticoid receptor
HY-13683 "Mife|60 61|GR
HY-13687 "IKK |13 21|IκB kinase
HY-13687 "IKK |23 25|IKK
HY-13687 "IKK |44 46|IKK
HY-13689 "Go 6|9 11|PKC
HY-13696 "MSX-|24 28|CXCR4
HY-13696 "MSX-|40 44|CXCR4
HY-13696 "MSX-|108 112|anti -
HY-13706 "CAY1|55 82|prostaglandin D2 receptor CRTH2
HY-13706 "CAY1|99 100|Ki
HY-13706 "CAY1|131 158|human thromboxane A2 receptor TP
HY-13706 "CAY1|160 161|Ki
HY-13706 "CAY1|186 187|PGD2 receptor DP
HY-13706 "CAY1|189 190|Ki
HY-13738A "Ral|495 498|, and
HY-13746B "Sar|26 58|S - adenosylmethionine decarboxylase
HY-13746B "Sar|60 64|SAMDC
HY-13773 "Moto|16 33|Toll - like receptor 8
HY-13779 "J-14|114 134|to the induction of brain
HY-13781 "Peme|51 52|Ki
HY-13781 "Peme|117 135|thymidylate synthase
HY-13781 "Peme|141 162|TS dihydrofolate reductase
HY-13781 "Peme|164 167|DHFR
HY-13783 "BIBF|24 48|transforming growth factor β
HY-13783 "BIBF|50 67|TGFβ ) type I receptor
HY-13783 "BIBF|69 72|Alk5
HY-13785 "ZM-3|101 104|EGFR
HY-13803 "Taze|71 72|Ki
HY-13804 "PP1 |12 14|Src
HY-13804 "PP1 |31 44|tyrosine kinase
HY-13804 "PP1 |74 76|Lck
HY-13804 "PP1 |80 82|Fyn
HY-13805 "PP2 |30 45|Src family kinases
HY-13805 "PP2 |76 78|Lck
HY-13805 "PP2 |82 84|Fyn
HY-13807 "UNC0|165 167|protein lysine methyltransferases GLP
HY-13807 "UNC0|201 203|GLP
HY-13807 "UNC0|244 246|GLP
HY-13807 "UNC0|378 380|GLP
HY-13807 "UNC0|398 464|protein lysine methyltransferases and protein arginine methyltransferases
HY-13812 "QNZ |38 42|NF - κB
HY-13812 "QNZ |71 75|TNF - α
HY-13819 "MK-8|6 18|aurora A kinase
HY-13820 "GSK2|46 59|protein kinase R
HY-13820 "GSK2|61 69|PKR)-like
HY-13823 "C646|50 53|histone acetyltransferase p300
HY-13823 "C646|67 68|Ki
HY-13823 "C646|100 117|acetyltransferases
HY-13838 "PLX6|3 3|a
HY-13838 "PLX6|144 159|was tested against
HY-13838 "PLX6|278 286|FMS and KIT
HY-13838 "PLX6|367 369|the
HY-13864 "PF-4|45 46|Ki
HY-13866 "Ro 3|22 24|PKC
HY-13866 "Ro 3|99 109|rat brain PKC
HY-13866 "Ro 3|158 167|MAPKAP - K1b
HY-13866 "Ro 3|169 172|MSK1
HY-13866 "Ro 3|174 177|S6K1
HY-13866 "Ro 3|236 239|MKK3
HY-13866 "Ro 3|241 244|MKK4
HY-13895 "WHI-|12 15|EGFR
HY-13895 "WHI-|33 40|modestly
HY-13895 "WHI-|47 50|JAK3
HY-13896 "PD16|62 63|393 of
HY-13896 "PD16|68 69|nM
HY-13896 "PD16|71 82|irreversibly
HY-13896 "PD16|91 97|Cys-773
HY-13896 "PD16|153 154|50
HY-13896 "PD16|212 235|human epidermoid carcinoma
HY-13896 "PD16|246 251|9-fold
HY-13896 "PD16|281 283|] ( 2
HY-13896 "PD16|293 300|decrease
HY-13896 "PD16|304 313|production
HY-13896 "PD16|361 363|LPS
HY-13896 "PD16|366 382|cardiomyocytes.[2
HY-13896 "PD16|477 477| 
HY-13896 "PD16|548 553|breast
HY-13896 "PD16|564 571|lines.[3
HY-13896 "PD16|618 622|ERK signaling in HaCaT
HY-13897 "CNX-|37 40|irreversible EGFR
HY-13898 "Tase|56 59|small molecule PI3 K
HY-13898 "Tase|65 66|Ki
HY-13902 "Berz|35 36|Ki
HY-13902 "Berz|72 74|ATM
HY-13902 "Berz|80 81|Ki
HY-13904 "Flum|17 28|multi - kinase
HY-13904 "Flum|79 83|c - Abl
HY-13905 "Flum|93 97|of 1.2
HY-13907 "TCS |59 62|FLT3
HY-13907 "TCS |178 181|FLT3
HY-13907 "TCS |272 275|TCS FLT3
HY-13909 "RGFP|77 81|HDACs
HY-13917 "PND-|36 38|186 FAK
HY-13928 "GW07|16 20|PPAR β
HY-13928 "GW07|48 57|human PPARδ
HY-13928 "GW07|87 96|human PPARδ
HY-13943 "CNX-|125 125|,
HY-13943 "CNX-|155 157|the
HY-13943 "CNX-|164 167|site
HY-13943 "CNX-|491 494|mass
HY-13945 "NVP-|21 23|and
HY-13953 "JIB-|17 41|Jumonji histone demethylase
HY-13954 "A-83|221 225|Target : BzATP
HY-13955 "Telm|39 64|angiotensin II type 1 receptor
HY-13955 "Telm|66 68|AT1
HY-13955 "Telm|116 127|AT1 receptors
HY-13960 "GSK1|45 55|BET proteins
HY-13967B "AMG|294 304|its activity
HY-13967B "AMG|544 549|with an
HY-13968 "JW 5|22 30|β - catenin
HY-13968 "JW 5|89 98|PARP domain
HY-13968 "JW 5|101 110|tankyrase 1
HY-13968 "JW 5|114 123|tankyrase 2
HY-13979 "DDR1|25 50|DDR1 receptor tyrosine kinase
HY-13979 "DDR1|506 513|collagen
HY-13980 "UNC0|27 29|42 GLP
HY-13993A "Ro |141 159|subunit combinations
HY-13993A "Ro |203 206|: 9 nM
HY-13994 "Mps1|45 48|Mps1
HY-13998 "Dasa|43 68|RNA - dependent RNA polymerase
HY-13998 "Dasa|81 91|HCV NS5B gene
HY-13998 "Dasa|101 126|recombinant NS5B polymerases
HY-13998 "Dasa|149 150|1a
HY-14134 "BMS-|119 128|HIV-1 gp120
HY-14134 "BMS-|134 144|CD4 receptor
HY-14137 "Rimo|52 70|cannabinoid receptor
HY-14137 "Rimo|92 98|Ki of 1.8
HY-14137 "Rimo|137 169|Mycobacterial membrane protein Large
HY-14167 "GW84|25 44|cannabinoid receptor 2
HY-14178 "VX-1|53 55|e ERK
HY-14178 "VX-1|60 61|Ki
HY-14179 "PPQ-|74 82|IC50 of ~90
HY-14179 "PPQ-|117 121|vitro
HY-14179 "PPQ-|402 416|pH , and therefore
HY-14179 "PPQ-|427 428|to
HY-14179 "PPQ-|447 475|dependent cellular partitioning
HY-14179 "PPQ-|513 521|confirmed
HY-14179 "PPQ-|573 608|stabilization of the channel closed state
HY-14179 "PPQ-|800 800|[
HY-14185 "Lixi|14 16|WAY
HY-14185 "Lixi|53 73|VPA vasopressin receptor V2
HY-14185 "Lixi|123 127|rat V2
HY-14247 "Fadr|62 70|aromatase
HY-14247A "Fad|50 58|aromatase
HY-14248 "Letr|8 16|aromatase
HY-14258A "Esc|107 119|of citalopram ,
HY-14258A "Esc|399 412|, histaminergic
HY-14258A "Esc|589 613|for other psychotropic drugs
HY-14258A "Esc|734 744|effective in
HY-14268 "Febu|509 512|with
HY-14268 "Febu|556 571|also vasoconstriction
HY-14268 "Febu|616 623|fructose
HY-14268 "Febu|630 630|2
HY-14274 "Anas|31 39|aromatase
HY-14280 "Enta|17 35|potent , peripherally
HY-14280 "Enta|42 51|catechol - O
HY-14280 "Enta|499 502|is more active than PC12
HY-14291 "Vild|430 430|,
HY-14291 "Vild|434 434|-
HY-14350 "AC-5|17 32|molecule protease
HY-14350 "AC-5|176 182|assays ,
HY-14350 "AC-5|216 222|nM. IC50
HY-14350 "AC-5|513 518|of PAR2
HY-14350 "AC-5|528 543|. AC-55541 was well
HY-14369 "Elag|12 28|human GnRH receptor
HY-14369 "Elag|30 34|GnRHR
HY-14369 "Elag|59 60|Ki
HY-14383 "RAD1|3 16|a potent , orally
HY-14383 "RAD1|81 82|) .
HY-14383 "RAD1|148 149|in
HY-14397 "Indo|42 45|COX1
HY-14397 "Indo|79 88|human COX-1
HY-14397 "Indo|92 96|COX-2
HY-14413 "SR33|59 60|Ki
HY-14418 "VU 0|52 64|mGlu4 receptor
HY-14418 "VU 0|98 109|rat receptors
HY-14418 "VU 0|154 167|mGlu8 receptors
HY-14418 "VU 0|199 203|mGlu6
HY-14418 "VU 0|207 220|mGlu7 receptors
HY-14418 "VU 0|330 334|mGlu6
HY-14418 "VU 0|338 351|mGlu7 receptors
HY-14418 "VU 0|385 398|mGlu8 receptors
HY-14426 "L-65|5 11|a potent
HY-14426 "L-65|22 30|selective
HY-14426 "L-65|69 69|.
HY-14426 "L-65|121 130|, selective
HY-14426 "L-65|138 147|agonist for
HY-14426 "L-65|176 184|receptors
HY-14426 "L-65|219 228|Displays 50
HY-14426 "L-65|258 278|receptors containing α1
HY-14426 "L-65|498 502|60 - 70
HY-14426 "L-65|556 559|, and
HY-14539 "Cloz|124 125|Ki
HY-14541 "Olan|50 67|5-HT2 serotonin and D2 dopamine receptor
HY-14541 "Olan|100 117|Receptor Olanzapine
HY-14541 "Olan|213 231|dopamine D2 receptors
HY-14541 "Olan|233 234|Ki
HY-14541 "Olan|273 282|muscarinic
HY-14541 "Olan|298 299|H1
HY-14541 "Olan|302 307|5-HT2C
HY-14541 "Olan|309 313|5-HT3
HY-14546 "Arip|21 39|human 5-HT1A receptor
HY-14546 "Arip|59 60|Ki
HY-14562 "TBPB|388 399|acetylcholine binding site NMDA receptor
HY-14566 "Done|10 10|)
HY-14566 "Done|194 205|respectively
HY-14574 "PF-0|54 60|aurora A aurora B
HY-14586 "Iros|13 28|steroid sulfatase
HY-14588 "Lopi|13 23|HIV protease
HY-14588 "Lopi|37 38|Ki
HY-14588 "Lopi|54 73|HIV protease Lopinavir
HY-14588 "Lopi|232 266|P - glycoprotein immunoreactive protein
HY-14588 "Lopi|367 371|CYP3A
HY-14588 "Lopi|451 461|human CYP1A2
HY-14612 "CPPH|398 405|- binding
HY-14612 "CPPH|619 624|values
HY-14612 "CPPH|693 700|response
HY-14649 "Reti|130 148|RAR nuclear receptors
HY-14660 "Dabr|35 37|Raf
HY-14660 "Dabr|63 67|C - Raf
HY-14660A "Dab|35 43|Raf kinase
HY-14660A "Dab|89 93|c - Raf
HY-14667 "Lomi|46 83|microsomal triglyceride - transfer protein
HY-14674 "CP-7|53 54|of
HY-14674 "CP-7|61 79|640-fold selectivity
HY-14674 "CP-7|506 521|nM [ IC50 nM , but is markedly
HY-14674 "CP-7|526 531|potent
HY-14691 "Refa|36 39|MEK1
HY-14691 "Refa|41 44|MEK2
HY-14711 "Reve|34 45|Aurora kinase
HY-14711 "Reve|84 90|Aurora A
HY-14711 "Reve|92 98|Aurora B
HY-14711 "Reve|102 108|Aurora C
HY-14715B "CCT|71 72|Ki
HY-14718A "Res|40 44|HDAC1
HY-14720 "Rabu|48 51|Chk1
HY-14721 "Tepo|38 42|c - Met
HY-14721 "Tepo|87 91|c - Met
HY-14731 "VE-8|43 44|Ki
HY-14734 "Anam|13 27|ghrelin receptor
HY-14734A "Ana|27 41|ghrelin receptor
HY-14740 "Elvi|11 22|HIV integrase
HY-14751 "Rola|50 70|neurokinin NK1 receptor
HY-14751 "Rola|86 87|Ki
HY-14761 "Bent|36 38|JNK
HY-14761 "Bent|79 82|JNK1
HY-14761 "Bent|84 87|JNK2
HY-14791A "(±)|93 105|cannabinoid-1
HY-14842B "Giv|67 70|HDAC
HY-14842B "Giv|106 110|HDAC1
HY-14861A "Las|51 71|5-HT1F receptor agonist
HY-14861A "Las|120 130|5-HT(1B ) and
HY-14861A "Las|188 193|; > 1000
HY-14861A "Las|199 213|, 5-HT1B/5-HT1D )
HY-14861A "Las|260 282|receptor in studies Lasmiditan showed
HY-14861A "Las|559 590|5-HT(1 ) 5-HT(1F ) receptor agonist LY334370 .
HY-14872 "Tide|21 25|GSK-3
HY-14874 "Topi|483 484|kg
HY-14874 "Topi|516 516|,
HY-14879A "Avi|44 54|β - lactamase
HY-14879A "Avi|77 92|β - lactamase TEM-1
HY-14879A "Avi|96 98|CTX
HY-14879B "Avi|40 50|β - lactamase
HY-14879B "Avi|69 84|β - lactamase TEM-1
HY-14914 "Azil|399 399|-
HY-14914 "Azil|414 415|an
HY-14914 "Azil|457 466|to washout (
HY-14914 "Azil|496 498|and
HY-14914 "Azil|575 577|1 ] .
HY-14932 "Pafu|235 247|2,5-bis[4-(N -
HY-14940 "Voli|40 52|5-HT2 receptor
HY-14940 "Voli|59 60|Ki
HY-14940 "Voli|100 112|5-HT2 receptor
HY-14940 "Voli|124 130|alpha-1
HY-14940 "Voli|134 146|DA D2 receptors
HY-14949C "Cev|117 123|tubulin
HY-14981 "GSK2|42 45|PDK1
HY-14985 "BAY |89 105|1 3606 Syk tyrosine kinase
HY-14985 "BAY |141 143|Btk
HY-14985 "BAY |145 147|Fyn
HY-14985 "BAY |153 155|Lyn
HY-14985 "BAY |160 162|Src
HY-14992 "Bay |45 46|0 Ki
HY-15001 "Stem|16 38|egenin aryl hydrocarbon receptor
HY-15001 "Stem|40 42|AhR
HY-15002 "AST |5 13|RET kinase
HY-15002 "AST |47 49|RET
HY-15023 "Clig|43 58|nonpeptide oxytocin receptor
HY-15023 "Clig|79 80|Ki
HY-15023 "Clig|114 129|oxytocin receptor
HY-15036 "Dicl|59 61|COX
HY-15036 "Dicl|95 104|human COX-1
HY-15036 "Dicl|108 112|COX-2
HY-15036 "Dicl|153 157|COX-2
HY-15036A "Dic|72 74|COX
HY-15036A "Dic|108 117|human COX-1
HY-15036A "Dic|121 125|COX-2
HY-15036A "Dic|166 170|COX-2
HY-15037 "Dicl|12 18|fenac GP 45840
HY-15037 "Dicl|74 76|COX
HY-15037 "Dicl|110 119|human COX-1
HY-15037 "Dicl|123 127|COX-2
HY-15037 "Dicl|168 172|COX-2
HY-15069 "Fana|79 82|NMDA
HY-15069 "Fana|88 89|Ki
HY-15069 "Fana|148 151|NMDA
HY-15069A "Fan|94 97|NMDA
HY-15069A "Fan|103 104|Ki
HY-15069A "Fan|163 166|NMDA
HY-15125 "Bay-|40 49|Bay - K-8644
HY-15136 "Lona|73 77|bioavailable farnesyl protein transferase H - ras
HY-15136 "Lona|79 83|K - ras
HY-15136 "Lona|87 91|N - ras
HY-15144 "Tric|39 51|ostatin HDAC class I / II
HY-15144 "Tric|78 81|HDAC
HY-15147 "XAV-|5 13|tankyrase
HY-15147 "XAV-|53 55|TNKS Wnt
HY-15147 "XAV-|57 65|β - catenin
HY-15158 "SBE1|67 71|SBE13
HY-15160 "TAK-|42 57|polo - like kinase 1
HY-15160B "TAK|58 73|polo - like kinase 1
HY-15164 "Icot|46 49|EGFR
HY-15164 "Icot|103 111|EGFRL858R
HY-15164 "Icot|113 117|T790 M
HY-15164 "Icot|119 127|EGFRT790 M
HY-15164A "Ico|34 37|EGFR
HY-15164A "Ico|91 99|EGFRL858R
HY-15164A "Ico|101 105|T790 M
HY-15164A "Ico|107 115|EGFRT790 M
HY-15166 "SB13|26 29|JAK2
HY-15166 "SB13|34 37|FLT3
HY-15166 "SB13|93 96|JAK2
HY-15166 "SB13|100 103|FLT3
HY-15174 "Dact|28 31|PI3 K
HY-15174 "Dact|35 44|mTOR kinase
HY-15185 "Niro|60 70|γ - secretase
HY-15186 "Ipat|56 58|Akt
HY-15186A "Ipa|69 71|Akt
HY-15186A "Ipa|140 142|PKA
HY-15187A "(R)|81 110|synthetic kinesin spindle protein
HY-15190 "NVP-|26 30|Hsp90
HY-15217 "CHR-|40 50|histone H3T3
HY-15222 "MI-2|3 22|Menin - MLL interaction
HY-15223 "MI-3|8 8|a -
HY-15223 "MI-3|102 104|The
HY-15223 "MI-3|110 110|-
HY-15223 "MI-3|214 222|μM for MI-2
HY-15223 "MI-3|248 251|only
HY-15223 "MI-3|510 513|small MI-3
HY-15224 "PCI-|90 101|HDAC isoforms
HY-15240 "c-Ki|25 29|c - Kit
HY-15240 "c-Ki|33 37|c - Met
HY-15241 "NVP-|20 21|is
HY-15241 "NVP-|316 318|non
HY-15241 "NVP-|613 616|e.g.
HY-15243 "Capr|38 70|growth hormone secretagogue receptor
HY-15243 "Capr|89 90|Ki
HY-15245 "GSK2|52 53|Ki
HY-15247 "Vist|33 36|mTOR
HY-15248 "GDC-|39 42|mTOR
HY-15248 "GDC-|57 58|Ki
HY-15249 "JZL |37 58|monoacylglycerol lipase
HY-15249 "JZL |116 138|fatty acid amide hydrolase
HY-15250 "JZL1|351 370|in our competitive ABPP
HY-15251 "Repa|46 68|chemokine receptors CXCR1
HY-15251 "Repa|72 76|CXCR2
HY-15259A "CP-|66 68|Acetyl - CoA carboxylase ACC
HY-15270 "BMS-|17 20|JAK2
HY-15270 "BMS-|63 66|JAK1
HY-15270 "BMS-|68 71|JAK3
HY-15273 "UNC0|27 36|GLP histone
HY-15275 "BMS-|70 74|E with
HY-15275 "BMS-|84 86|and
HY-15275 "BMS-|88 90|nM ,
HY-15275 "BMS-|213 216|cycD
HY-15275 "BMS-|336 342|binding
HY-15275 "BMS-|347 349|and
HY-15282 "E-64|77 82|papain
HY-15289 "Cipr|229 242|H3 autoreceptor
HY-15289 "Cipr|307 308|Ki
HY-15289 "Cipr|331 340|H3 receptor
HY-15290 "AIM-|74 81|molecule Ack1 Ack1
HY-15290 "AIM-|145 147|AKT
HY-15290 "AIM-|287 295|Ack1 AR Tyr(267
HY-15290 "AIM-|334 344|ATM enhancer
HY-15290 "AIM-|383 385|ATM
HY-15290 "AIM-|541 542|AR
HY-15290 "AIM-|545 547|PSA
HY-15290 "AIM-|586 587|AR
HY-15315 "Bari|39 42|JAK1
HY-15315 "Bari|46 49|JAK2
HY-15315A "Bar|46 49|JAK1
HY-15315A "Bar|51 54|JAK2
HY-15323 "PRT0|62 64|Syk
HY-15323 "PRT0|66 70|IC50 1
HY-15342 "Tima|37 56|D prostanoid receptor 2
HY-15343 "CEP-|55 58|JAK2
HY-15356 "BIO-|34 38|GSK-3
HY-15371 "Fors|13 37|adenylate cyclase activator
HY-15393 "VU03|353 357|allosteric site F585I
HY-15394 "rac-|30 47|otigotine Hcl is selectivity agonist
HY-15394 "rac-|243 264|other neuronal receptors
HY-15394 "rac-|266 271|Ki in nM
HY-15411 "MK-0|36 57|neuropeptide Y5 receptor
HY-15411 "MK-0|73 74|Ki
HY-15414 "Vort|21 26|5-HT1A
HY-15414 "Vort|42 54|5-HT7 receptor
HY-15414 "Vort|67 68|Ki
HY-15414A "Vor|59 64|5-HT1A
HY-15414A "Vor|80 92|5-HT7 receptor
HY-15414A "Vor|104 105|Ki
HY-15417 "ML-7|66 69|MLCK
HY-15418 "RS 5|16 36|CCR2 chemokine receptor
HY-15418 "RS 5|89 108|human recombinant CCR2
HY-15418 "RS 5|112 124|CCR1 receptors
HY-15420 "BML-|29 45|CB2 receptor ligand
HY-15420 "BML-|47 48|Ki
HY-15420 "BML-|126 136|CB2 receptor
HY-15420 "BML-|463 466|IL-6
HY-15420 "BML-|557 561|COX-2
HY-15424 "5-Io|20 34|adenosine kinase
HY-15425A "PF-|2 8|Citrate
HY-15425A "PF-|51 57|Ki of 4.3
HY-15431 "Capi|29 37|AKT kinase
HY-15438 "SB 4|79 80|Ki
HY-15441 "PF-0|26 46|human recombinant PDE9A
HY-15441 "PF-0|104 119|PDE family members
HY-15445 "CTEP|143 155|mGlu receptors
HY-15450A "INC|75 106|monocyte chemoattractant protein-1
HY-15451 "MDA |21 35|receptor agonist
HY-15451 "MDA |78 81|: CB2
HY-15451 "MDA |90 96|in vitro
HY-15451 "MDA |112 124|4-fold - higher
HY-15451 "MDA |152 161|at the human
HY-15451 "MDA |206 221|and nearly 70-fold
HY-15451 "MDA |248 259|than at the rat
HY-15451 "MDA |271 281|( K(i ) = 16.3 +
HY-15451 "MDA |342 358|] functional assays
HY-15451 "MDA |497 510|monophosphate (
HY-15455 "Rofl|138 151|PDE5 isoenzymes
HY-15456 "NVP-|48 49|Met ) .
HY-15456 "NVP-|513 513|,
HY-15457 "Tric|43 45|Akt
HY-15461 "Ertu|69 74|sodium
HY-15461A "Ert|88 93|sodium
HY-15463 "Imat|6 20|tyrosine kinases
HY-15463 "Imat|42 46|c - Kit
HY-15463 "Imat|52 54|Bcr - Abl
HY-15463 "Imat|59 63|PDGFR
HY-15463 "Imat|76 90|tyrosine kinases
HY-15468 "IOX2|11 29|prolyl hydroxylase-2
HY-15468 "IOX2|31 34|PHD2
HY-15469 "GW79|338 348|both sucrose and NaCl ATP and BzATP
HY-15469 "GW79|421 432|300–1000 nM GW
HY-15469 "GW79|538 547|, although using ATP as
HY-15469 "GW79|608 616|potency at
HY-15472 "PRX-|647 650|line
HY-15478 "WZ81|10 14|CXCR4
HY-15478 "WZ81|61 65|CXCR4
HY-15479 "TTP |10 12|CK2
HY-15479 "TTP |44 45|Ki
HY-15482 "D-64|427 434|of 62 nM by
HY-15482 "D-64|618 623|active
HY-15490 "PF-6|36 47|casein kinase
HY-15490 "PF-6|49 52|CK1ε
HY-15494 "Picr|32 65|insulin - like growth factor-1 receptor
HY-15494 "Picr|67 72|IGF-1R
HY-15511 "Tyrp|15 28|tyrosine kinase
HY-15511 "Tyrp|128 141|A9 tyrosine kinase
HY-15511 "Tyrp|168 170|TNF
HY-15511 "Tyrp|255 257|TNF
HY-15511 "Tyrp|355 380|PDGF receptor tyrosine kinase
HY-15511 "Tyrp|440 466|PDGF receptor tyrosine kinases
HY-15513 "TC-D|47 50|PK DAPK
HY-15518 "LCL1|4 6|1 IAP
HY-15521 "ETP-|17 20|mTOR
HY-15530 "CID-|33 47|antigen receptor
HY-15530 "CID-|57 61|NF - κB
HY-15531 "Vene|57 73|bioavailable Bcl-2
HY-15531 "Vene|88 89|Ki
HY-15535 "DMAT|20 22|CK2
HY-15538 "Ebro|307 308|l )
HY-15542B "FRA|6 24|p21-activated kinase
HY-15542B "FRA|26 28|PAK
HY-15556 "GSK2|14 17|ROCK
HY-15556 "GSK2|50 70|recombinant human ROCK1
HY-15557 "AZ20|81 84|mTOR
HY-15565 "APD6|184 201|glycated hemoglobin
HY-15601 "Vesa|67 74|Receptor
HY-15610 "GDC-|49 52|MEK1
HY-15640 "Caps|74 86|TRPV1 receptor
HY-15648 "GSK-|21 28|H3K27me3
HY-15649 "UNC1|228 237|containing
HY-15649 "UNC1|521 533|directly binds
HY-15649 "UNC1|541 557|via the Kme - binding
HY-15649 "UNC1|617 619|GFP
HY-15650 "SGC0|29 50|DOT1L methyltransferase
HY-15650 "SGC0|159 163|DOT1L
HY-15650 "SGC0|211 235|histone methyltransferases
HY-15650 "SGC0|380 382|MLL
HY-15650 "SGC0|397 403|SGC 0946
HY-15651 "Alve|520 525|- based
HY-15656 "Ceri|32 34|ALK
HY-15656A "Cer|67 69|dihydrochloride ALK
HY-15658 "GSK2|140 144|BAZ2A
HY-15658 "GSK2|356 363|Cellular
HY-15658 "GSK2|431 434|FRAP
HY-15658 "GSK2|460 462|GFP
HY-15666 "GZD8|57 59|and
HY-15666 "GZD8|97 98|0.34 and 0.68 nM
HY-15666 "GZD8|139 139|-
HY-15666 "GZD8|143 144|wt
HY-15666 "GZD8|374 378|) , and
HY-15666 "GZD8|486 494|Abl(WT ) or
HY-15676 "Idas|35 38|MDM2
HY-15682 "TTNP|16 18|RAR
HY-15682 "TTNP|56 64|human RARs
HY-15687 "SAR4|54 57|ROCK
HY-15687A "SAR|42 45|ROCK
HY-15689 "Epac|39 65|indoleamine 2,3-dioxigenase 1
HY-15707 "NS61|110 112|nM [
HY-15707 "NS61|224 228|amino
HY-15707 "NS61|233 261|residues conferring sensitivity
HY-15707 "NS61|297 302|NS6180
HY-15707 "NS61|312 338|endogenously expressed KCa3.1
HY-15707 "NS61|355 359|mouse
HY-15713 "NMS-|31 33|VCP
HY-15713 "NMS-|35 37|p97
HY-15722 "SB 2|198 207|Receptor in
HY-15729 "Roci|88 91|delivered kinase EGFR
HY-15729 "Roci|101 105|T790 M
HY-15729 "Roci|113 114|Ki
HY-15729 "Roci|124 132|EGFRL858R
HY-15729 "Roci|134 138|T790 M
HY-15729A "Roc|113 116|delivered kinase EGFR
HY-15729A "Roc|126 130|T790 M
HY-15729A "Roc|138 139|Ki
HY-15729A "Roc|149 157|EGFRL858R
HY-15729A "Roc|159 163|T790 M
HY-15730 "Pozi|16 20|HM781
HY-15730 "Pozi|130 130|/
HY-15730 "Pozi|238 249|respectively
HY-15730 "Pozi|302 307|family
HY-15730 "Pozi|312 318|. HM781 -
HY-15730 "Pozi|322 325|more
HY-15743 "Bira|57 61|IC50s
HY-15749 "XL22|72 78|kinase Bcr - Abl
HY-15749 "XL22|80 86|Aurora A
HY-15749 "XL22|95 97|Src
HY-15749 "XL22|101 103|Lyn
HY-15760 "Necr|123 142|death domain kinase RIP
HY-15760 "Necr|144 147|RIP1
HY-15761 "AZD2|24 28|GSK-3
HY-15762 "Vald|43 47|COX-2
HY-15762 "Vald|74 78|COX-2
HY-15764A "A 4|23 38|Src family kinases
HY-15764A "A 4|75 77|Src
HY-15764A "A 4|79 81|Lck
HY-15764A "A 4|85 87|Lyn
HY-15768 "Ilom|43 57|metalloprotease
HY-15768 "Ilom|59 61|MMP
HY-15768 "Ilom|77 78|Ki
HY-15771 "Tira|54 56|BTK
HY-15772 "Osim|50 53|EGFR
HY-15772 "Osim|111 115|T790 M
HY-15773 "PF-4|28 31|S6K1
HY-15773 "PF-4|46 47|Ki
HY-15777B "Rib|144 150|cyclin B
HY-15777C "Rib|158 164|cyclin B
HY-15780 "Brex|27 56|human 5-HT1A and dopamine receptor
HY-15780 "Brex|114 127|5-HT2A receptor
HY-15780 "Brex|143 144|Ki
HY-15797 "UNC2|216 227|versus Tyro3 .
HY-15797 "UNC2|235 237|had
HY-15797 "UNC2|256 266|, clearance ,
HY-15798 "UNC2|22 30|Mer kinase
HY-15798 "UNC2|61 69|Mer kinase
HY-15798 "UNC2|132 140|Mer kinase
HY-15798 "UNC2|193 195|EGF
HY-15798 "UNC2|219 234|chimeric receptor
HY-15798 "UNC2|269 271|Mer
HY-15798 "UNC2|303 306|domain EGFR
HY-15798 "UNC2|342 349|collagen
HY-15800A "CZC|154 157|4.76 type
HY-15802 "WZ40|34 43|NUAK kinase
HY-15816 "Ulix|57 60|ERK1
HY-15816 "Ulix|64 74|ERK2 kinases
HY-15816 "Ulix|99 102|ERK2
HY-15826 "SGC-|209 212|p300
HY-15826 "SGC-|214 216|CBP
HY-15826 "SGC-|259 261|CBP
HY-15826 "SGC-|265 270|~0.038
HY-15826 "SGC-|276 279|p300
HY-15826 "SGC-|308 310|CBP
HY-15826 "SGC-|333 336|FRAP
HY-15832 "GSK |24 38|Wip1 phosphatase
HY-15834A "Epr|9 18|nonpeptide
HY-15834A "Epr|152 159|cortical
HY-15841 "CEP-|34 36|FAK
HY-15841 "CEP-|38 40|ALK
HY-15841 "CEP-|67 69|FAK
HY-15841 "CEP-|129 131|FAK
HY-15841 "CEP-|140 142|ALK
HY-15841 "CEP-|183 185|FAK
HY-15841 "CEP-|187 189|ALK
HY-15841 "CEP-|255 257|ALK
HY-15841 "CEP-|261 263|FAK
HY-15841 "CEP-|328 341|WO 2013134353 A1
HY-15874 "Fibo|26 62|FLAP(5-Lipoxygenase - activating protein
HY-15874A "Fib|45 81|FLAP(5-Lipoxygenase - activating protein
HY-15878 "LDC0|21 24|CDK9
HY-15889A "AMG|44 47|FLT3
HY-15889A "AMG|49 52|CDK4
HY-15897 "LDN-|13 15|BMP
HY-15897 "LDN-|71 73|BMP
HY-15897 "LDN-|83 101|TGF - β type I receptors
HY-15897 "LDN-|208 211|ALK2
HY-15897 "LDN-|280 296|BMP type I receptors
HY-15897 "LDN-|494 507|fibrodysplasia
HY-15898 "Y-32|7 27|phenylpyrazoleanilide
HY-15898 "Y-32|44 51|inhibits
HY-15898 "Y-32|134 134|-
HY-15898 "Y-32|157 157|1
HY-15898 "Y-32|165 165|:
HY-15898 "Y-32|176 184|inhibited
HY-15898 "Y-32|362 376|destruction with
HY-15898 "Y-32|407 423|in arthritic joints
HY-15898 "Y-32|475 526|Y-320 in combination with anti - murine tumor necrosis factor
HY-15900 "Voxt|22 25|PI3 K
HY-15900 "Voxt|176 179|I PI3 K PK mTOR
HY-15951 "ML16|19 33|Cdc2-like kinase
HY-15965 "Upro|42 44|Akt
HY-15968 "Ento|49 51|Syk
HY-15971 "AMD |40 44|CXCR4
HY-15971 "AMD |63 69|12G5 mAb
HY-15971 "AMD |86 90|CXCR4
HY-15979A "H-8|36 48|protein kinase
HY-15979A "H-8|51 53|PKA
HY-15979A "H-8|97 99|PKC
HY-15982 "APY0|154 158|IL-12
HY-15986 "VER-|7 11|Hsp90
HY-16026 "Rico|38 42|HDAC6
HY-16026 "Rico|89 93|HDAC1
HY-16060 "Apal|38 53|androgen receptor
HY-16060 "Apal|55 56|AR
HY-16060 "Apal|76 77|AR
HY-16069 "Tuca|55 58|HER2
HY-16071 "AT13|37 41|multi
HY-16071 "AT13|118 123|AGC kinase p70S6 K
HY-16071 "AT13|125 127|PKA
HY-16071 "AT13|132 136|ROCKI
HY-16082 "AZD7|43 44|of
HY-16082 "AZD7|163 169|PDHK1/2
HY-16082 "AZD7|281 295|nM compounds in this
HY-16082 "AZD7|421 429|contrast ,
HY-16141 "Cile|27 34|integrin
HY-16141 "Cile|47 50|αvβ3
HY-16141 "Cile|54 65|αvβ5 receptor
HY-16273A "L-7|167 172|I Ki - Ras
HY-16273A "L-7|199 217|farnesyltransferase
HY-16273A "L-7|385 396|unprenylated
HY-16294 "LY20|24 47|glycogen synthase kinase-3
HY-16294 "LY20|49 53|GSK-3
HY-16297 "Abem|100 103|CDK4
HY-16297 "Abem|107 110|CDK6
HY-16305 "Mari|24 30|histone
HY-16339 "N3PT|102 105|N3-pyridyl vivo
HY-16339 "N3PT|411 411|1
HY-16346 "Netu|20 26|a highly
HY-16346 "Netu|52 69|and selective , active neurokinin-1
HY-16346 "Netu|124 125|1 ]
HY-16379 "Pacr|38 41|JAK2
HY-16379 "Pacr|56 70|JAK2V617F mutant
HY-16379 "Pacr|105 108|FLT3
HY-16391 "Glas|96 103|bioavailable smoothened human SMO
HY-16425 "RG28|4 22|brain - penetrant HDAC
HY-16425 "RG28|56 60|HDAC1
HY-16446 "SAR1|58 82|MET receptor tyrosine kinase
HY-16446 "SAR1|84 86|RTK
HY-16500 "Tolr|26 40|aldose reductase
HY-16526 "Pila|50 60|class I PI3Ks
HY-16567 "Asen|52 53|5A
HY-16567 "Asen|103 104|Ki
HY-16567 "Asen|150 165|Dopamine receptor
HY-16569 "Colc|8 14|tubulin
HY-16582 "Eris|18 34|odegib diphosphate LDE225 diphosphate
HY-16585 "VS-5|9 12|PI3K
HY-16585 "VS-5|14 23|mTOR kinase
HY-16585 "VS-5|100 103|mTOR
HY-16585 "VS-5|118 124|VS-5584
HY-16635 "Seti|58 74|a G protein - coupled
HY-16635 "Seti|156 164|selective
HY-16635 "Seti|261 277|( chemoattractant receptor - homologous a G protein - coupled
HY-16635 "Seti|590 596|of CRTH2
HY-16665 "iCRT|27 35|β - catenin
HY-16665 "iCRT|89 91|Wnt
HY-16665 "iCRT|107 116|luciferase
HY-16671 "CFTR|41 44|CFTR
HY-16671 "CFTR|79 82|CFTR
HY-16671 "CFTR|126 127|Ki
HY-16689 "VU 0|35 59|molecule neuronal K - Cl cotransporter
HY-16689 "VU 0|203 223|- Cl Na - K-2Cl cotransporter
HY-16689 "VU 0|356 404|neuronal - specific potassium - chloride cotransporter 2
HY-16689 "VU 0|476 497|Na - K-2Cl cotransporter 1
HY-16711 "SB22|24 28|CXCR2
HY-16712 "LDN-|26 29|ALK2
HY-16712 "LDN-|140 143|ALK2
HY-16712 "LDN-|218 221|ALK2
HY-16712 "LDN-|369 371|BMP
HY-16712 "LDN-|487 489|BMP
HY-16712 "LDN-|583 585|BMP
HY-16749 "Pexi|54 58|CSF1R
HY-16749 "Pexi|68 72|c - Kit
HY-16749 "Pexi|164 168|c - Kit
HY-16749 "Pexi|172 176|CSF1R
HY-16749 "Pexi|207 210|FLT3
HY-16749 "Pexi|212 214|KDR
HY-16749A "Pex|81 85|CSF1R
HY-16749A "Pex|95 99|c - Kit
HY-16749A "Pex|191 195|c - Kit
HY-16749A "Pex|199 203|CSF1R
HY-16749A "Pex|234 237|FLT3
HY-16749A "Pex|239 241|KDR
HY-16755 "Solc|50 53|JAK1
HY-16755 "Solc|117 120|JAK2
HY-16755 "Solc|122 125|JAK3
HY-16782 "Pexm|22 28|p38 MAPK
HY-16787 "ICA-|210 219|nanomolar potent nM nM Target inhibitory
HY-16900 "Roli|15 36|ram phosphodiesterases PDE4
HY-16900 "Roli|77 81|PDE4A
HY-16900A "(R)|123 127|PDE4A
HY-16910 "WIKI|21 23|Wnt
HY-16910 "WIKI|25 33|β - catenin
HY-16910 "WIKI|86 95|tankyrase 2
HY-16936 "JH-I|219 220|penetrant LRRK2 T JH
HY-16936 "JH-I|276 292|G2019S mutant LRRK2
HY-16936 "JH-I|294 295|JH
HY-16936 "JH-I|377 388|type LRRK2 G2019S mutant
HY-16956 "CC-2|21 30|mTOR kinase
HY-16956 "CC-2|50 59|mTOR kinase
HY-16961 "Sitr|45 66|receptor tyrosine kinase
HY-16961 "Sitr|68 70|RTK
HY-16961 "Sitr|180 183|FLT3
HY-16962 "CC-1|27 36|mTOR kinase
HY-16962A "CC-|41 50|mTOR kinase
HY-16965 "TH28|128 131|MTH1
HY-16965 "TH28|262 273|nudix protein
HY-16978 "TG6-|71 72|shows - , >
HY-16978 "TG6-|101 104|EP3 ,
HY-16978 "TG6-|182 191|over : serotonin
HY-16985 "Daro|37 52|androgen receptor
HY-16985 "Daro|54 55|AR
HY-16986 "EPZ0|675 678|( LCC
HY-17010 "Reta|130 135|E.coli
HY-17015 "Pera|401 413|neuraminidase neuraminidase
HY-17015 "Pera|468 489|influenza neuraminidase
HY-17041 "Daru|41 51|HIV protease
HY-17041 "Daru|104 105|Ki
HY-17041 "Daru|114 134|wild type HIV-1 protease
HY-17355 "Pram|10 11|is
HY-17355 "Pram|133 143|of 3.9 nM(D2S ) ; 2.2
HY-17355 "Pram|151 154|; 0.5
HY-17355 "Pram|170 176|) Target
HY-17355 "Pram|178 185|Dopamine
HY-17355 "Pram|314 320|are 3.9 , D2S , D3
HY-17355 "Pram|404 408|D1 and
HY-17372 "Rofe|37 41|COX-2
HY-17372 "Rofe|75 84|human COX-2
HY-17372 "Rofe|165 169|COX-2
HY-17379 "Ator|31 46|HMG - CoA reductase
HY-17380 "(S)-|36 55|β - adrenergic receptor
HY-17380 "(S)-|67 68|Ki
HY-17380 "(S)-|98 107|β2 receptor
HY-17385 "Atom|19 31|Tomoxetine Hcl
HY-17385 "Atom|85 86|Ki
HY-17385 "Atom|124 134|radioligand
HY-17385 "Atom|144 148|human
HY-17385 "Atom|160 162|DAT
HY-17385 "Atom|191 192|Ki
HY-17385 "Atom|196 203|human NET
HY-17385 "Atom|265 304|neurotransmitter receptors and transporters
HY-17385 "Atom|306 311|Ki > 1 μM
HY-17390 "Loxa|15 18|D2DR
HY-17390 "Loxa|151 155|vitro
HY-17390 "Loxa|232 236|brain
HY-17390 "Loxa|239 243|human
HY-17390 "Loxa|447 454|Loxapine
HY-17390 "Loxa|562 580|μM 2 concentrations of 0.2
HY-17390 "Loxa|585 591|μM and 20
HY-17390A "Lox|16 19|D2DR
HY-17390A "Lox|152 156|vitro
HY-17390A "Lox|233 237|brain
HY-17390A "Lox|240 244|human
HY-17390A "Lox|448 455|Loxapine
HY-17390A "Lox|563 581|μM 2 concentrations of 0.2
HY-17390A "Lox|586 592|μM and 20
HY-17395A "Ter|104 120|squalene epoxidase
HY-17395A "Ter|137 138|Ki
HY-17408 "Meva|31 35|HMGCR
HY-17408 "Meva|37 52|HMG - CoA reductase
HY-17408 "Meva|55 56|Ki
HY-17408 "Meva|211 212|cholesterol Ki
HY-17408 "Meva|296 299|cdk 2
HY-17408 "Meva|308 315|cyclin D1
HY-17408 "Meva|319 320|E1
HY-17408 "Meva|322 324|p21
HY-17408 "Meva|328 330|p27
HY-17408 "Meva|352 354|TNF
HY-17408 "Meva|363 367|NF - κB
HY-17416 "Guan|46 61|α2A - adrenoceptor
HY-17416 "Guan|114 130|α2B - adrenoceptors
HY-17416 "Guan|168 175|Receptor
HY-17416 "Guan|217 227|α2A receptor
HY-17416 "Guan|502 514|autoreceptors
HY-17443 "Sive|52 58|of human
HY-17443 "Sive|177 178|mouse 44
HY-17443 "Sive|181 181|[
HY-17443 "Sive|183 183|]
HY-17443 "Sive|221 223|not
HY-17443 "Sive|231 238|trypsin ,
HY-17443 "Sive|499 503|mg / kg
HY-17443 "Sive|555 579|by human neutrophil elastase
HY-17443B "Siv|53 59|of human
HY-17443B "Siv|178 179|mouse 44
HY-17443B "Siv|182 182|[
HY-17443B "Siv|184 184|]
HY-17443B "Siv|222 224|not
HY-17443B "Siv|232 239|trypsin ,
HY-17443B "Siv|500 504|mg / kg
HY-17443B "Siv|556 580|by human neutrophil elastase
HY-17453 "Salm|28 51|beta-2 adrenergic receptor
HY-17453 "Salm|70 71|Ki
HY-17461A "Cor|74 76|, is
HY-17461A "Cor|602 602|.
HY-17502 "Simv|7 8|statin MK
HY-17502 "Simv|38 53|HMG - CoA reductase
HY-17502 "Simv|59 60|Ki
HY-17504 "Rosu|327 341|astatin Calcium a constant of 8.5 μM
HY-17504 "Rosu|343 343|2
HY-17504 "Rosu|508 511|than
HY-17504 "Rosu|580 584|TNF - α
HY-17512 "Losa|7 27|angiotensin II receptor
HY-17512 "Losa|64 76|angiotensin II
HY-17512 "Losa|79 90|AT1 receptors
HY-17512A "Los|19 44|angiotensin II receptor type 1
HY-17512A "Los|46 48|AT1
HY-17512A "Los|86 98|angiotensin II
HY-17512A "Los|101 103|AT1
HY-17537 "APY2|95 104|IRE1α RNase
HY-17543 "ML-3|59 61|Rho
HY-17543 "ML-3|123 124|Ki
HY-17550 "Suni|329 333|and in
HY-17550 "Suni|339 339|.
HY-17550 "Suni|549 549|,
HY-17550 "Suni|569 607|rod test , nor modify spontaneous motility and
HY-17600 "Acal|42 44|BTK
HY-17603 "Beli|37 39|ALK
HY-17603 "Beli|80 83|wild
HY-17604 "Bexa|392 398|2 insulin
HY-17606 "Cene|43 73|sphingosine 1-phosphate 1 receptor
HY-17606 "Cene|106 119|WO 2016184939 A1
HY-17606 "Cene|123 136|WO 2011007324 A1
HY-18006 "NKP6|360 367|of which vitro(IC50=2.6 characterized by . Species
HY-18008 "PS-1|6 14|IκB kinase
HY-18008 "PS-1|16 18|IKK
HY-18030A "CEP|19 19|28122 a
HY-18030A "CEP|112 115|IC50
HY-18030A "CEP|290 296|induces
HY-18030A "CEP|460 460|:
HY-18055 "BVT-|16 51|11β - Hydroxysteroid dehydrogenase type 1
HY-18055 "BVT-|53 60|11β - HSD1
HY-18056 "PF-9|176 180|1 11βHSD1 vitro
HY-18056 "PF-9|244 244|assay against human (
HY-18086 "TCS |52 62|Pim-1 kianse
HY-18086 "TCS |122 125|MEK1
HY-18086 "TCS |172 185|Pim-1 TCS PIM-1 1
HY-18086 "TCS |212 226|ATP - binding site
HY-18086 "TCS |229 233|Pim-1
HY-18086 "TCS |439 447|serine / threonine kinases Pim-2 molecules TCS PIM-1 1
HY-18086 "TCS |525 529|Pim-1
HY-18161 "CCT2|38 41|FLT3
HY-18161 "CCT2|45 56|Aurora kinase
HY-18161 "CCT2|80 92|Aurora kinases
HY-18161 "CCT2|94 101|Aurora - A
HY-18161 "CCT2|121 128|Aurora - B
HY-18161 "CCT2|138 147|FLT3 kinase
HY-18161 "CCT2|162 172|FLT3 mutants
HY-18174 "Prex|72 75|competitive checkpoint kinase 1 Chk1
HY-18174 "Prex|101 102|Ki
HY-18174A "Pre|97 113|Chk1 protein kinase
HY-18174A "Pre|168 169|Ki
HY-18208 "Omap|27 45|metalloproteases ACE
HY-18208 "Omap|56 57|Ki
HY-18252 "Avan|169 175|Target :
HY-18299 "Purv|22 22|-
HY-18299 "Purv|32 46|kinase inhibitor
HY-18299 "Purv|51 54|IC50
HY-18299 "Purv|61 63|of 6
HY-18299 "Purv|91 97|nM for cdc2 / cyclin B
HY-18299 "Purv|162 162| 
HY-18299 "Purv|172 172|Value :
HY-18299 "Purv|190 199|; 6 nM(cdk2 /
HY-18299 "Purv|276 283|cdk5-p35
HY-18299 "Purv|291 291|vitro :
HY-18299 "Purv|346 353|1-cyclin
HY-18299 "Purv|362 365|complex from
HY-18299 "Purv|420 423|MAPK
HY-18299 "Purv|433 434|found to
HY-18299A "Pur|16 18|alanol CDK
HY-18299A "Pur|42 53|cdc2-cyclin B
HY-18299A "Pur|55 66|cdk2-cyclin A
HY-18299A "Pur|68 79|cdk2-cyclin E
HY-18299A "Pur|81 93|cdk4-cyclin D1
HY-18300 "Filg|27 30|JAK1
HY-18300 "Filg|77 80|JAK1
HY-18300 "Filg|82 85|JAK2
HY-18300 "Filg|87 90|JAK3
HY-18304 "BMS-|46 50|LIMK1
HY-18304 "BMS-|54 58|LIMK2
HY-18305 "BMS-|54 58|LIMK1
HY-18305 "BMS-|62 66|LIMK2
HY-18314 "GW 4|15 40|Tropomyosin - related kinase A
HY-18314 "GW 4|93 98|c - Raf1
HY-18346 "Moza|34 64|nonpeptide vasopressin V2 receptor
HY-18347A "Con|47 65|vasopressin receptor
HY-18347A "Con|71 72|Ki
HY-18347A "Con|97 115|rat liver V1A receptor
HY-18347A "Con|119 137|rat kidney V2 receptor
HY-18360 "TMP2|21 46|class IIa histone deacetylase
HY-18360 "TMP2|48 51|HDAC
HY-18602 "FIIN|28 31|FGFR
HY-18602 "FIIN|65 69|FGFR1
HY-18602 "FIIN|77 81|FGFR3
HY-18609 "PD15|12 21|EGFR family
HY-18609 "PD15|42 42|8
HY-18609 "PD15|59 62|EGFR
HY-18609 "PD15|64 68|ErbB2
HY-18609 "PD15|70 74|ErbB3
HY-18609 "PD15|79 83|ErbB4
HY-18610 "Dicl|27 37|inhibitor of
HY-18619 "YL-1|101 105|. IC50
HY-18619 "YL-1|243 258|dependent manner (
HY-18619 "YL-1|264 267|85.8
HY-18619 "YL-1|284 290|, YL-109
HY-18627A "PFI|180 193|SETD7 ( R)-PFI-2
HY-18627A "PFI|247 251|other
HY-18628 "UMI-|94 109|BH3 binding groove
HY-18628 "UMI-|121 122|Ki
HY-18628 "UMI-|167 192|anti - apoptotic Bcl-2 members
HY-18629 "SU95|79 82|CDK4
HY-18630A "Ro |29 31|OSC
HY-18630A "Ro |33 52|Oxidosqualene cyclase
HY-18634 "NSC3|124 126|p53
HY-18644 "CWHM|22 32|αV integrins
HY-18652 "Ro 5|26 28|MEK
HY-18652 "Ro 5|83 85|MEK
HY-18657 "TEPP|23 38|pyruvate kinase M2
HY-18657 "TEPP|40 43|PKM2
HY-18657 "TEPP|107 109|PKR
HY-18664 "PFI-|222 230|binding to
HY-18664 "PFI-|374 382|construct
HY-18664 "PFI-|412 422|- acetylated
HY-18665 "GSK-|256 264|histone H3
HY-18665 "GSK-|358 376|Halotagged histone H3
HY-18682 "Cent|50 65|polo - like kinase 4
HY-18682 "Cent|77 78|Ki
HY-18683 "Cent|43 46|inone - B PLK4
HY-18683 "Cent|62 63|Ki
HY-18690 "Enas|55 64|IDH2 mutant
HY-18696 "AMG-|11 19|and highly
HY-18696 "AMG-|195 214|exquisite selectivity
HY-18696 "AMG-|272 276|lipid
HY-18696 "AMG-|379 382|IC50
HY-18700 "BRD7|114 116|954 nM (
HY-18700 "BRD7|129 143|: HDAC BRD73954 is
HY-18700 "BRD7|147 151|first
HY-18700 "BRD7|295 304|to distinct
HY-18700 "BRD7|545 559|a robust increase
HY-18700 "BRD7|586 595|known HDAC6
HY-18700 "BRD7|612 618|histone
HY-18708 "Erda|47 56|FGFR family
HY-18712 "BG45|4 13|HDAC class I
HY-18712 "BG45|69 73|HDAC1
HY-18712 "BG45|177 181|HDAC1
HY-18712 "BG45|216 219|HDAC
HY-18714 "BRD7|22 30|bacterial
HY-18714 "BRD7|164 169|gyrase gyrase
HY-18714 "BRD7|184 187|aryl
HY-18714 "BRD7|226 234|anti - LSCe
HY-18731 "1400|76 77|NO synthase Ki
HY-18741 "VR23|52 63|trypsin - like
HY-18741 "VR23|86 102|chymotrypsin - like
HY-18741 "VR23|133 139|caspase
HY-18741 "VR23|181 202|trypsin - like proteasome
HY-18741 "VR23|211 240|nM(chymotrypsin - like proteasome
HY-18741 "VR23|247 268|caspase - like proteasome
HY-18741 "VR23|342 354|20S proteasome
HY-18750 "AZD3|54 57|EGFR
HY-18767 "Ivos|16 45|mutant isocitrate dehydrogenase 1
HY-18767 "Ivos|47 50|IDH1
HY-18768 "NCT-|52 75|aldehyde dehydrogenase 1A1
HY-18768 "NCT-|177 190|isozymes dehydrogenases
HY-18768 "NCT-|245 250|Target
HY-18937 "WEHI|114 124|RIPK2 kinase
HY-18937 "WEHI|168 172|NF - κB
HY-18937 "WEHI|195 197|NOD
HY-18937 "WEHI|521 539|WEHI-345 ameliorates
HY-18939 "N6-C|29 38|A1 receptor
HY-18951 "The |63 65|Btk
HY-18951 "The |134 136|Btk
HY-18951 "The |200 202|BTK
HY-18955 "BI-8|37 39|MEK
HY-18955 "BI-8|43 55|aurora kinases
HY-18955 "BI-8|87 95|human MEK2
HY-18955 "BI-8|99 102|AK - C
HY-18958 "CCT2|30 33|seletive Chk1
HY-18972 "PLX8|23 25|Raf
HY-18977 "KML2|144 162|proteomes human brain proteomes
HY-18977 "KML2|280 295|serine hydrolases
HY-18978 "GR79|29 47|adenosine A1 receptor
HY-18978 "GR79|56 57|Ki
HY-18978 "GR79|153 171|nM(Ki adenosine A1 receptor
HY-18986 "SAR4|6 12|a highly
HY-18988 "ETC-|52 60|β - catenin
HY-18998 "LMK-|23 29|HDAC4/5
HY-18998 "LMK-|66 70|HDAC1
HY-19317 "ITE |27 49|aryl hydrocarbon receptor
HY-19317 "ITE |51 53|AhR
HY-19317 "ITE |73 75|AHR
HY-19317 "ITE |82 83|Ki
HY-19320 "Orex|120 149|n 2 Receptor Orexin 2 Receptor Orexin 2 Receptor
HY-19320 "Orex|376 377|- Ki
HY-19323 "Cera|36 38|ATR
HY-19327 "ACY-|96 100|bioavailable HDAC6 HDAC1
HY-19329 "HA13|76 78|ATX
HY-19329 "HA13|120 122|ATX
HY-19329 "HA13|205 207|ATX
HY-19329 "HA13|361 363|ATX
HY-19344 "Lifi|19 26|integrin
HY-19344 "Lifi|114 119|ICAM-1
HY-19347 "WDR5|120 128|containing protein 5 WDR5 - 0103
HY-19347 "WDR5|137 139|MLL
HY-19347 "WDR5|194 196|MLL
HY-19347 "WDR5|323 337|core trimeric MLL
HY-19347 "WDR5|410 413|WDR5
HY-19347 "WDR5|454 456|0103 MLL
HY-19347 "WDR5|472 474|MLL
HY-19348 "Pime|26 30|tight
HY-19348 "Pime|50 59|class I HDAC
HY-19348 "Pime|61 65|HDAC 1
HY-19348 "Pime|155 166|class II HDACs
HY-19348 "Pime|184 188|HDAC1
HY-19348 "Pime|223 228|HDAC   
HY-19348 "Pime|288 289|Ki
HY-19348 "Pime|392 396|HDAC 8
HY-19351 "MN-6|10 18|tankyrase
HY-19370 "FPS-|36 37|Ki
HY-19522A "Sel|149 162|PPARγ receptors
HY-19533 "SCH |9 28|adenosine A2A receptor
HY-19540 "GSK8|5 28|isocitrate dehydrogenase 1
HY-19540 "GSK8|30 33|IDH1
HY-19540 "GSK8|59 69|IDH1 mutants
HY-19562 "PF-0|24 37|small - molecule
HY-19566 "NQDI|18 41|signal - regulating kinase 1
HY-19566 "NQDI|43 46|ASK1
HY-19566 "NQDI|53 54|Ki
HY-19568 "Pefi|14 16|JAK
HY-19568 "Pefi|60 63|JAK1
HY-19568 "Pefi|65 68|JAK2
HY-19568 "Pefi|70 73|JAK3
HY-19568 "Pefi|77 80|Tyk2
HY-19636 "JNJ-|184 188|but is
HY-19644 "GSK2|159 164|) the rat
HY-19712 "LJH6|32 34|RSK
HY-19712 "LJH6|130 132|RSK
HY-19712 "LJH6|166 168|RSK
HY-19713 "LJI3|20 22|RSK
HY-19713 "LJI3|74 77|RSK3
HY-19713 "LJI3|158 160|RSK
HY-19713 "LJI3|185 188|S6K1
HY-19713 "LJI3|296 304|HIP kinase
HY-19725 "A-11|31 36|BCL - XL
HY-19732 "BIBS|110 112|AII
HY-19732 "BIBS|268 270|7 nM
HY-19732 "BIBS|318 329|subtype . BIBS
HY-19732 "BIBS|403 418|AII concentration
HY-19732 "BIBS|500 503|vivo
HY-19733 "Luma|46 51|0.54 nM
HY-19733 "Luma|53 53|,
HY-19733 "Luma|110 133|postsynaptic D2 receptors (
HY-19733 "Luma|136 136|=
HY-19733 "Luma|151 158|blocker (
HY-19733 "Luma|179 182|0.54
HY-19733 "Luma|185 185|(
HY-19733 "Luma|189 197|for 5-HT2A
HY-19733 "Luma|262 277|for the D1 receptor
HY-19736 "TY-5|12 23|S1P3 receptor
HY-19736 "TY-5|61 62|Ki
HY-19736 "TY-5|91 102|S1P3 receptor
HY-19736 "TY-5|120 121|Ki
HY-19736 "TY-5|205 216|Target S1P3 receptor
HY-19736 "TY-5|254 265|S1P3 receptor
HY-19736 "TY-5|397 399|S1P3 receptor Rho
HY-19736 "TY-5|483 494|S1P3 receptor
HY-19736 "TY-5|528 535|Receptor
HY-19739 "JW74|47 49|Wnt
HY-19745 "BMS-|20 23|PD-1
HY-19745 "BMS-|25 36|PD - L1 protein
HY-19747 "HPOB|380 384|HDAC6
HY-19747 "HPOB|426 427|in
HY-19747 "HPOB|612 614|: on
HY-19752A "VU0|36 49|M1 agonists that
HY-19752A "VU0|214 219|appear
HY-19752A "VU0|248 263|an allosteric site
HY-19752A "VU0|295 305|competition
HY-19752A "VU0|335 342|21.4 ( rM2
HY-19795 "ML24|10 12|p97
HY-19795 "ML24|33 41|p97 ATPase
HY-19797A "ML2|23 25|p97
HY-19797A "ML2|46 54|p97 ATPase
HY-19800 "ML-0|32 49|GTP - binding protein
HY-19807 "Indi|181 184|CDK1
HY-19807 "Indi|186 192|cyclin B
HY-19816A "Avi|49 77|epidermal growth factor receptor
HY-19816A "Avi|79 82|EGFR
HY-19834 "Fene|40 72|noncovalent bruton 's tyrosine kinase
HY-19834 "Fene|74 76|Btk
HY-19834 "Fene|92 93|Ki
HY-19912 "Fruq|44 53|VEGFR 1/2/3
HY-19928 "Vact|82 85|ALK2
HY-19952 "Plec|8 13|capsid
HY-19952 "Plec|222 238|capsid proteins VP1
HY-19952 "Plec|240 242|VP3
HY-19952 "Plec|246 248|VP2
HY-19952 "Plec|282 287|capsid
HY-19957 "CH51|35 38|FGFR
HY-19957 "CH51|77 81|FGFR1
HY-19957 "CH51|89 93|FGFR3
HY-19958 "XEN9|202 214|XEN907 shows no
HY-19991 "BMS-|24 35|PD - L1 protein
HY-21098A "PD-|24 41|dopamine D4 receptor
HY-21098A "PD-|55 56|Ki
HY-30234A "Cle|22 40|H1 histamine receptor
HY-32718 "Peli|5 19|EKB-569;WAY - EKB
HY-32718 "Peli|51 54|EGFR
HY-32718 "Peli|94 96|Src
HY-32718 "Peli|98 100|MEK
HY-32718 "Peli|102 104|ERK
HY-32718 "Peli|108 112|ErbB2
HY-32721 "Nera|24 49|irreversible tyrosine kinase
HY-32721 "Nera|84 87|HER2
HY-32721 "Nera|91 94|EGFR
HY-50081 "CCR2|35 59|C - C chemokine receptor type 2
HY-50101A "Mav|85 89|CXCR4
HY-50101A "Mav|129 137|CXCR4 125I
HY-50108 "GW 4|11 13|FXR
HY-50175 "Laro|25 34|DP receptor
HY-50175 "Laro|49 50|Ki
HY-50175 "Laro|77 86|DP receptor
HY-50175 "Laro|92 99|TP Receptor
HY-50295 "CI-1|44 57|small - molecule
HY-50295 "CI-1|69 71|MEK
HY-50295 "CI-1|91 94|MEK1
HY-50514 "AT92|4 22|multitargeted kinase
HY-50514 "AT92|53 65|aurora kinase A
HY-50667 "Apix|43 50|Factor Xa
HY-50667 "Apix|55 56|Ki
HY-50675 "GRA |19 34|glucagon receptor
HY-50675 "GRA |64 85|human glucagon receptors
HY-50683 "JNJ-|77 77|-
HY-50683 "JNJ-|81 84|than
HY-50683 "JNJ-|158 162|vitro
HY-50683 "JNJ-|181 184|more
HY-50683 "JNJ-|189 196|600-fold
HY-50683 "JNJ-|395 400|- H1993
HY-50686 "Tiva|31 49|c - Met tyrosine kinase
HY-50686 "Tiva|63 64|Ki
HY-50696 "Nutl|46 47|n Ki
HY-50697 "A-74|36 47|P2X7 receptor
HY-50698 "BI 2|98 102|IFN - β
HY-50706 "Selu|21 23|MEK
HY-50706 "Selu|57 60|MEK1
HY-50710 "KU-0|25 28|mTOR
HY-50751 "Lini|41 44|VEGF
HY-50751 "Lini|48 60|PDGFR receptor
HY-50751 "Lini|101 106|PDGFRβ
HY-50751 "Lini|110 113|FLT3
HY-50752 "LY-4|95 99|Notch
HY-50759 "Ispi|35 39|Ki app
HY-50845 "Avag|38 38|γ
HY-50855 "Silm|43 55|casein kinase 2
HY-50855 "Silm|57 59|CK2
HY-50855 "Silm|75 76|Ki
HY-50855B "Sil|75 77|CK2
HY-50856 "Ruxo|122 125|JAK3
HY-50858 "Ruxo|113 116|JAK3
HY-50864 "GDC-|24 28|B - Raf
HY-50876 "(E)-|39 75|nicotinamide phosphoribosyltransferase
HY-50877 "GSK4|45 60|Polo - like kinase 1
HY-50877 "GSK4|81 82|Ki
HY-50878 "Criz|25 29|c - Met
HY-50878 "Criz|33 35|ALK
HY-50878A "Cri|39 43|c - Met
HY-50878A "Cri|47 49|ALK
HY-50883 "BMS |112 134|γ - secretase amyloid precursor protein
HY-50883 "BMS |136 138|APP
HY-50895 "Gefi|15 32|EGFR tyrosine kinase
HY-50895A "Gef|66 83|EGFR tyrosine kinase
HY-50896 "Erlo|76 85|EGFR kinase
HY-50898 "Lapa|23 26|EGFR
HY-50898 "Lapa|30 34|ErbB2
HY-50898A "Lap|24 27|EGFR
HY-50898A "Lap|31 35|ErbB2
HY-50903 "Riva|52 59|Factor Xa
HY-50903 "Riva|61 63|FXa
HY-50903 "Riva|97 104|anti - FXa
HY-50903 "Riva|123 124|Ki
HY-50905 "Dovi|82 85|tyrosine kinase FLT3
HY-50905 "Dovi|87 91|c - Kit
HY-50907 "ABT-|27 47|Bcl - xL,?Bcl-2?and?Bcl
HY-50912 "Pler|34 38|CXCR4
HY-50935 "Trog|50 54|human
HY-50940 "AT75|21 24|CDKs
HY-50940 "AT75|76 79|CDK4
HY-50940 "AT75|82 85|CDK6
HY-50940 "AT75|90 93|CDK9
HY-50943 "AT75|34 37|CDKs
HY-50943 "AT75|89 92|CDK4
HY-50943 "AT75|95 98|CDK6
HY-50943 "AT75|103 106|CDK9
HY-50946 "Imat|14 28|tyrosine kinases
HY-50946 "Imat|50 54|c - Kit
HY-50946 "Imat|60 62|Bcr - Abl
HY-50946 "Imat|67 71|PDGFR
HY-50946 "Imat|84 98|tyrosine kinases
HY-51424 "PLX-|96 108|c - Raf-1(Y340D
HY-51424 "PLX-|112 125|Y341D mutations
HY-51424 "PLX-|152 152|B
HY-51424 "PLX-|166 179|RafV600E wild - type B - Raf
HY-59047 "Toli|26 35|allosteric
HY-59047 "Toli|47 55|Lyn kinase
HY-70002 "Enza|20 35|androgen receptor
HY-70002 "Enza|37 38|AR
HY-70002A "N-d|71 87|androgen - receptor
HY-70002A "N-d|89 90|AR
HY-70006 "Gale|47 51|CYP17
HY-70013 "Abir|41 45|CYP17
HY-70035 "Otam|22 22|(
HY-70035 "Otam|165 171|: Factor
HY-70035 "Otam|672 674|the
HY-70057 "Safi|59 61|MAO
HY-70057 "Safi|114 116|MAO
HY-70057 "Safi|144 158|MAO - B Safinamide
HY-70057 "Safi|234 238|monoamine oxidase type B MAO - B
HY-70057 "Safi|503 512|Safinamide
HY-70057 "Safi|567 575|aspartate
HY-70059 "LY34|18 34|glutamate receptor
HY-70061 "Auro|39 45|I Aurora A
HY-70063 "Bupa|6 8|NVP
HY-70068 "SB40|45 48|Ki of
HY-70068 "SB40|75 85|and membrane
HY-70068 "SB40|200 213|hypocretin type
HY-70068 "SB40|390 398|receptor .
HY-70068 "SB40|411 423|indicates that
HY-70068 "SB40|445 452|cultures
HY-75800 "VX-2|51 60|polymerase
HY-75800 "VX-2|152 157|I482L.
HY-75800 "VX-2|481 483|the
HY-75800 "VX-2|523 524|1b
HY-76299 "Gala|16 35|acetylcholinesterase
HY-76299 "Gala|37 40|AChE
HY-76612 "SB40|44 49|with Ki
HY-76612 "SB40|74 80|cell and
HY-76612 "SB40|198 212|binds hypocretin
HY-76612 "SB40|390 400|OX2 receptor
HY-76612 "SB40|409 422|study indicates
HY-76612 "SB40|441 447|primary
HY-76948 "5-R-|97 104|Factor Xa
HY-76948 "5-R-|106 108|FXa
HY-76948 "5-R-|142 149|anti - FXa
HY-76948 "5-R-|168 169|Ki
HY-78349 "A 77|51 68|TGF - β type I receptor superfamily activin - like kinase
HY-78349 "A 77|142 153|A-83 - 01(Axon
HY-78349 "A 77|196 199|A-83
HY-78349 "A 77|204 210|A-83 - 01
HY-78349 "A 77|231 234|A-77
HY-78349 "A 77|266 269|01 A-77
HY-A0005 "Clof|55 77|ribonucleotide reductase
HY-A0005 "Clof|286 308|ribonucleotide reductase
HY-A0005 "Clof|323 325|DNA
HY-A0005 "Clof|520 530|cytochrome C
HY-A0007 "Roti|55 70|dopamine receptor
HY-A0007 "Roti|92 105|5-HT1A receptor
HY-A0007 "Roti|127 148|α2B - adrenergic receptor
HY-A0007 "Roti|154 155|Ki
HY-A0007 "Roti|209 210|dopamine D3 receptor and D2
HY-A0007 "Roti|212 213|D5
HY-A0007 "Roti|230 247|D4 receptors dopamine D1 receptor
HY-A0009 "Gala|303 325|nicotinic ACh receptors amyloid precursor protein
HY-A0012 "Dari|20 31|a selective M3
HY-A0012 "Dari|50 66|antagonist with pKi
HY-A0012 "Dari|181 185|curve
HY-A0013 "Bose|36 47|endothelin-1
HY-A0013 "Bose|64 75|ETB receptors
HY-A0013 "Bose|80 81|Ki
HY-A0013A "Bos|44 55|endothelin-1
HY-A0013A "Bos|72 83|ETB receptors
HY-A0013A "Bos|88 89|Ki
HY-A0024 "Tolt|196 205|pig bladder
HY-A0024 "Tolt|210 231|effectively inhibited by
HY-A0024 "Tolt|301 308|range and
HY-A0036 "Baze|41 56|estrogen receptor
HY-A0057 "Gaba|149 152|IC50
HY-A0057 "Gaba|158 163|: 140 nM
HY-A0057 "Gaba|289 295|release
HY-A0057 "Gaba|298 298|[
HY-A0057 "Gaba|492 508|. A large inhibition
HY-A0057A "Gab|150 153|IC50
HY-A0057A "Gab|159 164|: 140 nM
HY-A0057A "Gab|290 296|release
HY-A0057A "Gab|299 299|[
HY-A0057A "Gab|493 509|. A large inhibition
HY-A0077 "Perp|58 83|Alpha-1A adrenergic receptor
HY-A0077 "Perp|85 102|Dopamine receptor D2
HY-A0077 "Perp|107 117|D2L receptor
HY-A0077 "Perp|131 140|H1 receptor
HY-A0077 "Perp|146 147|Ki
HY-B0020 "Trop|120 124|70.1 ±
HY-B0020 "Trop|353 356|, MLA
HY-B0022 "Flut|154 154|mide : androgen  
HY-B0022 "Flut|545 549|along
HY-B0022 "Flut|638 642|319 mg
HY-B0068 "Azas|208 211|cancer chemotherapy anti
HY-B0068 "Azas|213 218|emetic
HY-B0068 "Azas|220 229|Azasetron  
HY-B0068 "Azas|239 249|the specific
HY-B0068 "Azas|257 259|of [
HY-B0068 "Azas|272 278|to 5-HT3
HY-B0072 "Trop|18 20|930 is a
HY-B0072 "Trop|76 86|agonist with
HY-B0072 "Trop|93 94|of
HY-B0072 "Trop|145 145|]
HY-B0072 "Trop|152 152|:
HY-B0072 "Trop|380 394|potent inhibitor
HY-B0138 "Keto|80 82|COX
HY-B0138 "Keto|127 131|COX-2
HY-B0144 "Pita|49 65|- CoA HMG - CoA ) reductase
HY-B0199 "Myco|67 99|inosine monophosphate dehydrogenase
HY-B0202 "Irbe|48 75|1 ( AT1 ) receptor antagonist with
HY-B0202 "Irbe|114 132|Irbesartan treatment
HY-B0202 "Irbe|200 201|2 (
HY-B0202 "Irbe|251 258|with EC50
HY-B0202 "Irbe|335 356|induces transcriptional
HY-B0202 "Irbe|742 751|losartan in
HY-B0203A "Neb|343 353|accelerated
HY-B0203A "Neb|597 605|Nebivolol
HY-B0205 "Cand|76 77|II
HY-B0205 "Cand|189 191|the
HY-B0205 "Cand|250 251|in
HY-B0205 "Cand|301 305|still
HY-B0205 "Cand|381 386|with an
HY-B0227 "Keto|79 81|COX
HY-B0227 "Keto|115 119|COX-2
HY-B0231 "Enal|29 56|angiotensin - converting enzyme
HY-B0231 "Enal|58 60|ACE
HY-B0274 "Chlo|79 79|histamine receptors , ,
HY-B0274 "Chlo|85 85|,
HY-B0274 "Chlo|88 88|,
HY-B0274 "Chlo|94 94|,
HY-B0274 "Chlo|150 151|nM
HY-B0274 "Chlo|153 153|3
HY-B0274 "Chlo|284 288|to as D1 ,
HY-B0274 "Chlo|302 305|with
HY-B0279 "Rami|16 43|angiotensin - converting enzyme
HY-B0279 "Rami|45 47|ACE
HY-B0286A "Chl|252 259|by 50%-70
HY-B0286A "Chl|274 290|. Chlorpheniramine
HY-B0286A "Chl|643 646|Oral
HY-B0298A "Cle|46 64|histamine H1 receptor
HY-B0309 "Felo|405 408|IC50
HY-B0309 "Felo|411 412|~8
HY-B0309 "Felo|572 578|VSMC and
HY-B0310 "Niza|19 40|receptor antagonist with
HY-B0310 "Niza|56 70|inhibits gastric
HY-B0310 "Niza|317 320|Nizatidine EC50
HY-B0310 "Niza|323 327|1.383
HY-B0310 "Niza|398 401|with
HY-B0362A "Phe|41 54|α - adrenoceptor
HY-B0363 "Nime|17 21|COX-2
HY-B0365A "Mem|94 106|NMDA receptors
HY-B0365A "Mem|134 135|Ki
HY-B0415 "Fluo|114 133|Receptor Fluocinolone
HY-B0415 "Fluo|530 553|Fluocinolone Acetonide(FA
HY-B0415 "Fluo|600 601|GR
HY-B0429 "Panc|83 83|:
HY-B0429 "Panc|690 701|nicotinic acetylcholine the nicotinic
HY-B0442A "Var|301 306|PDE6 16
HY-B0457 "Clom|168 180|5-HT Receptor hydrochloride
HY-B0457 "Clom|195 211|hydrochloride salt
HY-B0457 "Clom|214 225|clomipramine
HY-B0457 "Clom|254 258|( SERT
HY-B0457 "Clom|260 260|,
HY-B0457 "Clom|291 309|dopamine transporter
HY-B0457 "Clom|311 313|DAT
HY-B0457 "Clom|330 334|0.14 ,
HY-B0457 "Clom|337 339|and
HY-B0457 "Clom|357 381|Clomipramine hydrochloride
HY-B0457 "Clom|383 391|Anafranil
HY-B0457 "Clom|419 431|. Clomipramine
HY-B0457 "Clom|445 445|(
HY-B0457 "Clom|473 481|- reuptake
HY-B0457 "Clom|491 493|and
HY-B0457 "Clom|518 542|Clomipramine hydrochloride
HY-B0457 "Clom|544 552|Anafranil
HY-B0457 "Clom|569 582|inverse agonist
HY-B0457 "Clom|585 587|the
HY-B0457 "Clom|617 619|( Ki
HY-B0457 "Clom|621 623|162
HY-B0457 "Clom|638 640|( Ki
HY-B0457 "Clom|642 643|30
HY-B0483 "Tiox|56 70|lone , acne preparation
HY-B0483 "Tiox|96 107|  Tioxolone is
HY-B0483 "Tiox|130 138|anhydrase
HY-B0483 "Tiox|232 243|are typically
HY-B0483 "Tiox|249 250|in
HY-B0483 "Tiox|354 359|that is
HY-B0483 "Tiox|453 457|in the
HY-B0483 "Tiox|555 555|)
HY-B0483 "Tiox|644 646|thiocarbonate and
HY-B0500 "Alve|13 26|5-HT1A receptor
HY-B0539 "Desl|111 123|Desloratadine
HY-B0539 "Desl|293 299|IL-4 and
HY-B0539 "Desl|307 321|human basophils .
HY-B0539 "Desl|374 374|-
HY-B0539 "Desl|459 471|is also shown to
HY-B0553 "Meth|11 27|carbonic anhydrase
HY-B0553 "Meth|64 80|Carbonic Anhydrase
HY-B0553 "Meth|97 113|carbonic anhydrase
HY-B0553 "Meth|127 128|Ki
HY-B0553 "Meth|150 153|hCA I
HY-B0553 "Meth|155 159|hCA II
HY-B0553 "Meth|163 175|bCA IV isoforms
HY-B0553 "Meth|246 262|carbonic anhydrase
HY-B0573 "Prop|34 53|β - adrenergic receptor
HY-B0579 "Cycl|43 53|sporin cyclophilin
HY-B0602 "Desv|12 21|nlafaxine is serotonin (
HY-B0640 "Epin|30 32|stine(WAL801 ) is an and
HY-B0640 "Epin|637 644|an reaction
HY-B0732 "Itop|20 23|AChE
HY-B0732 "Itop|34 53|acetylcholinesterase
HY-B0732 "Itop|79 82|AChE
HY-B0732 "Itop|151 154|AChE
HY-B0732 "Itop|249 252|AChE
HY-B0732 "Itop|316 329|cholinesterase
HY-B0732 "Itop|331 333|ChE
HY-B0732 "Itop|426 428|ChE
HY-B0732 "Itop|526 529|AChE
HY-B0735A "Fen|467 473|maximum
HY-B0735A "Fen|517 526|obtained by fenoldopam the maximum
HY-B0735A "Fen|589 591|35.6 + /-
HY-B0760 "Feno|45 57|PPAR activitor
HY-B0760 "Feno|155 159|COX-2
HY-B0782 "Acet|11 27|carbonic anhydrase
HY-B0782 "Acet|29 33|CA ) IX
HY-B0788 "LY24|16 25|IκB kinase β
HY-B0789 "SU 6|5 20|Src family kinases
HY-B0789 "SU 6|60 62|Src
HY-B0789 "SU 6|68 70|Lyn
HY-B0789 "SU 6|75 77|Fyn
HY-B0791 "Alti|19 23|multi
HY-B0791 "Alti|107 110|targeted kinase FLT3
HY-B0792 "CZC-|22 28|of LRRK2
HY-B0793 "AZ-5|56 59|EGFR
HY-B0793 "AZ-5|107 111|T790 M
HY-B0793 "AZ-5|133 136|EGFR
HY-B0793 "AZ-5|140 144|ErbB4
HY-B1102 "Evan|121 135|acid transporter kainate receptor
HY-B1102 "Evan|394 405|serum albumin
HY-B1208 "Carb|51 55|nAChR
HY-B1208 "Carb|154 155|Ki
HY-B1208 "Carb|164 168|Target nAChR
HY-B1208 "Carb|170 174|mAChR
HY-B1208 "Carb|229 250|acetylcholine receptors
HY-B1208 "Carb|301 305|nAChR
HY-B1208 "Carb|310 335|muscarinic ( mAChR ) receptors
HY-B1208 "Carb|349 350|Ki
HY-B1480 "Etho|11 27|carbonic anhydrase
HY-B1480 "Etho|41 45|Ki of 1
HY-B1490 "Imip|26 45|serotonin transporter
HY-B1541 "Beme|27 39|5-HT3 receptor
HY-B1902 "Diav|20 41|dihydrofolate reductase
HY-B1902 "Diav|43 46|DHFR
HY-B1902 "Diav|62 63|Ki
HY-B2137 "S-(+|43 47|COX-2
HY-B2244 "Tacr|41 46|acetyl
HY-B2244 "Tacr|48 51|AChE
HY-B2244 "Tacr|56 62|butyryl
HY-I0383 "Cana|388 425|subtype 2 sodium - glucose transport protein
HY-I0678 "Rego|109 111|oxyde RET
HY-I0678 "Rego|115 119|Raf-1
HY-N0014 "Icar|113 126|PPARα activator
HY-N0018 "Daid|36 40|anti -
HY-N0018 "Daid|117 138|aldehyde dehydrogenase 2
HY-N0018 "Daid|166 181|anti - dipsotropic
HY-N0049 "Nuci|40 45|5-HT2C
HY-N0049 "Nuci|146 147|D5
HY-N0049 "Nuci|192 197|EC50=2.6 μM 5-HT1A
HY-N0049 "Nuci|216 223|EC50=2 μM
HY-N0096 "Rotu|20 29|dopamine D1
HY-N0096 "Rotu|31 46|D2 and D3 receptors
HY-N0096 "Rotu|121 126|5-HT1A
HY-N0102 "Isol|16 25|anti - tumor
HY-N0102 "Isol|79 93|aldose reductase
HY-N0215 "L-Ph|152 156|- Phenylalanine one of
HY-N0215 "L-Ph|172 185|amino acids used
HY-N0215 "L-Ph|188 204|biochemically form
HY-N0215 "L-Ph|254 268|antagonist at the
HY-N0233 "Bava|88 107|estrogen receptors ERα
HY-N0296A "Sco|38 47|muscarinic
HY-N0296A "Sco|59 71|5-HT3 receptor
HY-N0340 "Scop|42 43|of
HY-N0340 "Scop|106 111|muscarinic Target
HY-N0340 "Scop|207 214|drug with
HY-N0340 "Scop|349 356|Datura ) ,
HY-N0393 "Glab|118 131|anti - bacterial
HY-N0393 "Glab|133 146|anti - nephritic
HY-N0761 "3-Hy|145 166|α1-adrenergic receptors
HY-N0761 "3-Hy|168 175|IC50=1.4
HY-N0761 "3-Hy|199 209|β - endorphin
HY-N1374 "Magn|34 40|lin Shin - Yi
HY-N1374 "Magn|54 56|Ras
HY-N1374 "Magn|58 61|ERKs
HY-N1374 "Magn|108 111|ERK1
HY-N1374 "Magn|115 118|ERK2
HY-N1584 "Halo|115 135|prolyl - tRNA synthetase
HY-N1584 "Halo|164 165|Ki
HY-N1584 "Halo|168 171|18.3
HY-N1584 "Halo|232 236|TGF - β
HY-N1584A "Hal|140 160|prolyl - tRNA synthetase
HY-N1584A "Hal|189 190|Ki
HY-N1584A "Hal|193 196|18.3
HY-N1584A "Hal|257 261|TGF - β
HY-N1937 "Pris|28 49|reversible monoacylglycerol lipase
HY-N1943 "Aila|82 83|length androgen receptor AR
HY-N1943 "Aila|114 144|active truncated AR splice variants
HY-N1943 "Aila|146 152|AR1 - 651
HY-N2148 "Cyto|8 26|porone B Csn - B;Dothiorelone G
HY-N2148 "Cyto|49 74|nuclear orphan receptor Nur77
HY-P0018A "Pep|132 141|hemoglobin
HY-P0018A "Pep|143 148|pepsin
HY-P0018A "Pep|150 159|hemoglobin
HY-P0018A "Pep|170 175|casein
HY-P0018A "Pep|177 182|pepsin
HY-P0018A "Pep|184 198|casein - proctase
HY-P0018A "Pep|200 218|casein - acid protease
HY-P0018A "Pep|222 244|hemoglobin - acid protease
HY-P0018A "Pep|288 298|HIV protease
HY-P0023 "Cycl|43 54|αvβ3 integrin
HY-P0185 "Endo|49 64|μ - opioid receptor
HY-P0185 "Endo|97 114|kappa3 binding sites
HY-P0185 "Endo|120 121|Ki
HY-U00426 "BF7|7 41|phosphatidylinositol 4-kinase III beta
HY-U00433A "JM|61 67|hormone secretagogue receptor 1a GHS - R1a
HY-W018061 "Tr|40 43|NMDA
HY-100867A "TA|54 73|spleen tyrosine kinase
HY-100867A "TA|75 77|Syk
HY-101801 "Ac-|39 40|Ki
HY-101979A "CB|91 115|recombinant human arginase 1
HY-10219 "Rapa|15 21|AY 22989
HY-10219 "Rapa|43 46|mTOR
HY-10219 "Rapa|103 108|FKBP12
HY-103714A "En|56 58|ALK
HY-103714A "En|60 62|MET
HY-104065 "Pyr|36 39|EGFR
HY-104065 "Pyr|41 44|HER2
HY-10432 "A 83|22 49|TGF - β type I receptor ALK5 kinase
HY-10432 "A 83|51 54|type
HY-10432 "A 83|175 178|activin I nodal receptor ALK7 ALK7
HY-10683 "PKI-|52 55|PI3 K
HY-10683 "PKI-|66 71|PI3K - α
HY-10683 "PKI-|83 86|mTOR
HY-10683 "PKI-|117 120|mTOR
HY-10889 "Prel|44 68|human adenosine A2A receptor
HY-10889 "Prel|74 75|Ki
HY-10889 "Prel|122 139|adenosine receptors
HY-12012 "SB 2|40 44|GSK-3
HY-12030 "PIK-|13 16|0 PI3 K
HY-12071 "LDN1|7 9|BMP
HY-12071 "LDN1|44 47|ALK2
HY-12201 "TAK-|57 63|aurora A
HY-12286 "PI-1|72 75|0.14
HY-12286 "PI-1|252 252|:
HY-12286 "PI-1|293 304|constitutive
HY-12286 "PI-1|315 318|over
HY-12286 "PI-1|322 337|immunoproteasome
HY-12286 "PI-1|463 479|PI-1840 inhibits CT
HY-12286 "PI-1|513 534|of proteasome substrates
HY-12296 "AMG |101 104|MDM2
HY-12382 "NMS-|42 45|MPS1
HY-12432A "Gil|29 32|FLT3
HY-12432A "Gil|34 36|AXL
HY-12484 "BMH-|64 77|molecule RNA polymerase I
HY-12484 "BMH-|79 82|Pol I
HY-12484 "BMH-|171 177|RNA Pol I
HY-12484 "BMH-|296 298|ATM
HY-12484 "BMH-|306 313|DNA - PKcs
HY-12484 "BMH-|384 387|Pol I
HY-12857 "Brig|32 34|ALK
HY-13259 "MG-1|39 51|2 20S proteasome
HY-13259 "MG-1|85 96|chymotrypsin
HY-13274 "JTC-|14 33|opioid receptor - like1
HY-13274 "JTC-|35 47|ORL1 ) receptor
HY-13274 "JTC-|68 79|ORL1 receptor
HY-13274 "JTC-|85 86|Ki
HY-13323 "CX-5|51 64|RNA polymerase I
HY-13443 "Exen|39 68|acid peptide glucagon - like peptide-1 receptor
HY-13443A "Exe|47 76|acid peptide glucagon - like peptide-1 receptor
HY-13808 "UNC |290 292|tox
HY-13808 "UNC |530 532|tox
HY-13912 "IWP-|16 18|Wnt
HY-14894 "Ipra|633 634|of
HY-15498 "Rime|37 65|calcitonin gene - related peptide
HY-15498 "Rime|67 79|CGRP ) receptor
HY-15498 "Rime|95 96|Ki
HY-15598 "20-H|366 376|dysfunction
HY-15598 "20-H|491 495|large
HY-15598 "20-H|524 525|K+
HY-15598 "20-H|566 567|on
HY-15598 "20-H|573 573|[ 1 ]
HY-15772A "Osi|68 71|EGFR
HY-15772A "Osi|129 133|T790 M
HY-15825 "IWP |44 46|0.5
HY-15825 "IWP |76 80|vitro
HY-15825 "IWP |416 416|)
HY-15889 "AMG |40 43|FLT3
HY-15889 "AMG |45 48|CDK4
HY-15989 "SM-1|51 61|XIAP protein
HY-16297A "Abe|74 77|CDK4
HY-16297A "Abe|81 84|CDK6
HY-17024 "Cycl|9 16|Hedgehog
HY-17024 "Cycl|18 19|Hh
HY-17024 "Cycl|59 60|Hh
HY-17034 "Mede|63 64|Ki
HY-18595 "BI 2|12 41|HIV-1 noncatalytic site integrase
HY-32351A "Cal|104 105|Ki
HY-32351A "Cal|124 142|PTH secretion and mRNA
HY-50671 "Zosu|36 49|P - glycoprotein
HY-50671 "Zosu|55 56|Ki
HY-50673 "Dact|37 46|I PI3 K mTOR kinase
HY-50673 "Dact|122 125|mTOR
HY-50767 "Palb|7 8|PD
HY-50767 "Palb|29 32|CDK4
HY-50767 "Palb|36 39|CDK6
HY-50908 "Defo|44 47|mTOR
HY-50908 "Defo|66 83|ribosomal protein S6
HY-76251 "Etod|85 87|lac COX
HY-79077 "Osim|70 73|EGFR
HY-79077 "Osim|131 135|T790 M
HY-80003 "QL47|34 42|BTK kinase
HY-80003 "QL47|86 88|Btk
HY-80003 "QL47|109 117|BTK kinase
HY-80003 "QL47|171 173|BTK
HY-80003 "QL47|369 378|BTK protein
HY-B0032 "Lura|65 74|dopamine D2
HY-B0032 "Lura|196 209|5-HT1A receptor
HY-B0032A "Lur|36 45|dopamine D2
HY-B0032A "Lur|137 150|5-HT1A receptor
HY-B0183 "Ella|62 64|CK2
HY-B0183 "Ella|95 96|Ki
HY-B0366A "Cyp|13 29|histamine receptor
HY-B0366A "Cyp|43 55|5-HT2 receptor
HY-B0366A "Cyp|133 143|histamine H2
HY-B0366A "Cyp|409 414|serotonergic systems 5-HT(2
HY-N0488 "Vinc|168 169|Ki
HY-P0009A "Cet|52 64|gonadotropin - releasing hormone ( GnRH ) receptor
HY-P0018B "Pep|124 133|hemoglobin
HY-P0018B "Pep|135 140|pepsin
HY-P0018B "Pep|142 151|hemoglobin
HY-P0018B "Pep|162 167|casein
HY-P0018B "Pep|169 174|pepsin
HY-P0018B "Pep|176 190|casein - proctase
HY-P0018B "Pep|192 210|casein - acid protease
HY-P0018B "Pep|214 236|hemoglobin - acid protease
HY-P0018B "Pep|280 290|HIV protease
HY-P0117 "Tat-|45 54|peptide density-95
HY-P0117 "Tat-|56 61|PSD-95
HY-P0117 "Tat-|108 117|PSD-95 PDZ domain 2
HY-P0117 "Tat-|140 149|Tat - NR2B9c
HY-P0117 "Tat-|161 164|NMDA
HY-P0117 "Tat-|173 175|p38
HY-P0171 "Moti|39 43|CXCR4
HY-P0220A "PAC|32 44|PACAP receptor
HY-P0220A "PAC|83 100|PACAP type I receptor
HY-P0220A "PAC|102 124|PACAP type II receptor VIP1
HY-P0220A "PAC|129 151|PACAP type II receptor VIP2
HY-P0227 "SHU |12 42|human melanocortin 3 and 4 receptors
HY-P1029 "MLCK|21 42|myosin light chain kinase
HY-P1029 "MLCK|44 47|MLCK
HY-P1029 "MLCK|86 96|CaM kinase II
HY-P1030 "Hemo|33 52|neurokinin-1 receptor
HY-P1030 "Hemo|58 59|Ki
HY-P1030 "Hemo|80 95|human NK1 receptor
HY-P1030 "Hemo|99 114|human NK2 receptor
HY-P1037 "Moti|31 51|motilin receptor ligand
HY-P1037 "Moti|56 57|Ki
HY-P1087 "Adre|51 66|μ - opioid receptor
HY-P1087 "Adre|72 73|Ki
HY-P1548A "β-C|3 7|RP human
HY-P1548A "β-C|18 35|calcitonin peptides
HY-P1548A "β-C|56 87|calcitonin - receptor - like receptor
HY-P1548A "β-C|89 92|CRLR
HY-P1548A "β-C|97 105|receptor -
HY-100013A1 "(|65 77|GPR88 receptor
HY-100022 "eFT|56 59|MNK1 MNK2
HY-10011 "SCH |32 36|CXCR2
HY-100115 "TA-|7 10|2 p38 MAPK
HY-100115 "TA-|56 58|p38
HY-100130 "N-[|33 49|adenosine receptor
HY-100130 "N-[|64 65|Ki
HY-100130 "N-[|120 121|Ki
HY-100201 "A-1|403 427|H2 histone methyltransferases
HY-100315 "Tyr|89 93|sine kinase tyrosine kinase FGFR1
HY-100342 "Ibr|51 56|tinib - biotin biotin
HY-100342 "Ibr|148 150|BTK
HY-100368A "ME|62 65|embryonic leucine zipper kinase MELK
HY-100388 "SHP|37 40|SHP2
HY-100388A "SH|53 56|SHP2
HY-100402 "CFM|233 243|showing that
HY-100419 "BFH|64 75|VEGFR2 kinase
HY-100423A "KP|62 65|CRM1
HY-100441 "Tre|23 25|DP1
HY-100443B "(-|22 24|FXR
HY-100443B "(-|55 57|FXR
HY-100459 "GSK|27 35|RET kinase
HY-100462 "PTP|15 42|B - IN-2 protein tyrosine phosphatase 1B
HY-100462 "PTP|44 48|PTP1B
HY-100470 "NSC|20 23|PI3 K
HY-100470 "NSC|27 30|mTOR
HY-100506 "GLP|20 35|integrin receptor
HY-100626 "WNK|78 81|pan - WNK - kinase WNK 2
HY-100626 "WNK|83 85|WNK
HY-100681 "GSK|28 48|lactate dehydrogenase A
HY-100684 "FAP|42 68|fibroblast activation protein
HY-100684 "FAP|104 123|prolyl oligopeptidase
HY-100740 "Lan|106 107|Ki
HY-100742A "(R|17 37|lactate dehydrogenase A
HY-100844 "GS-|61 84|signal - regulating kinase 1
HY-100844 "GS-|86 89|ASK1
HY-10095 "Olce|52 81|calcitonin gene - related peptide 1
HY-10095 "Olce|83 87|CGRP1
HY-10095 "Olce|116 123|Ki of 14.4
HY-10095A "Olc|73 102|calcitonin gene - related peptide 1
HY-10095A "Olc|104 108|CGRP1
HY-10095A "Olc|142 149|Ki of 14.4
HY-101026 "CCT|40 68|heat shock transcription factor 1
HY-101146 "SF2|40 43|PI3 K
HY-101146 "SF2|112 115|PK mTOR
HY-101147 "YKL|9 12|salt
HY-101189 "JNJ|34 52|histamine H4 receptor
HY-101189 "JNJ|68 69|Ki
HY-101267 "CHM|36 62|type II irreversible BMX kinase
HY-101284 "DMU|74 79|CYP1A1
HY-101386 "PZM|22 36|μ opioid receptor
HY-101467A "Tr|62 65|CDK4
HY-101467A "Tr|69 72|CDK6
HY-101490 "PDE|43 56|WO2016/55618 A1
HY-101494 "LY3|34 37|ERK1
HY-101494 "LY3|41 44|ERK2
HY-101507 "Pic|27 43|TRPC1/4/5 channels
HY-101564 "JNJ|23 46|pseudo - irreversible PRMT5
HY-101565 "AMG|63 64|bioavailable MCL-1 Ki
HY-101569 "LXS|51 53|protein kinase C PKC
HY-101640 "TPA|45 46|Ki
HY-101718 "Ati|28 36|centrally
HY-101718 "Ati|81 82|penetrant kappa opioid receptor Ki
HY-101760 "GSK|32 35|RIP1
HY-101768 "PRN|30 36|FGFR1 - 4
HY-101780 "EDO|10 13|HDAC
HY-101780 "EDO|32 36|HDAC1
HY-101784 "NE |71 74|Anti
HY-101793 "BMS|48 69|Bruton ’s tyrosine kinase
HY-101793 "BMS|71 73|Btk
HY-101805 "SK1|13 30|sphingosine kinase 1
HY-101842 "ND-|44 64|acetyl - CoA carboxylase
HY-101842 "ND-|66 68|ACC
HY-101842 "ND-|97 112|recombinant hACC1
HY-101845 "FIT|51 52|Ki
HY-10185 "TG 1|20 24|multi
HY-10185 "TG 1|62 84|targeted kinase receptor tyrosine kinases
HY-10185 "TG 1|88 97|Src kinases
HY-10185 "TG 1|161 165|FGFR1
HY-10185 "TG 1|184 186|Fyn
HY-10185 "TG 1|192 194|Lck
HY-10185 "TG 1|196 198|Lyn
HY-10185 "TG 1|200 202|Src
HY-101856 "BMS|54 75|Bruton 's tyrosine kinase
HY-101856 "BMS|77 79|BTK
HY-101857 "MGA|33 63|monoacylglycerol acyltransferase
HY-101870B "IN|53 66|WO 2017044730 A1
HY-101922 "IRA|10 47|interleukin-1 receptor associated kinase 4
HY-101977 "Sel|37 45|TRK kinase
HY-102011 "BMS|18 22|PD - L1
HY-102031 "PI3|62 75|δ WO 2015055071 A1
HY-102033 "Oxa|27 30|HDAC
HY-102060 "WM-|31 55|histone acetyltransferases
HY-102080 "SAF|20 39|FK506-binding protein
HY-102080 "SAF|65 66|Ki
HY-10210 "Reta|56 60|Hsp90
HY-10210 "Reta|84 88|Hsp90
HY-10230 "Mido|26 30|multi
HY-10230 "Mido|84 86|protein kinase Syk
HY-10230 "Mido|94 96|Akt
HY-10230 "Mido|98 100|PKA
HY-10230 "Mido|102 106|c - Kit
HY-10230 "Mido|108 112|c - Fgr
HY-10230 "Mido|114 118|c - Src
HY-10230 "Mido|120 123|FLT3
HY-103002 "SU5|39 50|VEGFR2 kinase
HY-103040 "Zur|25 37|GABAA receptor
HY-103040 "Zur|79 97|α4β3δ GABAA receptors
HY-103082 "CLK|28 43|Cdc2-like kinase 1
HY-103082 "CLK|45 48|CLK1
HY-103085 "T-3|70 73|specific histone demethylase LSD1
HY-10319 "Azai|39 42|ROCK
HY-10319 "Azai|78 88|human ROCK-1
HY-10333 "BMS-|40 43|EGFR
HY-10333 "BMS-|77 80|EGFR
HY-10333 "BMS-|82 85|HER 2
HY-103350 "CA-|22 31|cathepsin B
HY-103350 "CA-|37 41|Ki of 2
HY-10346 "AV-4|12 15|2 EGFR
HY-10346 "AV-4|61 64|EGFR
HY-10346 "AV-4|76 84|EGFRT790 M
HY-10346 "AV-4|86 94|EGFRL858R
HY-10346 "AV-4|96 100|T790 M
HY-10346 "AV-4|104 108|ErbB2
HY-10346A "AV-|13 16|EGFR
HY-10346A "AV-|62 65|EGFR
HY-10346A "AV-|77 85|EGFRT790 M
HY-10346A "AV-|87 95|EGFRL858R
HY-10346A "AV-|97 101|T790 M
HY-10346A "AV-|105 109|ErbB2
HY-103482 "JNJ|21 32|MMP-9 zymogen
HY-103490 "Tak|24 27|TAK1
HY-103704 "LY2|26 28|FXR
HY-104009A "GS|79 80|Ki
HY-104010 "Asc|48 50|allosteric Bcr - Abl
HY-104065B "Py|55 58|EGFR
HY-104065B "Py|60 63|HER2
HY-10408 "Ki-2|12 22|selective c -
HY-10408 "Ki-2|71 79|2 nM ; 6 fold
HY-10408 "Ki-2|106 122|VEGFR2(IC50=12 nM )
HY-10411 "AZ96|35 44|JAK2 kinase
HY-10411 "AZ96|50 51|Ki
HY-10483 "SCH-|60 66|aurora A
HY-10502A "Tip|128 138|farnib S Tipifarnib S
HY-10530 "Varl|48 68|small molecule pan - EGFR
HY-10530 "Varl|104 107|HER2
HY-10559 "Nelo|54 59|5-HT2C
HY-10560 "Tema|23 36|5-HT2A receptor
HY-10560 "Tema|52 53|Ki
HY-10644 "Lck |44 58|nhibitor 2 tyrosine kinases
HY-10644 "Lck |72 74|BTK
HY-10644 "Lck |133 135|Lck
HY-10644 "Lck |137 139|Btk
HY-10644 "Lck |141 143|Lyn
HY-10644 "Lck |145 147|Btk
HY-10644 "Lck |211 213|Src family kinase Lck
HY-10644 "Lck |223 232|2(Compound
HY-10644 "Lck |244 245|48
HY-10644 "Lck |276 290|tyrosine kinases
HY-10644 "Lck |307 323|71 tyrosine kinases
HY-107139 "JNJ|24 44|melanocortin receptor 1
HY-107139 "JNJ|46 49|MC1R
HY-107139 "JNJ|54 74|melanocortin receptor 5
HY-107139 "JNJ|200 208|NDP - α - MSH
HY-107139 "JNJ|226 234|human MC1R
HY-10721 "PF-A|46 48|Akt
HY-10721 "PF-A|116 118|PKA
HY-107216 "G-1|60 61|Ki
HY-107414 "SKA|15 29|KCa3.1 activator
HY-107414 "SKA|53 55|109
HY-107418 "Tro|38 40|FXR
HY-107429 "Abr|54 57|JAK1
HY-107429 "Abr|92 95|JAK1
HY-107429 "Abr|99 102|JAK2
HY-107429 "Abr|214 218|STAT1
HY-107429 "Abr|220 224|STAT3
HY-107429 "Abr|228 232|STAT5
HY-107455 "A-4|42 45|p300
HY-107455 "A-4|47 49|CBP
HY-107455 "A-4|79 82|p300
HY-107455 "A-4|86 88|CBP
HY-107709 "MK-|31 51|acetyl - CoA carboxylase
HY-10794 "MF49|32 40|novel and selective E prostanoid receptor 4
HY-10794 "MF49|87 97|affinity for
HY-10794 "MF49|101 103|EP4
HY-10794 "MF49|118 119|of
HY-10794 "MF49|197 211|0.7 nM Target selectivity over
HY-107988 "MK-|24 49|AMP - activated protein kinase
HY-107988 "MK-|51 54|AMPK
HY-10811 "GNE-|59 62|mTOR
HY-10811 "GNE-|139 142|mTOR
HY-10825 "DG05|54 55|B4
HY-108318 "RK-|36 38|Lck
HY-108318 "RK-|57 59|Lck
HY-108339 "PF-|44 75|monoacylglycerol acyltransferase 3
HY-108435 "GNE|30 32|CBP
HY-108435 "GNE|61 62|TR
HY-108677 "L-3|57 59|non
HY-108677 "L-3|68 83|peptide oxytocin receptor
HY-108677 "L-3|144 159|oxytocin receptor
HY-108699 "TM-|17 17|G
HY-108699 "TM-|45 49|Coupled Receptor GPR39
HY-108699 "TM-|124 128|human
HY-108705 "BI-|18 29|BCL6 degrader
HY-108705 "BI-|44 52|BTB domain
HY-108705 "BI-|55 58|BCL6
HY-10873 "N-De|104 105|Ki
HY-10873 "N-De|131 140|VEGFR -1 , -2
HY-108741A "Pl|18 35|guanylate cyclase - C
HY-108741A "Pl|37 49|GC - C ) receptor
HY-108900 "Leu|23 43|leucyl - tRNA synthetase
HY-109053 "Del|27 29|JAK
HY-109053 "Del|70 73|JAK1
HY-109053 "Del|75 78|JAK2
HY-109053 "Del|80 83|JAK3
HY-109053 "Del|87 90|Tyk2
HY-109068 "Par|28 32|PI3Kδ
HY-109078 "Vec|35 37|BTK ITK
HY-109095 "Nem|27 40|orexin receptor
HY-109095 "Nem|124 134|Ox1 receptor
HY-109095 "Nem|138 148|Ox2 receptor
HY-109588 "NIT|43 60|anti - mycobacterial
HY-11010 "AS60|6 8|JNK
HY-11010 "AS60|52 67|JNK human isoforms
HY-11011 "A-77|39 41|Src - family Lck
HY-11011 "A-77|79 81|Lck
HY-11011 "A-77|119 121|Fyn
HY-11011 "A-77|131 145|Src family kinase
HY-11011 "A-77|194 196|Lck
HY-11042 "GNE-|29 32|PI3 K
HY-11042 "GNE-|34 39|IC50=4
HY-11087 "SD 0|12 23|p38 MAP kinase
HY-11087 "SD 0|93 96|TNF -
HY-111099 "GLP|26 29|CFTR
HY-111099 "GLP|82 85|CFTR
HY-111101 "AZ1|39 76|Interleukin-1 receptor associated kinase 4
HY-111108 "LDH|37 61|human lactate dehydrogenase
HY-111108 "LDH|63 65|LDH
HY-111139 "MS4|128 130|CBP
HY-111200 "Vab|45 50|5-HT2C
HY-111271 "L 8|59 60|Ki
HY-111350 "FT8|24 50|ubiquitin - specific protease 7
HY-111361 "FN-|23 26|FLT3
HY-111361 "FN-|30 32|CDK
HY-111361 "FN-|72 75|CDK2
HY-111361 "FN-|85 88|cyclin A CDK4
HY-111361 "FN-|90 97|cyclin D1
HY-111361 "FN-|99 102|CDK6
HY-111361 "FN-|104 111|cyclin D1
HY-111361 "FN-|115 118|FLT3
HY-111365 "TES|25 82|human α - amino - β - carboxymuconate - ε - semialdehyde decarboxylase
HY-111365 "TES|84 88|ACMSD
HY-111443 "TR |26 47|thyroid hormone receptor
HY-111443 "TR |49 50|TR
HY-111453 "AZD|33 54|glucocorticoid receptor
HY-111454 "SR1|7 24|mu - opioid - receptor
HY-111458 "GSK|67 71|USP20
HY-111458 "GSK|73 74|Ub
HY-111458 "GSK|76 78|Rho
HY-111483 "AZD|25 28|ERK2
HY-111486 "LSZ|40 55|estrogen receptor
HY-111510 "IPI|25 33|PI3 K p110δ
HY-111767 "BAY|24 43|A2B adenosine receptor
HY-111767 "BAY|125 147|rat A2B adenosine receptor
HY-111767 "BAY|173 174|Ki
HY-111767 "BAY|184 208|human A2B adenosine receptor
HY-111767 "BAY|233 234|A1
HY-112066 "SHI|4 42|human serine hydroxymethyltransferse 1 and 2
HY-112088 "AZD|6 9|CDK9
HY-112088 "AZD|56 68|20160376287 A1
HY-112094 "WNK|27 32|Lysine
HY-112094 "WNK|34 43|WNK ) kinase
HY-112140 "JH-|51 53|ALK
HY-112140 "JH-|86 134|echinoderm microtubule - associated protein - like 4-ALK
HY-112157 "PF-|32 60|penetrant β - site amyloid precursor protein
HY-112162 "BOS|21 37|monopolar spindle 1
HY-112162 "BOS|39 42|MPS1
HY-112166 "PRN|81 83|BTK
HY-112272A "Le|8 12|G1 T38
HY-112272A "Le|61 64|CDK4
HY-112272A "Le|66 69|CDK6
HY-112272A "Le|94 97|CDK4
HY-112272A "Le|110 113|CDK6
HY-112299 "TAS|7 10|EGFR
HY-112301 "Pra|42 44|RET
HY-112301 "Pra|74 90|wild type RET kinase
HY-112427 "Sir|20 27|sirtuin 2
HY-112433 "NIK|23 27|NF - κB
HY-112619 "TES|24 81|human α?Amino - β - carboxymuconate - ε - semialdehyde Decarboxylase
HY-112654 "GCN|33 62|serine / threonine - protein kinase
HY-112654 "GCN|77 93|nonderepressible 2
HY-112654 "GCN|95 98|GCN2
HY-112681 "PKC|26 39|PKC - θinhibitor
HY-112701 "CCR|162 183|CCR6 inhibitor 1 markedly
HY-112701 "CCR|190 192|ERK
HY-112701 "CCR|209 212|CCR6
HY-112734 "4'-|36 49|Cytochrome P450
HY-112734 "4'-|77 98|human P450 1B1-dependent
HY-112778 "NFA|33 36|IL-2
HY-112831 "BI-|26 30|PDE9A
HY-112831 "BI-|143 147|PDE3A
HY-112831 "BI-|155 159|PDE5A
HY-112895 "UT-|23 38|androgen receptor
HY-112895 "UT-|40 41|AR
HY-112895 "UT-|59 60|Ki
HY-112895 "UT-|71 76|UT-155
HY-112895 "UT-|86 87|AR
HY-113854 "AZD|15 36|glucocorticoid receptor
HY-113854 "AZD|38 39|GR
HY-113854 "AZD|155 156|GR
HY-114141 "BI-|43 76|chemoattractant receptor - homologous
HY-114177 "PF-|51 72|cyclin - dependent kinase
HY-114177 "PF-|74 76|CDK
HY-114177 "PF-|83 84|Ki
HY-114177 "PF-|123 126|CDK4
HY-114177 "PF-|130 133|CDK6
HY-114228 "PRO|54 67|AC BET degrader-2 Extra - Terminal
HY-114228 "PRO|69 71|BET
HY-114258 "LY3|44 57|Aurora - A kinase
HY-114258 "LY3|72 73|Ki
HY-114263 "NXT|36 41|PPAR - α
HY-114263 "NXT|112 133|PPARα nuclear hormone receptor
HY-114263 "NXT|157 158|GR
HY-114330A "ZK|47 75|urokinase plasminogen activator
HY-114330A "ZK|77 79|uPA
HY-114330A "ZK|132 134|uPA
HY-114330A "ZK|136 138|tPA
HY-114330A "ZK|143 149|plasmin
HY-114331 "DLK|31 49|leucine zipper kinase
HY-114331 "DLK|69 73|Ki of 3
HY-114331 "DLK|77 84|DLK - IN-1
HY-114739 "MA-|46 85|peroxisome proliferator activated receptor δ
HY-116009 "RMC|47 50|SHP2
HY-117410 "Vip|39 70|prostate - specific membrane antigen
HY-117410 "Vip|72 75|PSMA
HY-117410 "Vip|92 93|Ki
HY-117771 "DO3|58 63|lipase
HY-117771 "DO3|115 117|SAG
HY-119940 "(re|31 43|CDK9-Cyclin T1
HY-119940 "(re|100 103|CDK9
HY-119940 "(re|113 116|CDKs
HY-120012 "AZD|61 82|glucocorticoid receptor
HY-120856 "ARN|41 44|salt
HY-12169 "Mari|81 85|MMP-2
HY-12214A "NVP|4 7|2 CDK9
HY-12293 "LY28|36 44|ATP kinase
HY-12293 "LY28|61 64|CDK9
HY-12297 "Sulf|42 55|tyrosine kinase
HY-12297 "Sulf|83 87|FGFR1
HY-12297 "Sulf|91 95|CSF1R
HY-12305 "Q-VD|123 130|caspases
HY-12305 "Q-VD|140 147|caspase 1
HY-12305 "Q-VD|164 172|Q - VD - OPha
HY-12333 "G-74|1 2|is
HY-12333 "G-74|216 223|respectively ] Target :
HY-12333 "G-74|397 406|inhibitory
HY-12333 "G-74|516 524|displayed
HY-12336 "NIBR|69 74|2 GPR183
HY-12345 "ML36|423 446|potassium channels , Kir2.1
HY-12345 "ML36|496 501|member
HY-12359 "TPPB|51 53|- derived protein kinase C PKC
HY-12359 "TPPB|69 70|Ki
HY-12405 "CGP-|230 236|from the
HY-12405 "CGP-|282 290|TH - enzyme
HY-12405 "CGP-|317 320|were
HY-12405 "CGP-|330 331|by
HY-12405 "CGP-|391 404|was ineffective
HY-12405 "CGP-|406 407|1 ]
HY-12405 "CGP-|409 417|[ 125I]CGP
HY-12405 "CGP-|527 528|in
HY-12405 "CGP-|599 599|,
HY-12411 "AMG-|12 51|glucokinase - glucokinase regulatory protein
HY-12411 "AMG-|64 70|GK - GKRP
HY-12420 "JNJ-|40 43|MELK
HY-12423A "TAS|20 57|VEGFRand hepatocyte growth factor receptor
HY-12423A "TAS|59 63|c - Met
HY-12423A "TAS|65 84|HGFR)-targeted kinase
HY-12425 "DGAT|82 91|human DGAT1
HY-12429 "Becl|39 47|thumb site
HY-12429 "Becl|54 72|hepatitis C virus ( HCV
HY-12429 "Becl|74 103|NS5B RNA - dependent RNA polymerase
HY-12429 "Becl|116 145|recombinant NS5B proteins from HCV
HY-12434 "INT-|9 26|farnesoid X receptor
HY-12437 "BDP5|26 36|ROCK and MRCK
HY-12445 "CDKI|4 14|a potent CDK9
HY-12445 "CDKI|36 49|shows selective
HY-12445 "CDKI|137 141|nM/80
HY-12445 "CDKI|229 230|( n
HY-12445 "CDKI|255 261|0.08μM ±
HY-12445 "CDKI|309 314|normal
HY-12445 "CDKI|316 316|-
HY-12445 "CDKI|341 341|= 10 ) and +
HY-12467 "OTS-|49 58|TOPK kinase
HY-12488 "LY25|25 29|CXCR4
HY-12488 "LY25|64 68|CXCR4
HY-12492 "VER-|43 69|pyruvate dehydrogenase kinase
HY-12510 "Meth|34 46|mGlu5 receptor
HY-12510 "Meth|161 173|mGlu5 receptor
HY-12510 "Meth|560 571|methoxy - PEPy
HY-12522 "PF-0|329 333|/ kg to
HY-12522 "PF-0|340 347|Han rats ,
HY-12528 "DBPR|140 143|bioavailable DPP4
HY-12528 "DBPR|173 177|DPP IV
HY-12528 "DBPR|243 248|DPP - II
HY-12528 "DBPR|298 309|plasma DPP - IV
HY-12528 "DBPR|422 427|DPP - IV
HY-12594 "Pari|51 56|3/4A NS3/4A
HY-12648A "FAS|32 48|fatty acid synthase
HY-12648A "FAS|50 52|FAS
HY-12648A "FAS|73 86|WO 2012064642 A1
HY-12680 "PRN6|47 57|T cell kinase
HY-12680 "PRN6|73 88|lymphocyte kinase
HY-12761 "A-83|54 72|high potencies at CB(2
HY-12764 "6-OA|207 215|in 35S]GTPγS
HY-12764 "6-OA|559 560|of
HY-12828 "KH-C|42 65|CDC2-like kinase isoforms 1
HY-12828 "KH-C|318 322|TNF - α
HY-12828 "KH-C|369 378|SR proteins
HY-12828 "KH-C|391 395|TNF - α
HY-12828 "KH-C|506 510|asHTF
HY-12839 "p38 |45 47|p38
HY-12864 "Bril|48 71|estrogen receptor degrader
HY-12867 "PT-2|34 35|Ki
HY-12871 "Atuv|112 117|P - TEFb
HY-12871 "Atuv|119 122|CDK9
HY-12871 "Atuv|146 149|supresses CDK9
HY-12871B "Atu|52 56|PTEFb
HY-12871B "Atu|58 61|CDK9
HY-12871B "Atu|105 108|CDK9
HY-12871C "Atu|20 42|eciclib S - Enantiomer BAY-1143572 S - Enantiomer
HY-12871C "Atu|66 69|CDK9
HY-12871C "Atu|93 96|CDK9
HY-12872 "Naza|46 49|EGFR
HY-12872 "Naza|64 65|Ki
HY-12872 "Naza|96 110|EGFR(L858R/790 M
HY-12879 "IWP-|17 19|Wnt
HY-12883 "PF 0|48 63|WO/2010/079443 A1
HY-12947 "GNE-|10 28|leucine zipper kinase
HY-12947 "GNE-|48 49|Ki
HY-12960 "SKLB|188 188|a
HY-12971 "Namp|38 42|NAMPT
HY-12971 "Namp|53 57|Nampt
HY-13033 "CDK-|23 26|CDK9
HY-13033 "CDK-|108 111|CDK9
HY-13057 "Gluc|13 16|MGMT
HY-13057 "Gluc|35 72|O6-methylguanine - DNAmethyl - transferase
HY-13057 "Gluc|74 77|MGMT
HY-13233B "Tal|142 147|peptidase IV DPP - IV
HY-13233B "Tal|163 164|Ki
HY-13250 "Silv|109 115|myc - LUC
HY-13250 "Silv|126 150|tub - LUC luciferase reporter protein
HY-13250 "Silv|176 196|Anti - cancer activity[1
HY-13254A "A-6|55 56|Ki
HY-13299 "MK80|1 8|is a novel
HY-13299 "MK80|124 128|nM ( Wt
HY-13299 "MK80|169 174|/ Ron in
HY-13314 "Tese|46 59|tyrosine kinase
HY-13314 "Tese|78 81|EGFR
HY-13314 "Tese|83 87|ErbB2
HY-13314 "Tese|93 96|Flt4
HY-13314 "Tese|100 110|EphB4 kinase
HY-13427 "Alli|28 33|a novel
HY-13427 "Alli|87 87|3
HY-13427 "Alli|130 133|more
HY-13427 "Alli|140 166|to ErbB2-overexpressing cells
HY-13427 "Alli|168 176|3000-fold
HY-13427 "Alli|189 192|for ErbB
HY-13427 "Alli|285 293|Allitinib
HY-13427 "Alli|303 304|as
HY-13427 "Alli|514 520|thereby
HY-13427 "Alli|530 532|the
HY-13427 "Alli|597 605|selective
HY-13427 "Alli|648 648|,
HY-13427 "Alli|662 662|.
HY-13428 "Tuba|99 103|HDAC1
HY-13560 "AVN-|12 21|a selective
HY-13560 "AVN-|65 76|against human
HY-13560 "AVN-|82 85|with
HY-13560 "AVN-|127 128|nM
HY-13560 "AVN-|200 209|of exposure
HY-13560 "AVN-|220 221|of
HY-13560 "AVN-|279 279|-
HY-13560 "AVN-|467 473|. AVN944
HY-13560 "AVN-|606 606|in ,
HY-13560 "AVN-|642 646|lines
HY-13560 "AVN-|650 659|suppressed
HY-13564 "Bati|73 77|MMP-2
HY-13564 "Bati|93 97|MMP-3
HY-13775 "XL01|502 511|  Targets for
HY-13806 "XL38|34 37|mTOR
HY-13862 "AZD1|23 26|GSK3
HY-13862 "AZD1|52 72|recombinant human GSK3α
HY-13867 "Bisi|63 86|dolylmaleimide I reversible protein kinase C
HY-13867 "Bisi|88 90|PKC
HY-13867 "Bisi|106 107|Ki
HY-13961 "GLPG|30 32|JAK
HY-13961 "GLPG|64 67|JAK1
HY-13961 "GLPG|69 72|JAK2
HY-13961 "GLPG|74 77|JAK3
HY-14127 "R121|11 36|small - molecule CRF1 receptor
HY-14127 "R121|52 56|Ki of 2
HY-14127 "R121|68 79|CRF1 receptor
HY-14127 "R121|115 126|CRF2 receptor
HY-14127 "R121|128 145|CRF - binding protein
HY-14176 "Comp|7 17|γ - secretase
HY-14176 "Comp|56 56|bloks β - amyloid(40 β
HY-14176 "Comp|73 77|amyloid(42 Notch
HY-14181A "Cin|35 50|guanylate cyclase
HY-14305A "BMS|154 170|inhibit cytochrome
HY-14305A "BMS|183 186|1A2 ,
HY-14305A "BMS|190 195|, 2C19 ,
HY-14305A "BMS|199 215|2D6 with IC50values
HY-14305A "BMS|275 278|weak 18 to
HY-14305A "BMS|350 354|over a
HY-14338A "Ida|22 43|Lu AE58054 Hydrochloride
HY-14338A "Ida|66 78|5-HT6 receptor
HY-14338A "Ida|94 95|Ki
HY-14342 "MK-5|126 127|46 is 25 nM [ 1
HY-14434 "Asun|15 45|hepatitis C virus ( HCV ) NS3 protease
HY-14435 "Pyri|11 13|JAK
HY-14435 "Pyri|48 56|JAK kinase
HY-14435 "Pyri|81 84|JAK2
HY-14435 "Pyri|99 102|JAK3
HY-14435 "Pyri|114 117|JAK1
HY-14435 "Pyri|185 206|protein tyrosine kinases
HY-14533 "K 01|17 31|destabilizes AβO
HY-14533 "K 01|33 41|β - amyloid
HY-14533 "K 01|90 98|Amyloid - β
HY-14622A "Nec|82 102|ostatin 2 TNF - alpha Necrostatin 2
HY-14622A "Nec|465 468|TNF -
HY-14622A "Nec|471 475|5-(1H
HY-14622A "Nec|514 518|Indol-3-ylmethyl)-2-thiohydantoins 5-(1H
HY-14622B "Nec|82 102|ostatin 2 TNF - alpha Necrostatin 2
HY-14622B "Nec|465 468|TNF -
HY-14622B "Nec|471 475|5-(1H
HY-14622B "Nec|514 518|Indol-3-ylmethyl)-2-thiohydantoins 5-(1H
HY-14719 "RO49|38 40|MEK
HY-14719 "RO49|82 85|MEK1
HY-14719 "RO49|87 90|MEK2
HY-14839 "Evat|20 30|EP2 receptor
HY-14875 "Veru|9 46|corticotropin - releasing factor receptor 1
HY-14875 "Veru|48 51|CRF1
HY-14875 "Veru|98 101|CRF1
HY-14875 "Veru|111 116|CRF - BP
HY-14885 "Elig|39 62|glucocerebroside synthase
HY-14885A "Eli|52 75|glucocerebroside synthase
HY-15043 "ELN-|45 62|inhibits the binding
HY-15141 "Stau|44 57|protein kinases
HY-15141 "Stau|91 93|PKC
HY-15141 "Stau|95 97|PKA
HY-15141 "Stau|99 103|c - Fgr
HY-15141 "Stau|108 126|Phosphorylase kinase
HY-15148 "Tipr|62 74|HIV-1 protease
HY-15148 "Tipr|103 107|multi
HY-15149 "Romi|14 18|HDAC1
HY-15257 "Mavo|42 54|mGlu5 receptor
HY-15260A "XL4|61 64|Cdc7
HY-15260A "XL4|129 131|CK2
HY-15272 "WAY-|40 43|mTOR
HY-15272 "WAY-|71 85|recombinant mTOR
HY-15272 "WAY-|93 99|WAY-600
HY-15272 "WAY-|106 109|mTOR
HY-15319 "AMG |18 35|chemokine receptor 3
HY-15320 "NBI-|107 108|Ki
HY-15391 "Luci|43 46|FGFR
HY-15391 "Luci|99 103|FGFR1
HY-15403A "Atr|25 42|endothelin receptor
HY-15426 "PF-0|33 36|PDE8
HY-15427 "GDC-|24 26|BTK
HY-15427 "GDC-|53 55|BTK
HY-15427A "GDC|351 353|nM/6.4 and
HY-15433 "Quis|46 49|HDAC
HY-15433 "Quis|80 84|HDAC1
HY-15434 "NG25|13 16|TAK1
HY-15434 "NG25|20 25|MAP4K2
HY-15452A "Sel|19 36|sistat S - enantiomer EX-527 S - enantiomer
HY-15452A "Sel|94 115|Selisistat S - enantiomer
HY-15460 "CHIR|45 59|LpxC deacetylase
HY-15460 "CHIR|85 86|Ki
HY-15465 "KN-9|97 98|calmodulin - dependent kinase type II Ki
HY-15465A "KN-|56 96|inhibitor calmodulin - dependent kinase type II
HY-15465A "KN-|110 111|Ki
HY-15465B "KN-|63 77|neuronal CaMK - II
HY-15465B "KN-|83 84|Ki
HY-15497 "AZD7|362 373|postprandial
HY-15504A "RGB|9 11|CDK
HY-15504A "RGB|52 64|cyclin T1-CDK9
HY-15504A "RGB|66 78|cyclin B1-CDK1
HY-15504A "RGB|80 91|cyclin E - CDK2
HY-15504A "RGB|93 105|cyclin D1-CDK4
HY-15504A "RGB|107 118|cyclin E - CDK3
HY-15504A "RGB|190 193|TAK1
HY-15504A "RGB|195 198|Jak2
HY-15504A "RGB|202 205|MEK1
HY-15506 "TAK-|19 23|PDGFR
HY-15515 "SEA0|36 52|Na+-Ca2 + exchanger
HY-15517A "KN-|59 91|2 Ca2+/calmodulin - dependent kinase II
HY-15517A "KN-|122 124|CaM
HY-15517A "KN-|144 145|Ki
HY-15517B "KN-|59 91|2 Ca2+/calmodulin - dependent kinase II
HY-15517B "KN-|122 124|CaM
HY-15517B "KN-|144 145|Ki
HY-15532 "SCH9|59 62|Chk1
HY-15532B "SCH|116 119|Chk1
HY-15533 "LY 3|26 35|Cathepsin S
HY-15533 "LY 3|37 40|Cat S
HY-15533 "LY 3|86 89|mCat
HY-15536 "Cebr|26 39|opioid receptor
HY-15536 "Cebr|109 116|human NOP
HY-15536 "Cebr|122 124|KOP
HY-15536 "Cebr|148 150|delta - opioid peptide DOP
HY-15555 "EPZ0|44 45|Ki
HY-15555 "EPZ0|84 87|EZH1
HY-15590 "AZ-2|52 52|Trk kinase A B
HY-15590 "AZ-2|100 104|C FGFR1
HY-15590 "AZ-2|144 146|Lck
HY-15591A "TMC|101 104|RdRp
HY-15591A "TMC|232 264|HCV NS5B RNA - dependent RNA polymerase
HY-15591A "TMC|535 536|1a
HY-15594A "Phe|45 46|G4
HY-15594A "Phe|85 97|DinG helicases
HY-15595A "360|59 68|telomerase
HY-15595A "360|97 106|telomerase
HY-15595A "360|109 112|TRAP
HY-15595A "360|114 115|G4
HY-15600 "UPF-|473 476|totally , but
HY-15600 "UPF-|480 490|compound was
HY-15607A "WEH|40 45|Bcl - XL
HY-15617 "JNK-|12 14|JNK
HY-15617 "JNK-|50 53|JNK1
HY-15617 "JNK-|55 58|JNK2
HY-15685 "Ripa|33 36|ROCK
HY-15697 "TUG-|115 126|GPR40 in vitro
HY-15697 "TUG-|128 143|TUG-770 ( Compound
HY-15708 "LY27|401 415|( an uptake pattern
HY-15709 "AL 0|29 50|glucocorticoid receptor
HY-15709 "AL 0|52 53|GR
HY-15709 "AL 0|69 70|Ki
HY-15720A "H-1|50 53|ROCK
HY-15720A "H-1|69 70|Ki
HY-15737 "DB07|23 26|JNK1
HY-15748 "JNJ-|59 76|Glutamate 2 receptor
HY-15769 "WHI-|14 25|multi - kinase
HY-15769 "WHI-|44 46|RET
HY-15769 "WHI-|48 50|KDR
HY-15769 "WHI-|54 57|EGFR
HY-15770 "TR-1|55 62|integrin
HY-15770 "TR-1|132 139|integrin
HY-15770 "TR-1|166 184|human alpha(4)beta(7
HY-15770 "TR-1|191 218|125)I - MAdCAM - Ig fusion protein
HY-15770 "TR-1|352 360|MAdCAM - Ig
HY-15775 "Argi|33 47|ase human arginases I
HY-15776 "HG-9|32 35|salt
HY-15778 "AVE |31 55|angiotensin-(1 - 7 ) receptor
HY-15778A "AVE|42 58|Ang-(1 - 7 ) receptor
HY-15789 "Elba|15 51|hepatitis C virus nonstructural protein 5A
HY-15789 "Elba|53 59|HCV NS5A
HY-15789 "Elba|105 106|1a
HY-15793 "NBI-|44 63|8782(alpha monoamine transporter
HY-15793 "NBI-|86 87|Ki
HY-15793 "NBI-|178 179|Ki
HY-15793 "NBI-|210 229|monoamine transporter
HY-15793 "NBI-|288 289|Ki
HY-15796 "GNE0|4 10|77 a highly
HY-15796 "GNE0|18 26|selective
HY-15796 "GNE0|253 254|leucine - Ki
HY-15799 "AZD1|26 38|P2Y12 receptor
HY-15799 "AZD1|128 140|P2Y12 receptor
HY-15801 "HG-1|26 28|ALK
HY-15801 "HG-1|74 76|ALK
HY-15851 "Reve|69 78|M3 receptor
HY-15851 "Reve|84 85|Ki
HY-15853 "MK-7|43 44|Ki
HY-15891 "GW31|69 95|human neutrophil elastase(HNE
HY-15891 "GW31|160 177|neutrophil elastase
HY-15891 "GW31|181 183|HNE
HY-15891 "GW31|222 241|human serine proteases
HY-15891 "GW31|262 268|trypsin
HY-15891 "GW31|270 279|cathepsin G
HY-15891 "GW31|284 290|plasmin
HY-15891 "GW31|299 310|chymotrypsin
HY-15891 "GW31|314 339|tissue plasminogen activator
HY-15894 "BQ-7|34 44|ETB receptor
HY-15894 "BQ-7|66 76|ET-1 binding
HY-15894 "BQ-7|79 90|ETB receptors
HY-15947 "Ravo|40 48|ERK kinase
HY-15947 "Ravo|86 89|ERK1
HY-15947 "Ravo|93 96|ERK2
HY-15947A "Rav|87 95|ERK kinase
HY-15947A "Rav|130 133|ERK1
HY-15947A "Rav|137 140|ERK2
HY-15954 "NVP-|26 29|MDM2
HY-15954B "NVP|34 37|MDM2
HY-15955 "CPI-|55 67|nM nM for wt EZH2
HY-15955 "CPI-|81 92|respectively
HY-15955 "CPI-|126 127|in
HY-15955 "CPI-|367 382|H3K27me2 levels in
HY-15956A "CPI|90 93|EZH1
HY-15959 "Savo|41 45|c - Met
HY-15984 "VER-|7 11|Hsp90
HY-15989A "SM-|65 75|XIAP protein
HY-15991 "Tena|37 40|Na+/H+ exchanger NHE3
HY-15992 "BIBF|53 64|VEGFR2 kinase
HY-15996 "Sevi|23 49|CYP17 lyase inhibitor(h - Lyase
HY-15996 "Sevi|98 114|lyase / hydroxylase
HY-15996A "Sev|78 104|CYP17 lyase inhibitor(h - Lyase
HY-15996B "Sev|76 96|CYP17 lyase inhibitor(h
HY-16025 "ACTB|50 54|FGFR1
HY-16104 "BIX |22 30|S6 kinase 2
HY-16111 "BMS-|26 44|farnesyl transferase
HY-16209 "Foro|40 62|nucleoside phosphorylase
HY-16209 "Foro|64 66|PNP
HY-16276 "Osil|35 54|human 11β - hydroxylase
HY-16420 "R112|30 38|Syk kinase
HY-16420 "R112|44 49|Ki of 96
HY-16420 "R112|65 73|Syk kinase
HY-16420 "R112|126 128|Syk
HY-16420 "R112|303 305|IgE
HY-16420 "R112|475 485|IgE receptor
HY-16462 "CDK9|7 36|special cyclin - dependent kinase 9
HY-16462 "CDK9|38 41|CDK9
HY-16474 "Relu|37 65|gonadotropin - releasing hormone
HY-16474 "Relu|67 70|GnRH
HY-16474 "Relu|219 222|GnRH
HY-16504 "Trep|22 24|DP1
HY-16590 "X-37|17 19|ALK
HY-16643 "Iine|34 92|nonabsorbable ASBT(apical sodium - dependent bile acid transporter
HY-16643 "Iine|104 116|hASBT IC50=42 ±
HY-16681 "AGN |72 80|nM for RARα
HY-16681 "AGN |113 115|nM (
HY-16681 "AGN |257 259|50 %
HY-16681 "AGN |289 291|by all three lines at led
HY-16681 "AGN |337 348|in G1 followed
HY-16681 "AGN |351 360|apoptosis .
HY-16684 "AGN |145 152|RAR Trans
HY-16699 "Next|75 78|rastat HDAC
HY-16699 "Next|108 112|HDAC6
HY-16699 "Next|122 132|Nexturastat
HY-16699 "Next|389 399|Class 2 HDAC isozymes Nexturastat
HY-16727 "Pres|29 43|bioavailable RSV
HY-16751 "Rali|138 153|rat IP receptor human DP1 receptor
HY-16763 "Asap|26 36|DP1 receptor
HY-16763 "Asap|52 53|Ki
HY-16901 "Firs|37 57|acetyl - CoA carboxylase
HY-16901 "Firs|59 61|ACC
HY-16903 "PKC-|64 66|PKC
HY-16903 "PKC-|98 106|human PKCβ
HY-16903 "PKC-|187 191|PKC mu
HY-16935 "Mava|107 120|rep CYP isoforms 3A4
HY-16935 "Mava|149 150|Ki
HY-16935 "Mava|155 159|TRPV1
HY-16935 "Mava|275 303|recombinant human TRPV1 channels
HY-16935 "Mava|305 312|Mavatrep
HY-16935 "Mava|404 417|hTRPV1 channels
HY-16935 "Mava|420 428|Capsaicin
HY-16963 "GW62|17 28|novel , potent
HY-16963 "GW62|337 349|nM ) . IC50 affinity ( pKb )
HY-16963 "GW62|363 365|+ /-
HY-16963 "GW62|688 690|and
HY-16966 "SBI-|87 96|autophagy kinase ULK1 ULK1 kinase
HY-16966 "SBI-|138 141|kinase ULK2
HY-16966 "SBI-|176 179|ULK2
HY-16966 "SBI-|241 243|456
HY-16966 "SBI-|400 403|mTOR
HY-16966 "SBI-|529 532|mTOR
HY-16976 "GDC-|6 14|Pim kinase
HY-16976 "GDC-|89 90|Ki
HY-16976 "GDC-|95 103|PIM1 LC-3 K
HY-16999 "RO89|143 146|IC50
HY-16999 "RO89|259 266|p53-MDM2
HY-16999 "RO89|398 399|with potential of
HY-16999 "RO89|452 471|consistent with its non
HY-17377 "Vicr|76 79|CCR5
HY-17377 "Vicr|86 87|Ki
HY-17377 "Vicr|157 161|ADA - M
HY-17446 "Icat|48 67|bradykinin B2 receptor
HY-17446 "Icat|79 80|Ki
HY-17458 "Azil|293 299|whereas
HY-17605 "Bict|32 45|HIV-1 integrase
HY-17634 "Glec|14 30|HCV NS3/4A protease
HY-17646 "Verd|56 70|myeloperoxidase
HY-18007 "ALW-|10 32|Eph family tyrosine kinase
HY-18010 "PCI |31 33|Btk
HY-18010 "PCI |122 148|Btk kinase PCI 29732(compound 1
HY-18010 "PCI |173 175|Btk
HY-18010 "PCI |215 222|PCI 29732
HY-18010 "PCI |274 288|Tec family kinase
HY-18010 "PCI |346 356|human CD20 + B
HY-18010 "PCI |377 379|BCR
HY-18010 "PCI |438 458|B - cell activation genes
HY-18010 "PCI |551 553|BCR
HY-18018 "RN48|449 457|monocytes
HY-18018 "RN48|466 468|7.0
HY-18018 "RN48|496 515|- induced expression of
HY-18018 "RN48|535 541|CD69 , in
HY-18162 "JNJ-|54 63|glutamate 2
HY-18227 "B-Ra|25 25|B
HY-18271 "CaMK|105 108|I - IN-1 MLCK
HY-18271 "CaMK|123 125|PKC
HY-18303 "AMG-|22 24|Lck
HY-18303 "AMG-|99 106|anti - CD3
HY-18303 "AMG-|126 129|IL-2
HY-18303 "AMG-|155 157|Lck
HY-18303 "AMG-|239 241|Lck
HY-18303 "AMG-|304 306|KDR
HY-18303 "AMG-|310 312|SRC
HY-18303 "AMG-|316 319|MAPK
HY-18303 "AMG-|406 408|JNK
HY-18303 "AMG-|482 501|EGFP - KRASG12V protein
HY-18303 "AMG-|517 520|EGFP
HY-18332C "DOV|60 75|dopamine reuptake
HY-18351 "Indo|22 40|topoisomerase 1(Top1
HY-18353 "mTOR|26 29|mTOR
HY-18353 "mTOR|44 45|Ki
HY-18353 "mTOR|54 57|mTOR
HY-18601 "(±)-|52 60|I - D allosteric IN integrase
HY-18601 "(±)-|66 70|LEDGF
HY-18601 "(±)-|155 163|p75 binding site ] Target integrase
HY-18601 "(±)-|205 208|BI - D
HY-18603 "FIIN|28 31|FGFR
HY-18603 "FIIN|69 73|FGFR1
HY-18603 "FIIN|81 85|FGFR3
HY-18613 "CAY1|33 37|HDAC6
HY-18613 "CAY1|93 97|HDAC1
HY-18620 "DZ20|3 22|a potent and reversible
HY-18620 "DZ20|207 210|than
HY-18620 "DZ20|289 290|little cytotoxicity up to
HY-18620 "DZ20|464 472|Similarly
HY-18620 "DZ20|474 488|little effect was
HY-18620 "DZ20|493 494|in
HY-18620 "DZ20|545 547|μM =
HY-18620 "DZ20|553 553|±
HY-18620 "DZ20|556 559|, 1 μM
HY-18621 "OTS5|43 52|TOPK kinase
HY-18654 "ADX8|54 71|glutamate receptor 4
HY-18667 "LTV-|55 81|lymphoid tyrosine phosphatase
HY-18667 "LTV-|232 234|TCR
HY-18667 "LTV-|301 302|Ki
HY-18668 "Inte|19 39|small molecule integrin
HY-18668 "Inte|128 135|Integrin
HY-18676 "OSU-|18 38|integrin - linked kinase
HY-18676 "OSU-|40 42|ILK
HY-18717 "Muta|24 52|t IDH1-IN-2 mutant Isocitrate dehydrogenase
HY-18717 "Muta|54 56|IDH
HY-18719A "End|173 175|alpha ERα
HY-18719A "End|243 252|manner with
HY-18770B "Nav|87 88|Ki
HY-18947 "HDAC|106 110|HDAC1
HY-18957 "Lifi|32 34|Raf
HY-18957 "Lifi|44 47|EGFR
HY-18957 "Lifi|85 104|recombinant BRafV600E
HY-18957 "Lifi|108 111|EGFR
HY-18997 "PLX7|23 26|BRAF
HY-18997 "PLX7|78 80|RAS
HY-19328 "ACY-|39 57|histone deacetylase 6
HY-19337 "ORM-|33 39|human AR
HY-19337 "ORM-|97 98|AR
HY-19337 "ORM-|165 195|luciferase reporter gene construct
HY-19337 "ORM-|218 225|androgen
HY-19337 "ORM-|255 256|AR
HY-19337 "ORM-|293 294|Ki
HY-19354 "Agla|147 152|factor
HY-19354 "Agla|168 169|of
HY-19354 "Agla|180 181|on
HY-19354 "Agla|443 452|Aglafoline
HY-19354 "Agla|499 499|.
HY-19354 "Agla|661 668|affected
HY-19366 "Nav1|268 281|WO 2011103196 A1
HY-19366 "Nav1|338 352|WO/2011103196 A1
HY-19369 "L-68|23 48|Amyloid β - Protein precursor γ
HY-19369 "L-68|204 208|Notch
HY-19369 "L-68|233 237|Notch
HY-19369 "L-68|341 352|Hes1 proteins
HY-19369 "L-68|368 378|γ - secretase
HY-19487 "Ribo|333 341|growth Ribocil - B
HY-19487 "Ribo|397 404|Ribocil -
HY-19529 "Ro 4|13 50|synthetic non - peptide endothelin receptor
HY-19529 "Ro 4|90 93|125I
HY-19529 "Ro 4|95 98|ET-1
HY-19529 "Ro 4|132 142|ETA receptor
HY-19529 "Ro 4|297 306|ET receptor
HY-19529 "Ro 4|375 378|ET-1
HY-19530 "PF-2|33 40|protein E
HY-19530 "PF-2|42 47|CENP - E
HY-19530 "PF-2|69 74|CENP - E
HY-19544 "JAK3|34 35|IN-1 of
HY-19544 "JAK3|83 86|1050
HY-19544 "JAK3|145 145|a
HY-19544 "JAK3|149 150|of
HY-19544 "JAK3|157 161|tools
HY-19544 "JAK3|261 261|a
HY-19544 "JAK3|343 345|5.0
HY-19569 "Upad|37 47|Janus kinase
HY-19569 "Upad|49 51|JAK
HY-19612B "DDP|57 89|histone lysine - specific demethylase
HY-19631 "Ilgi|68 71|JAK2
HY-19631 "Ilgi|133 136|JAK2
HY-19631 "Ilgi|141 144|JAK1
HY-19631 "Ilgi|157 160|JAK3
HY-19631 "Ilgi|176 179|Tyk2
HY-19631A "Ilg|51 54|JAK2
HY-19631A "Ilg|116 119|JAK2
HY-19631A "Ilg|124 127|JAK1
HY-19631A "Ilg|140 143|JAK3
HY-19631A "Ilg|159 162|Tyk2
HY-19631B "Ilg|77 80|JAK2
HY-19631B "Ilg|142 145|JAK2
HY-19631B "Ilg|150 153|JAK1
HY-19631B "Ilg|166 169|JAK3
HY-19631B "Ilg|185 188|Tyk2
HY-19635A "G-5|36 55|p21-activated kinase 1
HY-19635A "G-5|57 60|PAK1
HY-19635A "G-5|76 77|Ki
HY-19702 "PKR-|6 19|pyruvate kinase
HY-19702 "PKR-|21 23|PKR
HY-19702 "PKR-|102 104|PKR
HY-19702 "PKR-|113 115|PKR
HY-19702 "PKR-|124 126|PKR
HY-19702 "PKR-|135 137|PKR
HY-19702 "PKR-|181 183|PKR
HY-19719 "Mira|67 69|Akt
HY-19768 "Dani|30 34|CXCR2
HY-19778 "(R)-|14 17|CFTR
HY-19778A "BPO|19 22|CFTR
HY-19803 "Naqu|73 76|irreversible EGFR
HY-19803 "Naqu|110 120|EGFR mutants
HY-19803 "Naqu|132 135|EGFR
HY-19810 "MI-5|37 41|menin
HY-19810 "MI-5|45 61|MLL fusion proteins
HY-19822A "Ela|76 91|estrogen receptor
HY-19822A "Ela|93 95|ERR
HY-19870 "Setm|40 60|melanocortin 4 receptor
HY-19937 "Saro|15 54|peroxisome proliferator - activated receptor
HY-19937 "Saro|56 59|PPAR
HY-19937A "Sar|25 64|peroxisome proliferator - activated receptor
HY-19937A "Sar|66 69|PPAR
HY-19974 "TAK-|92 98|and orally binding
HY-19974 "TAK-|110 115|MIP-1α
HY-19974 "TAK-|171 175|CCR2b
HY-19981 "Dera|34 47|tyrosine kinase
HY-19981 "Dera|87 93|FGFR1 - 3
HY-40354C "(3S|65 68|JAK3
HY-50663 "MK 0|23 38|glucagon receptor
HY-50703 "MK-2|2 9|is a novel
HY-50703 "MK-2|112 122|Met in vitro :
HY-50703 "MK-2|238 243|nM ) are
HY-50703 "MK-2|295 297|2.5
HY-50703 "MK-2|302 308|whereas
HY-50703 "MK-2|395 400|to be 8-
HY-50703 "MK-2|438 442|Met . [
HY-50735 "Fiac|648 654|toxic to
HY-50846 "SCH7|20 23|ERK1
HY-50846 "SCH7|27 30|ERK2
HY-50856A "Rux|86 91|litinib S JAK1/2
HY-50875 "BCX |35 41|factor D
HY-50875 "BCX |117 123|trypsin
HY-50875 "BCX |140 146|Factor D
HY-50875 "BCX |184 190|Factor D
HY-50875 "BCX |192 210|C1s BCX 1470(Thrombin
HY-50875 "BCX |223 236|serine protease
HY-50875 "BCX |247 262|BCX 1470(Thrombin
HY-50875 "BCX |382 384|Cls and factor D RPA
HY-77251 "TAK1|29 49|MAP4K2 TGFβ - activated kinase 1
HY-77251 "TAK1|51 54|TAK1
HY-77251 "TAK1|59 107|mitogen - activated protein kinase kinase kinase kinase 2
HY-79136 "Pasi|13 22|) is a stable
HY-80002 "BMX-|49 62|tyrosine kinase
HY-80002 "BMX-|182 184|’s tyrosine kinase BTK
HY-80002 "BMX-|255 258|JAK3
HY-80002 "BMX-|260 263|EGFR
HY-80002 "BMX-|271 273|Tec
HY-D0713 "7ACC|240 250|transport prothrombin
HY-N0841 "Bruc|600 608|bruceine A
HY-P0097A "Non|22 35|peptide hormone
HY-P0097A "Non|46 76|α - Melanocyte - stimulating hormone
HY-P0097A "Non|78 82|α - MSH
HY-P0165 "Tasp|21 41|glucagon - like peptide 1
HY-P0165 "Tasp|43 47|GLP-1
HY-U00431 "CCG|18 25|G protein
HY-U00431 "CCG|65 87|RGS4-Gαo protein - protein
HY-U00461 "Ket|81 85|hexokinase KHK - C
HY-U00461 "Ket|89 93|KHK - A
HY-U00461 "Ket|129 141|20170183328 A1
HY-X0150 "JSH-|29 32|CDK9
